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BACKGROUND AND AIM: Histological abnormalities in protocol biopsies of 
liver allografts are common, particularly idiopathic post-transplant chronic 
hepatitis (IPTH) and fibrosis. Recently, emerging evidence suggests that 
antibody-mediated rejection (AMR) might play a role in acute and chronic liver 
allograft injury, but this is not well defined as in other allograft organs. This 
research consisted of a histopathological study of liver allografts, with 
emphasis on IPTH and AMR. The aim was to investigate IPTH as a cause of 
allograft loss, and to correlate histological findings of post-transplant biopsies, 
including IPTH, fibrosis and specific cell phenotypes, with signs of AMR and 
with gene expression profile. METHODOLOGY:	Three cohorts corresponding to 
three distinct post-transplantation settings were analysed: failed allografts 
removed at retransplantation, long-term protocol biopsies of clinically 
asymptomatic liver recipients, and for cause biopsies with a diagnosis of 
cellular/T-cell mediated rejection (TCMR). Several parameters of allograft 
injury were scored by two pathologists on HE and reticulin stained slides. 
Fibrosis was digitally measured in Sirius Red slides (collagen proportionate 
area). Multiplex immunostaining with quantum dots and fluorescent dyes was 
performed and digital image analysis was conducted to quantify B cells, 
plasma cells and T cells and their subtypes. RNA was extracted from biopsies 
and analysed with RNA sequencing, and the results compared to gene 
signatures of known liver pathologies. RESULTS: A steady increase in IPTH 
leading to allograft loss was observed, and this was the main reason for 
retransplantation conducted >10 years after primary transplantation in children 
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in the most recent era. The protocol biopsies of 73% of children were 
abnormal, and IPTH associated with fibrosis was the most common finding. 
Donor-specific antibodies (DSA) were present in 69% of recipients, mainly 
class II DSA, and were associated with lobular inflammation. Portal 
microvascular C4d positivity (C4d+) was linked to a humoral inflammatory cell 
profile (B cells and plasma cells), central perivenulitis, lobular inflammation, 
and each sinusoidal and centrilobular fibrosis. The combination of DSA+C4d+ 
was also associated with central perivenulitis and sinusoidal fibrosis, and 
additionally, to interface activity. B cells and plasma cells were linked to fibrosis 
in all compartments. In biopsies with rejection, portal microvascular C4d+ was 
a specific and sensitive indicator of DSA II. Bile duct loss in this group was 
strongly linked to DSA, and portal fibrosis to DSA+C4d+. Considering current 
Banff criteria for AMR, 12% of patients in the protocol biopsy group, and a 
fourth of patients in the rejection cohort had a diagnosis of chronic and acute 
AMR established, respectively. Gene expression profiles were not significantly 
different between patients with and without DSA. 
CONCLUSION: IPTH can slowly evolve to allograft failure. The associations 
found in both biopsy cohorts (protocol and rejection) between fibrosis and 
DSA+C4d+ (and a humoral inflammatory profile in protocol biopsies) suggest 
that unexplained fibrosis in both settings is likely connected to AMR. In long-
term post-transplant biopsies of asymptomatic children, unexplained 
inflammation, especially interface activity, central perivenulitis and lobular 
inflammation (even mild), also seem to represent chronic ongoing AMR. When 
diagnosis of TCMR is established, the possibility of concurrent AMR should 
be carefully considered, and the finding of bile duct loss should be regarded 
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as a potential sign of AMR. Gene signatures of AMR could not be found. This 
highlights the importance of histological assessment in monitoring allograft 














































































































1.1.1 Long-term allograft histology 
 Since first performed by Starzl and colleagues in 1963[1], human liver 
transplantation (LT) has advanced dramatically and is now well established as 
the treatment of choice in patients with severe chronic and acute liver diseases 
of several aetiologies[2-6].  In the United Kingdom, over a thousand LTs were 
conducted in the year April 2017 to March 2018[7].  
 Over the last decades, advances in organ preservation, surgical 
techniques, selection of candidates and donors, critical care, and 
immunosuppression have immensely improved the outcome for transplant 
patients[8-10]. This improvement has essentially been related to a reduction of 
complications in the first 12 months post-transplantation[8,10-11]. In addition, the 
new generation of antivirals should decrease considerably the incidence of 
viral hepatitis C recurrence following LT[12]. 
 In this context, the physical integrity of the allograft in the long-term, as 
well as conditions that interfere with it outside the spectrum of recurrent viral 
hepatitis, have increasingly gained relevance[12-13]. Histopathological 
assessment of liver allograft biopsies plays an important role in patient 
management after LT, particularly in the context of subclinical allograft injury, 
as it provides relevant information not available through peripheral blood tests 
or molecular analysis[14-16]. 
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 In the last decade, long-term follow-up studies have shown that liver 
allograft biopsy specimens obtained years after transplantation frequently 
display inflammatory changes of chronic hepatitis that cannot be ascribed to a 
particular cause, termed ‘unexplained chronic hepatitis’ or ‘idiopathic post-
transplant chronic hepatitis’ (IPTH)[17-22]. Its prevalence increases with time 
after LT, with an incidence of about 60% at 10 years post-transplantation[20,23]. 
 The histological picture of IPTH includes a predominantly portal-based 
mononuclear inflammatory infiltrate, interface hepatitis, and lobular 
inflammation, in the absence of bile duct damage, ductopenia or obvious 
endotheliitis[2,23-25]. Some authors believe that IPTH could represent a form of 
rejection[20,23-24,26]. Late episodes of acute T-cell-mediated rejection (TCMR), 
occurring several months post-transplant, frequently present particular 
histological changes distinct from those of early acute rejection. These 
changes include milder, mostly lymphocytic inflammatory infiltrate and lack the 
classical features of TCMR such as obvious bile duct injury and endotheliitis. 
These histological features overlap with those of IPTH, chronic viral hepatitis 
and autoimmune/de novo autoimmune hepatitis[21,23-24,26-27]. 
 Importantly, IPTH is associated with progressive fibrosis, leading to 
advanced stage fibrosis/cirrhosis[23]. Seyam and colleagues[26] found that 
nearly 40% of adults who developed cirrhosis after liver transplantation had 
no obvious aetiology for the fibrosis, and previous biopsies of all of them 
showed IPTH. Fibrosis is also a very common finding of late post-transplant 
biopsies, especially in children[14,23,28-31]. 
 Liver fibrosis is the liver wound healing response to recurrent or 
continuing injury and results from disproportionate accumulation of 
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extracellular matrix proteins, particularly collagen[32]. It typically happens in 
chronic liver disease, in an attempt of the liver to heal from repeated 
injury[32,33]. When acute liver damage occurs, liver cells usually regenerate, 
inflammatory cells effectively remove cellular debris, and some remodelling of 
the extracellular matrix happens. If injury persists chronically, however, the 
regenerative process might not be able to replace lost tissue. In that case, 
excessive collagen is deposited in portal tracts, lobule and/or surrounding 
central veins, creating fibrous septa and changing the liver architecture[33]. 
Thus, the development of fibrosis is a natural but harmful process that 
happens in the progression of chronic liver disease[34-35]. 
 Scoring methods exist to quantify liver fibrosis. The suitability of 
traditional scoring systems such as METAVIR[36] and Ishak[37] for quantifying 
fibrosis in liver allografts has been questioned, since these systems were 
designed to evaluate fibrosis in native livers with chronic viral hepatitis[36-39]. 
The scores were created to stage livers in which the fibrogenic process is 
primarily portal-based and only affects the lobule and perivenular region in 
advanced stages. In liver allografts, however, the process of collagen 
deposition can target both portal and central/perivenular areas or even be 
mostly directed against the latter, especially in the paediatric population[40-41]. 
 In the transplantation setting, Venturi and colleagues[42] proposed a 
new scoring system specifically designed to quantify fibrosis of liver allografts 
of children. It includes the staging of fibrosis in three compartments: portal 
tracts, central veins (zone 3), and sinusoids (zone 1 and 2). The detailed 
system is depicted in  
Table 1. 
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 Although the LAFSc[42] system proposed by Venturi and colleagues has 
the advantage of assessing fibrosis in three compartments, it does not rank 
portal fibrosis in a detailed manner as does the Ishak system. For instance, 
early bridging fibrosis and end-stage cirrhosis are classified equally at the 
same “level” of portal fibrosis (stage 3) by the LAFSc, whilst in the Ishak 
system, they are assigned to considerably different categories (stage 3 and 
stage 6, respectively). 
 
Table 1. Liver graft fibrosis semiquantitative scoring system (LAFSc)[42] 
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 An additional possibility for staging fibrosis in the liver allograft is to 
digitally quantify the ratio of fibrosis in relation to the whole biopsy area, termed 
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collagen proportionate area (CPA), by image analysis of the biopsy slides. For 
this digital quantitative assessment, it is necessary to apply a staining for 
collagen with good contrast between positivity and background, such as Sirius 
Red (Picrosirius red). 
 Some authors suggest this is a more robust method to assess liver 
fibrosis than conventional scores, with less inter-observer variability and better 
correlation with clinical outcome[43-47].  Of note, most of the studies that have 
employed CPA to quantify fibrosis were performed in native liver samples, and 
a few in liver allografts with recurrent viral hepatitis[43,47-49]. Therefore, digital 
quantification of fibrosis through CPA is still not well-established in the 
assessment of fibrosis post-transplantation for a vast range of allograft 
conditions. 
 In the last decade, several studies from different centres have reported 
high prevalence of fibrosis in late post-transplant biopsies, especially of 
paediatric liver recipients, including patients with normal liver 
biochemistry[23,28,41,50-51]. Some authors have suggested that fibrosis in these 
patients might be a result of late rejection, which can have a humoral 
component[52-53], but this hypothesis needs further confirmation. 
1.1.2 Donor-specific antibodies and antibody-mediated rejection 
in the liver graft 
 Donor-specific antibodies (DSA) are antibodies developed by the 
transplant recipient which can react against molecules present in the donor 
organ, causing tissue damage.  The deleterious effects of DSA, particularly 
those produced against donor HLA molecules, for the allograft and their 
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negative impact on transplant outcome have been consistently recognized in 
most solid organ transplantation settings[60-66]. 
 DSA can be present prior to transplantation (preformed or pre-existent 
DSA) or can be produced after the donor organ is implanted (de novo DSA).  
In the former, they are produced in response to previous sensitisation of the 
recipient with foreign antigens during blood transfusion, pregnancy or former 
transplantation[76-77]. Preformed DSA that continue to be detected after 
transplantation are called persistent. Anti-HLA DSA can be directed towards 
class I or class II HLA molecules. 
 In contrast to what has been described in kidney, pancreas, and heart 
transplantation, until recently the liver allograft was considered resistant to 
injury caused by DSA[21,54-57]. Several factors contribute to this immunological 
peculiarity, including:  
1) large hepatic sinusoidal surface which dilutes pre-formed antibodies;   
2) secretion of soluble class I HLA (human leukocyte antigen) antigens by 
the allograft, that bind to recipient alloantibodies forming immune 
complexes that are then phagocytised by Kupffer cells;   
3) the ability of Kupffer cells to clear not only immune complexes, but also 
platelet aggregates, activated complement and antibodies;   
4) restricted expression of HLA class II molecules in the liver 
microvasculature;  
5) the marked ability of the hepatocyte to regenerate after injury;  
6) continuous contact with intestinal microbial products leading to a 
tolerogenic setting with low HLA II expression[12,57-59]. Some of these 
mechanisms are depicted in Figure 1 (extracted from Taner et al, 2014[57]). 
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Figure 1. Mechanisms behind the liver graft resistance to injury 




 More recently, a number of reports have described associations 
between circulating DSA, particularly de novo DSA, and liver tissue injury, 
including acute and chronic rejection, fibrosis, chronic inflammation, overall 
allograft outcome, biliary complications and the failure to develop operational 
tolerance[21,28,55,57,67-75]. Despite these associations, a pathogenic role for DSA 
in acute and chronic allograft damage has not been unambiguously 
established in liver transplantation. 
Whereas preformed DSA seem to have significant effect on the 
outcome of other transplanted organs, such as kidney and heart, in the context 
of liver transplantation, most pre-existent DSA, especially against class I HLA 
antigens, disappear soon after transplantation with no obvious allograft 
	 18	
damage[58]. Pre-existent DSA of high MFI, especially class II, are more likely 
to persist and are associated with higher risk of TCMR, and possibly, 
combined TCMR and antibody-mediated rejection (AMR)[58,80-81]. 
 The low frequency of anti-class I HLA DSA post-liver transplantation 
could be linked to the vast physiological expression of HLA I in all liver cell 
types (it is only weaker in hepatocytes)[58,82-83]. As mentioned above, soluble 
class I HLA is secreted by the liver graft and inactivated by Kupffer cells[57]. On 
the other hand, the expression of HLA II in normal livers is restricted to 
dendritic cells in portal, perivenular and subcapsular regions[84].  The lower 
expression and secretion of class II HLA could lead to less efficient clearing of 
these antibodies in the liver graft[12]. 
 De novo DSA develop in 8-15% of patients who undergo liver 
transplantation, most commonly towards the class II HLA-DQ isotype[85-86]. 
Since DQ is the HLA molecule with the lowest expression in the liver, the 
higher frequency of anti-HLA-DQ DSA might result from the liver incapability 
to absorb and remove it from the circulation[86]. Another factor that may 
contribute to the higher prevalence of HLA-DQ antibodies is the fact that the 
genes that encode both the α and β chains of HLA-DQ are polymorphic, in 
contrast to what happens with other HLA class II proteins such as HLA-DR, 
which are polymorphic only in the β chain[87]. 
 Since the development of the original assays capable of detecting 
circulating anti-HLA antibodies, which were based on complement-dependent 
cytotoxicity (CDC), the detection of these antibodies has greatly improved. The 
assays have evolved from the use of donor cell-based methods to current 
solid-phase immunoassays, such as the Luminex platform, that enables 
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specific and semiquantitative detection of HLA antibodies[57,78]. In this method, 
the strength of the binding between an anti-HLA antibody and its antigen is 
measured through the mean fluorescence intensity, or MFI[79]. 
 Despite associations between circulating DSA and graft injury, at 
present the diagnosis of AMR in the liver is not as well established as it is for 
kidney, heart and lung allografts[88].  In fact, until recently, there were no 
consensus histological criteria for the diagnosis of acute AMR in the liver[59]. 
Recently, the Banff study group on allograft pathology proposed diagnostic 
criteria for acute AMR in the liver, comprising circulating DSA, tissue C4d 
staining, compatible histology and the exclusion of other causes that may 
produce similar injury[89]. 
 It is possible that some histological features previously attributed to 
TCMR, such as mixed inflammatory infiltrate including eosinophils, may 
correspond to a combination of TCMR and AMR[59]. Combined TCMR and 
AMR is common in rejection episodes across a variety of solid organ allografts, 
and the same overlap has been described in the liver setting[59,90]. In fact, the 
lack of adequate criteria to accurately differentiate TCMR and AMR makes it 
difficult to diagnose liver AMR outside of the early post-transplant period, 
making it challenging to establish or refute a role for humoral rejection in 
patients with late acute or chronic graft injury[57,59,91]. 
 Inflammatory insults such as TCMR or recurrent hepatitis C 
induce/upregulate the expression of HLA molecules in the liver allograft 
(particularly class II expression in endothelial cells, biliary cells and 
hepatocytes)[92-93], leading to or increasing DSA production and consequently 
antibody-mediated injury[12,58,94]. This mechanism explains why acute AMR 
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can improve with treatment not specifically directed at antibodies, since the 
decrease in inflammation downregulates the expression of class II HLA in the 
liver[12,58]. 
 Chronic AMR normally manifests as an indolent injury, with low-grade 
lymphoplasmacytic inflammation in portal and perivenular sites, subclinical 
progressive fibrosis in patients with normal/mildly abnormal liver biochemistry, 
and with variable C4d positivity on immunohistochemistry[58,95-96].  Chronic 
AMR in the liver allograft is likely to be more prevalent than previously 
thought[28,95]. 
 In 2016, the Banff group first proposed diagnostic criteria for chronic 
AMR in liver allografts. Similar to acute AMR, diagnosis was based on DSA, 
C4d, histology and exclusion of other injuries[53]. However, in comparison with 
the diagnostic criteria for acute AMR, the histological parameters of chronic 
AMR are less specific and less well validated, making this diagnostic 
challenging[88]. The range of pathological manifestations and consequences of 
potential AMR in patients with chronic liver injury is in need of additional 
study[28,97].  
 C4d is a complement split product whose presence marks activation of 
the classical/lecithin pathway of the complement cascade. It is an established 
marker of AMR in kidney and heart transplantation[99]. The fact that C4d binds 
to tissue near the spot of activation, by a covalent bond that does not normally 
break, make this marker suitable for recognition through 
immunohistochemistry in transplantation[99]. However, the sensitivity of C4d 
immunohistochemistry in formalin-fixed, paraffin embedded (FFPE) biopsy 
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specimens as a marker of antibody-mediated damage is lower outside of the 
early acute AMR setting[58,98-99].  
 The inclusion of C4d immunostaining in the transplantation setting 
allowed direct visualization of the link between DSA and tissue injury at places 
where antibodies bind in grafts. This produced growing interest in antibody-
mediated mechanisms and their involvement in rejection[100]. C4d might also 
work as a biomarker to help identify patients at risk of antibody-mediated 
injury/disease in other contexts, such as autoimmune diseases and 
pregnancy[100]. 
 Tissue immunostaining for C4d is currently required for the diagnosis 
of AMR in all solid organ allografts. Nevertheless, its functional significance 
and diagnostic utility in the liver transplantation have never been as well 
established as in cardiac and renal allografts[21,101]. Some studies have 
questioned the reliability of C4d in fixed tissue sections and suggested that 
immunofluorescence (IF) on frozen tissue should be the gold standard[102]. 
However, in most centres, only FFPE tissue sections are available for 
immunostaining. Other authors have described different patterns of C4d 
positivity to be associated with AMR[55,97,103]. 
 A recent multicentre study on C4d staining of FFPE liver graft biopsies 
found that strong, diffuse C4d staining in portal veins and portal capillaries was 
recognisable in typical cases of acute AMR[98]. Nonetheless, this study only 
included gold standard cases: typical acute AMR leading to graft failure within 
the first month post-transplantation. The performance of C4d staining in cases 
of AMR outside of the classical early acute context has not been properly 
approached[88,98,104].  
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 The process of AMR involves activation of B cells and plasma cells, 
which produce antibodies that bind to HLA (and less frequently non-HLA) 
molecules present in the graft[56,88,105]. Acutely, these antibodies lead to 
complement fixation, causing tissue damage and coagulation, and activation 
of complement also stimulates macrophages and neutrophils which further 
injure the endothelium[55,61]. Moreover, antibodies and complement seem to 
induce gene expression in endothelial cells, causing arteries and basement 
membrane remodelling that results in permanent anatomical damage and 
compromise graft function irreversibly[61]. 
1.1.3 B cells, plasma cells and a possible local role 
 At present, little is comprehended about the role of B cells in native and 
grafted liver, probably due to the small number of resident B cells in healthy 
liver and the consequent difficulty of experimentally isolating and analysing 
them[106]. B cells mature in the bone marrow, and their activation, 
differentiation and proliferation happen inside lymphoid follicles in secondary 
lymphoid organs, including lymph node, tonsil, spleen, and mucosal lymphoid 
tissue[107-108]. 
 The classical role attributed to B cells is participation in humoral 
immunity. The process starts when B cells inside lymphoid follicles are 
activated by antigens, receive T-cell help, form germinal centres and 
differentiate into plasma cells that secrete antibodies, or into memory B-
cells[108]. More recent studies have suggested antibody-independent roles for 
B cells, including secretion of inflammatory cytokines, antigen presentation 
and regulation of T cells and dendritic cells[109].  
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 The research of Novobrantseva et al.[110] on liver regeneration following 
acute injury found that B cells were required for the development of fibrosis, 
and B cell–deficient mice had markedly reduced collagen deposition 
compared to controls. Interestingly, the effects of B cells on liver fibrosis were 
antibody-independent, as mice with normal B cells but no immunoglobulin had 
similar collagen deposition as controls. T cells did not have a role in that 
particular model of liver fibrosis, as T cell-deficient mice showed similar fibrosis 
as the control group[110]. Thus, the role of B cells in liver fibrosis seems to be 
mediated by local mechanisms.   
 A link between B cell activation and fibrosis has also been verified in 
humans with systemic sclerosis. Characteristic B lymphocyte gene signatures 
were found in skin biopsies of patients with this disease[112]. Abnormally 
enhanced B cell proliferation was also demonstrated in lung tissue affected by 
systemic sclerosis[113].  Additionally, a study demonstrated that human B cells 
can express granzyme B (GrzB) after stimulation (vaccination) with viral 
antigens[114]. 
 The GrzB molecule consists of a cytolytic granule protein with 
proapoptotic effects, classically associated with effector cells such as CD8+ T 
cells and natural killer (NK) cells, and it had not previously been observed in 
B lymphocytes. It was postulated that expression of GrzB by B cells 
corresponded to a mechanism for an early immune response to certain viral 
infections, capable of inducing viral cell death, while T cells are still being 
recruited[114]. GrzB-secreting B cells were also found to induce tumour cell 
apoptosis by delivering GrzB to neoplastic cells. Additionally, roles alternative 
to apoptotic have been attributed to granzymes, such as matrix degradation 
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or remodelling[114-116]. These extracellular functions could explain the 
relationship between B cells and fibrosis. 
 A recent study found that the majority of plasma cells in human tonsils 
express GrzB[117-118]. Through immunofluorescence, the authors verified both 
immunoglobulin and GrzB expression in different cellular compartments within 
the same plasma cell. This finding could potentially reflect a local role for 
plasma cells, challenging the traditional idea that these cells only act by 
secreting antibodies that act remotely. 
 Plasma cells have classically been considered essentially as a short-
lived end-stage product of the B cell differentiation line[108]. This idea is 
changing, as plasma cells have now been shown to live for long periods of 
time in appropriate survival niches such as inflamed tissue, lymphoid organs 
and bone marrow, and they play a role in immunological memory. This means 
that plasma cells present in damaged liver grafts are capable of surviving for 
long periods and could possibly have local roles besides producing 
antibodies[108]. Although it has been hypothesized that the presence of B cells 
and particularly of plasma cells may be implicated in the development of 
fibrosis associated with IPTH in liver grafts[18], this relationship has not been 
investigated.  
1.1.4 New technologies 
 Currently, biopsy assessment represents the gold standard method for 
evaluation of liver allograft health. It is particularly important to detect 
subclinical injuries such as inflammation and fibrosis, and to direct the 
management of immunosuppressive therapies[13,119-121]. Several technologies 
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are emerging as important complementary tools in the study of hepatic 
pathology, such as multiplex staining with Quantum dots, microarray high 
throughput gene expression profiling and more recently, next generation RNA-
sequencing. 
 These new methods have the potential to greatly improve the 
information that can be obtained from histology[122]. Furthermore, they can 
help understand the immunological mechanisms of tissue injury and of 
allograft acceptance and will eventually be incorporated into the routine 
histology workflow and very likely exert a transformative impact in the field [122]. 
In the last decade, quantum dots (Qdots) have increasingly been used 
in histology. Qdots are non-organic fluorophores that consist of semiconductor 
nanocrystals with singular optical properties in comparison to organic 
fluorophores(Tholouli, 2008 #72). They have exceedingly high fluorescence 
efficiency, wide excitation range of wavelengths and narrow, symmetric 
emission spectra due to their defined crystalline structure[123]. Because most 
atoms in each Qdot crystal are excited simultaneously, the result is a strong 
emission signal. 
The advantages of quantum dots over conventional fluorophores used 
in routine immunofluorescence include brighter emission signals, minimal 
photobleaching, and the ability to permanently mount and store the slides 
conventionally without significant signal loss[16,123-124]. These distinctive optical 
properties make them near-perfect fluorescent markers, and there has been 
rapid development of their use for bioimaging[16,124]. Furthermore, the ability of 
Qdots to be conjugated to a variety of biological targets, such as antibodies 
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conventionally used for immunostaining, is of particular relevance to histology 
research[124].  
All these features have attracted increasing interest over recent years 
in the use of Qdots. In particular, their narrow emission wavelength enables 
the combination of various distinctive Qdots to different antibodies, thus 
allowing multiplex immunostaining for quantification and co-localization of up 
to 5 antigens simultaneously in a single tissue section[16,123]. This is a key 
advantage of Qdots when compared to conventional immunohistochemistry, 
which usually allows quantification of one or two antigens per tissue section. 
It is particularly useful for classifying and quantifying different cell populations 
in a biopsy. 
 A recent study observed that, in addition to superior brightness and 
photostability when compared to organic fluorophores, Qdots show less 
autofluorescence due to the lower wavelength excitation needed to obtain a 
signal[125]. These fluorophores are both sensitive and specific, even for tissues 
usually viewed as problematic due to high autofluorescence, such as liver and 
kidney[125]. The research concludes that Qdots, with an appropriate light 
source and detection system, may be the best choice for multiplex 
immunostaining and quantification of molecular signals on FFPE tissue 
sections[125]. 
 Genetics and molecular biology have also undergone a massive 
revolution in the past few decades. Progress in chemistry and engineering 
have enabled faster and more accurate study of large sets of genes and their 
products through techniques such as genomics, transcriptomics, 
metabolomics and proteomics[126]. The development of high-throughput 
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technologies and matching computational analyses have led to important 
changes in gene expression studies, which have expanded from the 
measurement of few transcripts at a time to the analysis of whole genome 
transcriptomes[127].  
 In the last decade, microarray technology has been used to study 
transplantation, research T-cell mediated acute rejection and chronic rejection, 
and identify the gene signatures of operational tolerance[128]. The aim of 
microarray studies is to compare gene expression between two different 
groups with a single difference (rejection versus no-rejection), and results may 
be used to predict which patients might have a particular outcome/condition 
(i.e, rejection, tolerance) based on their gene expression profile[128-129]. 
 Microarray experiments provide expression levels for thousands of 
genes, generating vast amounts of data. The complexity of the resulting data 
is due both to the high number of genes evaluated per sample and to the 
disparity between the number of genes and relatively small number of samples 
usually analysed in most experiments[126,128]. These complex datasets cannot 
be properly analysed using traditional comparative statistics and require 
appropriate bioinformatics/biostatistics knowledge, team work, and familiarity 
with relevant software to ensure good criteria for quality control, classification, 
normalization, clustering and pathway analysis[128]. The conventional p value 
for reliability is replaced by q-value (called false discovery rate, FDR), another 
adjustment necessary for the analysis of high-dimensional datasets that takes 
into account the problems posed by multiple hypothesis testing[126]. 
 Microarray has produced significant data in transplantation research 
and has been the main method for profiling large-scale gene expression until 
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a few years ago. Nevertheless, this technology has limitations, including the 
requirement for previous knowledge about genome sequences, high levels of 
background noise due to cross-hybridization and the limited dynamic scope of 
gene detection (it is easier to detect signals from highly expressed genes) 
because of signal background and saturation. Additionally, the comparison of 
levels of gene expression between different experiments is challenging with 
the data requiring complicated normalization[129]. 
 The more recent emergence of next-generation sequencing (NGS) 
technologies, particularly RNA sequencing (RNA-Seq) for mapping and 
quantifying transcriptomes (complete sets of transcripts in a cell), has clear 
advantages over microarrays and is likely to further revolutionize 
transcriptomic analysis[127,129-130].   
 In RNA sequencing, small RNA fragments are isolated and purified and 
then converted to a library of cDNA fragments with adaptors attached to the 
end or both ends of each fragment[127,129]. The cDNA molecules in the library 
are identified by high-throughput sequencing and overlapping short 
sequences are obtained. These resulting reads are aligned with a reference 
genome or transcriptome to produce a base-resolution profile of expression 
for each gene. They can also be assembled de novo in order to create a 
genome-scale transcription map containing the structure and expression level 
of each gene[127,129]. The sequencing process involves millions of parallel 
reactions, and RNA-Seq allows fast sequencing of large sections of RNA or 
DNA covering entire genomes[131].  
  The advantages of RNA-Seq over microarray include higher reliability, 
higher specificity, more effective detection of rare or low abundant transcripts, 
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larger dynamic range (it can quantify small sequencing reads), unbiased 
recognition of new transcripts (since there is no need for transcript-specific 
probes), and elimination of the risk of probe design errors, which are 
reasonably common in microarray[128-129].  In fact, RNA-Seq represents the first 
sequencing-based technology which enables examination of the entire 
transcriptome in a highly automated and quantitative way[129]. 
 The technical advances in the last years have also enabled complex 
molecular analysis of suboptimal biological material, such as formalin-fixed, 
paraffin-embedded biopsy specimens. Currently, next-generation 
technologies, including RNA-Seq, can be effectively applied to archival 
diagnostic FFPE tissue. Two recent studies have analysed human FFPE 
biopsy specimens of prostate cancer using two different gene expression 
platforms (Ion AmpliSeq Transcriptome Human Gene Expression Kit and 
Affymetrix Human Exon 1.0 ST GeneChip). They demonstrated that very small 
quantities of RNA (a few nanograms) obtained from FFPE diagnostic biopsy 
specimens can generate high-quality data enabling successful gene 
expression profiling[132-133]. Other recent studies have also successfully 
analysed gene expression in human tissue obtained from FFPE sections using 
Ion AmpliSeq gene expression platform[134-137]. 
 Londoño et al. recently studied protocol biopsies of adult liver recipient 
grafts that were more than 10 years old, and were able to correlate histology 
with molecular analysis[138]. The gene expression profiling was assessed using 
RNA-Seq (Ion AmpliSeq platform) on RNA obtained from recipient FFPE liver 
biopsies.  The authors found that inflammatory subclinical injury, which was 
present in 67% of patients, was associated with gene expression profiles 
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indicating TCMR. More specifically, portal inflammation, interface hepatitis and 
portal fibrosis were correlated with up-regulation of genes previously known to 
be associated with TCMR molecular pathways. Interestingly, the patients who 
had the highest levels of rejection-related genes developed progressive graft 
fibrosis during follow-up. However, fibrosis during follow-up was measured 
indirectly through transient elastography, not on biopsy. 
1.2 Research gap 
 A review of the literature indicated a need for further research on long-
term histological changes in liver allografts, particularly idiopathic post-
transplant hepatitis and fibrosis. Study is needed to clarify correlation of these 
conditions with circulating DSA, tissue C4d staining and gene expression 
patterns. Moreover, while it is documented that IPTH is associated with fibrosis 
and potentially leads to allograft failure, there are few if any studies 
investigating patterns of injury in failed liver grafts removed at 
retransplantation that gauge the impact of IPTH. There is also a shortage of 
research analysing specific inflammatory cell types in long-term liver allograft 
biopsies (such as T cell subsets, B cells and plasma cells) and correlating 
those with histological parameters and signs of humoral injury. While a 
potential local role for B cells and plasma cells is indicated, expression of 
granzyme B by these cells has not yet been investigated in human liver.  
Finally, there has been growing interest in DSA in liver transplantation, but the 
effector role of these antibodies in mediating acute and chronic graft damage 
remains contentious in the liver allograft. Despite advances in the use of RNA 
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sequencing in transplantation, there are no studies using next-generation 
sequencing to investigate gene expression patterns in liver recipients with and 
without DSA. 
1.3 Research Hypothesis 
 DSAs have a pathogenic role in acute and chronic liver graft injury; 
AMR is involved in the development of idiopathic post-transplant hepatitis and 
graft fibrosis leading to graft failure, and possibly in some cases of T-cell 
mediated rejection. B cells and plasma cells may have a local role linked to 
the development of graft fibrosis. Gene expression analysis could deliver 
greater understanding of long term liver graft injury. 
1.4 Research aims 
An opportunity to study liver transplantation histology in patient cohorts 
at King’s College Hospital prompted research based on the above discussion. 
The following research aims were defined: 
• Investigate whether idiopathic post-transplant hepatitis can progress to 
liver allograft failure 
• Characterise long-term protocol biopsies histologically, including the 
inflammatory cell population, and correlate histological parameters with 
DSA and C4d 
• Verify whether the associations present in protocol biopsies are also 
present in for-cause biopsies with rejection 
• Investigate expression of granzyme B by B cells and plasma cells 
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• Analyse whether the presence of DSA, or association with tissue C4d 
staining, is linked with specific histological findings and molecular 
profiling in the context of T-cell-mediated rejection and of long-term 
subclinical graft damage. 
1.5 Studies on three liver transplant patient cohorts 
 The current chapter introduced the research hypothesis and aims of 
this study, based on a review of the literature. The subsequent research 
involved three distinct patient cohorts, approached using different methods 
and showing distinct results, therefore a specific chapter is dedicated to each 
cohort, with respective methods, results and discussion (Chapters 3-5).  
Chapter 2 consists of a study on the causes of allograft failure based 
on liver recipients who underwent retransplantation at King’s College Hospital 
over a period of 27 years. Chapter 3 contains a detailed study of long-term 
liver protocol biopsies of children, emphasizing AMR and the link between 
inflammation, fibrosis, DSA and C4d. Chapter 4 is a study of for cause biopsies 
with rejection and compares histology, DSA and gene expression. 
 In Chapter 5, the connections between the three study cohorts are 
discussed and final considerations and conclusions made. The final sections 
are: Bibliographic References and Personal Bibliography. 
1.6 Ethical approval 
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 Ethical approval was obtained to use archival FFPE liver biopsies from 
King’s College Hospital patients from the National Research Ethics Service 
Committee London: King’s College Research Ethics Committee REC 
05/Q0703/239. For DSA testing, liver recipients’ serum samples from the 
Institute of Liver Studies paediatric biobank were used.  Biobank samples are 
obtained with appropriate consent in place for clinical and research use. 
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2 FAILED LIVER ALLOGRAFTS 
2.1 RATIONALE FOR STUDYING EXPLANTED ALLOGRAFTS  
The first stage of the current research consisted of investigating the 
causes of graft failure leading to retransplantation from the histological 
perspective, and to examine possible changes in histology with the evolution 
of clinical care and immunosuppression throughout the years. An analysis of 
failed allografts was made, because they represent the endpoint of several 
pathogenic processes affecting the transplanted liver and because the amount 
of tissue available allowed a more detailed and accurate histological 
assessment in comparison to needle biopsies. A review was made of the 
histology of all liver allografts that were removed at retransplantation at King’s 
College Hospital, in a period from the beginning of the transplantation 
programme in 1987 until 2014. This study has been published in Clinical 
Transplantation in 2017[139]. 
2.2 MATERIAL AND METHODS  
2.2.1 Patients and Data 
The first study was drawn from all patients submitted to liver 
retransplantation at least once at King’s College Hospital from January 1987 
to April 2014. The initial selection was made using the Institute of Liver 
Studies[139] histology electronic database, which allows searching of 
histological reports by specimen type. Because the electronic records were 
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introduced from 2000, the histology paper archive was also searched for 
histological reports of grafts removed from 1987 to 1999. To ensure all failed 
allografts were included, another researcher examined the paper files 
independently. In order to ensure accuracy of the data retrieved, the 
information from the histology reports was compared with the Liver Transplant 
Coordinator’s list of liver recipients. Additional information was retrieved as 
necessary using the Electronic Patients Records (EPR) and the Institute of 
Liver Studies Clinical Electronic Database (Liverware).  Histological slides 
were reviewed by two pathologists (L.N.S. and A.Q.) in those cases without a 
well-defined diagnosis or with conflicting histology and clinical information. 
The following clinical data on each patient/graft was included: 
recipient’s gender and age, reason for primary transplantation and 
retransplantation, time spent between the primary and subsequent 
transplant(s) and the date of regraft.  All liver recipients who were at least 17 
years old at the time of the primary transplant were considered adults, and 
those who were younger, children. In order to examine possible changes in 
the histology of failed grafts over the years, the study was divided into three 
eras: era A, from 1987 to 1994; era B, from 1995 to 2001  and era C, from 
2002 to 2014. The division into eras was intended to reflect progress in 
immunosuppression as well as the centre’s increasing expertise in LT. 
In the first era, the initial standard immunosuppressive regime in adults 
and children was cyclosporine, azathioprine and steroid. The latter was 
withdrawn 3 months following transplantation in adults in all eras, except in 
those patients with primary autoimmune liver disease. In the second era, adult 
recipients received cyclosporine or tacrolimus, according to aetiology of liver 
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disease or involvement in a randomised controlled trial, and steroid for 3 
months (or indefinitely for patients with autoimmune disease). In both eras B 
and C, paediatric patients were given tacrolimus and steroid, and the dose of 
steroid in children was reduced to 0.01mg/kg after 3 weeks of transplantation. 
In era C, adult recipients received tacrolimus, and 3 months of steroids (Table 
2). Specific antibodies were used electively in eras B and C in approximately 
20% of patients. The following drugs were used on individual cases: 
mycophenolate, sirolimus, basiliximab, anti-thymocyte globulin (ATG), and a 
bolus of high-dose corticosteroid followed by mono/polyclonal antibodies. 
 
Table 2. Standard immunosuppression in each era in adults and 
children 
Era Adults Children 
A (87-94) CsA + AZA (+ 3 months of steroid)* CsA + AZA + steroid 
B (95-01) CsA + AZA or TAC (+ 3 months of steroid)* TAC + steroid 
C (02-14) TAC (+ 3 months of steroid)* TAC + steroid 
    CsA, cyclosporine; AZA, azathioprine; TAC, tacrolimus 
 
* Steroid was continued indefinitely in adult recipients who underwent 




For each failed allograft removed at retransplantation, the complete 
histological report was reviewed. The report included the pathologist’s 
macroscopic and microscopic description of the specimen, diagnosis and 
comments. The latter usually consisted of the link that the pathologist had 
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made between histological findings and clinical setting, questions and 
requests for further information and/or suggestions for other conditions to 
investigate. 
Failed grafts were classified into one of the following categories: 
Hepatic artery thrombosis: clinical diagnosis of hepatic artery thrombosis, 
documented by imaging, and compatible histology;  Chronic rejection: 
histology showing chronic ductopenic rejection fitting the Banff criteria[165];  
Acute rejection
[166]: acute TCMR on histology meeting the Banff criteria[167];  
Recurrent: clinically recurrent primary liver disease and corresponding 
histology;  Primary non-function (PNF): early graft failure and acute liver 
injury histologically with no recognizable technical or immunological aetiology;  
Biliary: clinical diagnosis of cholangiopathy documented by imaging and 
confirmed histologically without concomitant hepatic artery thrombosis 
(ischaemic cholangiopathy secondary to HAT was considered into the HAT 
category);  Miscellaneous: graft loss for a well-defined condition that did not 
fit into one of the previous categories, such as venous thrombosis, 
haemorrhage leading to ischaemia, post-transplant lymphoproliferative 
disorder and liver abscesses with biliary sepsis combined to hepatitis B 
recurrence;  Unknown: idiopathic graft failure despite review of histological 
and clinical data; IPTH: cases clinically labelled as chronic graft dysfunction, 
with histology showing unspecific, mostly lymphocytic inflammation and 
concomitant fibrosis (at least bridging/Ishak stage 3), with no obvious aetiology 
for the graft injury despite review of clinical records and biopsy slides. These 
cases were not classified into the unknown category because they shared a 
particular pattern of damage, distinct from the other grafts in that category. 
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The histology of these grafts was further examined by reviewing both the 
explanted grafts and previous biopsies from those patients.  
2.2.3 Statistical analysis 
 Data were analysed statistically using SPSS version 23.0 (IBM Corp, 
2015). Continuous variables were presented as median and range whilst 
categorical variables were presented as number and percentage. The Fisher’s 
exact test was used to compare categorical variables.  
2.3 RESULTS 
The number of primary liver transplants performed in King’s College 
Hospital between January 1987 and April 2014 was 4236, of which 3298 were 
in adult and 938 in paediatric recipients. The number of primary 
transplantations in each era was 741 (era A), 1198 (era B) and 2297 (era C). 
In total, 8.4% of adults (276) and 12.6% of children (118) experienced 
successive liver transplantation at least once, receiving 460 allografts. The 
overall rate of retransplantation remained constant through the eras (10.8%), 
with 80, 130 and 250 regrafts in eras A, B and C respectively. The average 
adult recipient age at retransplant was 44.7 years, and average paediatric age 
6.8 years.  Recipients were half male, half female with a few extra male at 
55.5% and 50.7% of adults and children, respectively. 
Overall, hepatic artery thrombosis was the main indication for 
retransplantation in adults (28.8%) followed by liver disease recurrence 
(21.8%) then chronic rejection (16.5%, Table 3). In paediatric recipients, the 
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leading reasons for subsequent transplantation were, again, hepatic artery 
thrombosis (28.8%), but then chronic rejection (18.7%) followed by biliary 
complications (12.9%) (Table 4). The proportion of retransplantation for other 
indications in adults and children are detailed in Table 3 and Table 4, 
respectively.
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Table 3. Indications  for  retransplantation  in  adults	
INDICATION Era A, n (%) Era B, n (%) Era C, n (%) Total, n (%) 
HAT 9  (15.3) 24  (26.7) 62  (36.1) 95 (29.6) 
Recurrent 11  (18.6) 26  (28.9) 33  (19.2) 70  (21.8) 
CR 21  (33.9) 12  (13.3) 20  (11.6) 53  (16.5) 
PNF 2  (  3.4) 10  (11.1) 15  (  8.7) 27  (  8.4) 
Miscellaneous 5  (  8.4) 8  (  8.9) 14  (  8.1) 27  (  8.4) 
Unknown 9  (15.2) 3  (  3.3) 9  (  5.2) 21  (  6.5) 
IPTH 0  (  0  ) 3  (  3.3) 11  (  6.4) 14  (  4.4) 
Biliary 1  ( 1.7) 4  (  4.4) 5  (  2.9) 10  (  3.1) 
ACR 1  ( 1.7) 0  (  0   ) 3  (  1.7) 4  (  1.2) 
Total 59  (18.4) 90 (28.0) 172  (53.6) 321  (100) 
HAT, hepatic artery thrombosis;  CR, chronic rejection;  PNF, primary non-
function;  IPTH, idiopathic posttransplant hepatitis;  ACR, acute rejection; n,  
number of retransplantation;  %, percentage of retransplantation.	
 
Table 4 (below). Indications  for  retransplantation  in  children 
INDICATION Era A, n (%) Era B, n (%) Era C, n (%) Total, n (%) 
HAT   2  (  9.5) 14     (35.0) 22    (28.2) 40    (28.8) 
CR   5  (23.8) 11     (27.5) 10    (12.8) 26    (18.7) 
Biliary   3  (14.3) 4    (10.0) 11    (14.1) 18    (12.9) 
Unknown   4  (19.0) 3      (7.5) 7     ( 9.0) 14    (10.1) 
Miscellaneous   2  (  9.5) 4    (10.0) 8    (10.3) 14    (10.1) 
IPTH   0  (     0) 1      (2.5) 11    (14.1) 12    ( 8.6) 
PNF   3  (14.3) 2      (5.0) 4     ( 5.1) 9    ( 6.5) 
ACR   2  (  9.5) 1      (2.5) 2     ( 2.6) 5    ( 3.5) 
Recurrent   0  (    0) 0         (0) 3    ( 3.8) 3    ( 2.2) 
Total 21 (15.1) 40    (28.8) 78   (56.1) 139    (100) 
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HAT, hepatic artery thrombosis;  CR, chronic rejection;  IPTH, idiopathic posttransplant 
hepatitis;  PNF, primary non-function;  ACR, acute rejection;  n,  number of 
retransplantation;  %, percentage of retransplantation. 
 
Further examination was then made of the two diagnostic categories without an 
obvious reason for retransplantation: unknown and IPTH.  In the unknown group, 94% 
of the cases (91% of the adults and all the children) presented clinically with acute 
graft dysfunction, usually in the first weeks post-transplant, frequently referred as non-
thrombotic infarct. Histologically, all allografts displayed areas of infarction, usually 
confluent, in the absence of vascular thrombosis, except in two cases (one had 
thrombus in large portal vein and hepatic artery branches and the other showed 
thrombosis of small veins in the hilum). 
Concomitant acute rejection was present in half (49%) of the patients with acute 
unknown graft failure. In 30% of allografts, the centrilobular region was reported as 
the main site of graft injury (centrilobular cell loss/coagulative necrosis). In a third of 
patients (36%), AMR was considered in the differential diagnosis but was not 
established. These cases in particular presented as an acute graft failure in the early 
post-transplant period and showed massive necrosis and/or obvious arteritis 
accompanied by moderate to severe cellular rejection. 
The remaining minority of cases in the unknown category (5.7%) presented 
clinically with a chronic graft dysfunction whose cause was not clear after histological 
examination. Histological findings of their explants included perivenular and bridging 
cell loss and congestion without fibrosis, thick fibro-adipose adhesions at the liver 
surface, ischaemic changes, and in one case, vascular changes indicating chronic 
rejection without associated bile duct injury/loss. 
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With regards to the failed allografts in the IPTH category, all exhibited a 
mononuclear inflammatory cell infiltrate on histology, which affected portal tracts, 
interface and sometimes also centrilobular areas (Figure 8). Two-thirds (65%) of the 
allografts in this category already had advanced-stage fibrosis with features of 
cirrhosis[168], whilst a third (35%) had bridging fibrosis without advanced nodular 
transformation. These failed allografts showed different degrees of inflammatory 
activity, plasmacytosis, cholestasis and pericentral fibrosis (including centro-central 
bridging). 
Injury to small or large intrahepatic ducts, portal or centrilobular venular 
endothelium and/or foamy cell arteriopathy were not present, and the overall 
histological picture was dominated by fibrosis, variable degrees of architectural 
distortion and chronic hepatitis. There were no specific histological or clinical features 
to allow diagnosis of specific aetiologies for the process of graft deterioration. Hepatitis 
E, however, was not tested in many cases and could not be tested retrospectively. 
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Figure 2.  Failed liver graft, removed 18 years posttransplant for biliary atresia.  
Bridging fibrosis with parenchymal nodular transformation and chronic porto-septal 
hepatitis (H&E, 100x). 
The analysis of previous biopsies of grafts with IPTH revealed that, besides 
portal inflammation, most paediatric recipients had former  central perivenulitis (75%) 
and perivenular fibrosis (58%). In adults, the percentage of central perivenulitis was 
33%, and perivenular fibrosis 25%. Nonetheless, 50% of adults’ grafts already showed 
advanced stage fibrosis at the time of the first posttransplant biopsy. In these cases, 
the initial target of the fibrosing process could not be established. By the time of graft 
removal, 58% of children and 75% of adults in the IPTH hepatitis category showed 
advanced stage fibrosis.  
Considering the eras: the contribution of chronic rejection as a reason for 
retransplantation decreased steadily in adults, from 34% to 13% and 12% in eras A, 
B and C, respectively (Figure 3).  On the other hand, IPTH hepatitis, which was not an 
indication for regraft in adults in the first era, accounted for 6.4% of the graft failures 
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in the last era. Hepatic artery thrombosis also increased as a reason for subsequent 
transplantation, from 15.3% to 26.7% and 36% in eras A, B and C respectively. The 
difference in proportion of transplantation for these causes across the 3 eras were 
statistically significant (p<0.001, Fisher’s exact test). 
The percentage of paediatric retransplantation for chronic rejection increased 
from 24% in the first to 28% in the second era, and then dropped to 13% in the last 
era.  Similar to the adult group, IPTH hepatitis also showed a consistent rise in 
children, from none in the first era to 2.5% and 14% of explanted grafts in eras B and 
C, respectively, becoming the second leading indication for retransplantation in era C, 
together with biliary complications (Figure 4). Hepatic artery thrombosis accounted for 
9.5% of paediatric retransplantation in era A and 28% in era C, being the main reason 
for regraft in era C. The difference in proportion of transplantation for these causes 




Figure 3.  Indications  for  retransplantation in adults.  ACR, acute rejection;  Bil, 
biliary;  CR, chronic rejection;  IPTH, idiopathic posttransplant hepatitis;  HAT, hepatic 
artery thrombosis;  Misc, miscellaneous;  PNF, primary non-function;  Rec, recurrent 
liver disease;  Unkn, unknown. 
 
 
Figure 4.  Indications  for  retransplantation  in  children.  ACR, acute rejection;  
Bil, biliary;  CR, chronic rejection;  IPTH, idiopathic posttransplant hepatitis;  HAT, 
hepatic artery thrombosis;  Misc, miscellaneous;  PNF, primary non-function;  Rec, 
recurrent liver disease;  Unkn, unknown.  
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 The survival of liver recipients and allografts following transplantation has 
generally increased through the years (Chapter 1). This has resulted in growing 
interest in long-term graft pathology and histological damage, particularly in paediatric 
recipients, whose allografts should ideally last many decades after 
transplantation[14,19,21,23-24,39,170]. Considering the long-term outcome, and in order to 
reflect the current clinical and surgical practice, allografts removed 10 years or longer 
after the primary LT in the most recent era (era C) were examined (Table 5). In adult 
patients, recurrent liver disease accounted for just over half of late graft failures (54%). 
The following main indications were IPTH and hepatic artery thrombosis, each 
representing about one-fourth of retransplants. 
 In paediatric liver recipients, IPTH was the leading reason for late 
retransplantation in the last era, responsible for 40% of regrafts. Biliary complications 
accounted for 20% and chronic rejection for 15% of cases. Two children underwent 
retransplantation for recurrent liver disease. They were both initially transplanted for 
primary sclerosing cholangitis (PSC), had a clinical history and cholangiography 
compatible with recurrent PSC, and their graft histology was highly consistent with 
primary disease recurrence (both patients showed chronic cholangiopathy with 
cholangitis, ductopenia of small bile ducts, cholestasis, biliary-type bridging fibrosis). 
 
Table 5. Indications for retransplantation in era C >10 years post-LT  
INDICATION ADULTS,  n (%) CHILDREN,  n (%) 
Recurrent 14  (54) 2  (10) 
IPTH 5  (19) 8  (40) 
HAT 4  (15) 2  (10) 
Miscellaneous 2  (8) 1  (5) 
Biliary 1  (4) 4  (20) 
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CR 0  (0) 3  (15) 
Total 26 (100) 20 (100) 
 IPTH, idiopathic posttransplant hepatitis;  HAT, hepatic artery thrombosis; 
CR, chronic rejection 
 
Average time elapsed between primary and successive transplantation for each 
indication, in all eras, was analysed (Table 6). IPTH showed the longest time to 
retransplantation in children (10.8 years). In adults, recurrent autoimmune liver 
disease and IPTH presented virtually the same longest time to regraft (8.8 years). 
Figure 5 and Figure 6 depict the median and time range from transplantation to 
retransplantation for each indication in adults and children, respectively. In both 
figures, each asterisk signifies an extreme outlier (a value >3 times the interquartile 
range from a quartile), and each circle shows other (non-extreme) outliers, values 
between 1.5-3 interquartile range from the upper or lower edge of the box. 
Table 6. Time to retransplantation 
 
INDICATION 
TIME (median and SD in years) 
ADULTS CHILDREN 
PNF   0.01 (0.006)  0.01 (0.01) 
Unknown 0.03 (0.03)  0.45 (5.45) 
ACR 0.08 (1.38)  0.22 (0.95) 
HAT 0.18 (3.60)  0.07 (3.29) 
Miscellaneous 0.32 (5.00)  3.06 (6.39) 
CR 1.02 (2.81)  0.97 (3.80) 
Biliary 3.13 (3.48)  0.96 (4.78) 
IPTH 8.76 (5.72) 10.82 (3.49) 











SD, standard deviation;  PNF, primary non-function;  ACR, acute rejection;  HAT, 
hepatic artery thrombosis;  CR, chronic rejection;   IPTH, idiopathic posttransplant 




Figure 5. Time to retransplantation per indication in adults. PNF, primary non-
function;  HAT, hepatic artery thrombosis;  ACR, acute rejection;  CR, chronic 




Figure 6. Time to retransplantation per indication in children. PNF, primary non-
function; HAT, hepatic artery thrombosis; ACR, acute rejection; CR, chronic rejection;  




Causes for liver retransplantation were reviewed, focusing on the histology of 
failed allografts. The study benefitted from a large historical series, with biopsies 
available from the foundation of KCH’s transplant program throughout its development 
over 27 years. Analysis showed a change in the histology of the explanted allografts 
during this period and in particular through the three eras defined essentially by 
changes in immunosuppression. The frequency of retransplantation was 8.5% in 
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adults and 13% in children.  In general, the main cause of allograft loss was hepatic 
artery thrombosis, representing over a fourth of explants in both age groups. 
Comparable rates of HAT have been reported by other centres[171-172]. 
The total numbers and proportion of chronic rejection suffered significant 
decrease from the first to the last era in both adults and children, reflecting the change 
in immunosuppressive drugs, especially the introduction of tacrolimus[172-175]. The 
reason for the small increase in the proportion of retransplantation for chronic rejection 
in children from era A to era B (from 24% to 28%) is not clear. While this could be 
explained if many children who lost their allografts in era B had actually undergone 
primary LT in era A, as they would have received cyclosporine as the initial 
immunosuppression; in fact, 82% of children who underwent retransplantation in era 
B also had their primary transplant in that same era. Therefore, no explanation was 
found for this temporarily increase in the rate of chronic rejection in the paediatric 
population in era B. It is also possible that some of these children, despite transplanted 
in era B when tacrolimus was given, might have received cyclosporine, but the lack of 
data on immunosuppression for virtually all patients who underwent LT in eras A and 
B prevented further conclusions.  
Idiopathic posttransplant hepatitis, on the other hand, has gained importance 
over the years, becoming the main cause of late retransplantation in children in the 
last era and accounting for 14% of all graft failures in this age group in era C. This 
histological pattern of injury was more frequent in paediatric recipients than in adults, 
an observation consistent with previous data reporting higher frequency of IPTH and 
fibrosis in children[23,121,170].  As mentioned in Chapter 1, IPTH is a common histological 
finding in long-term protocol biopsies of children, is linked to the development of 
advanced stage fibrosis, and is likely to represent a form of rejection[14,20,23,26,53]. 
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Additionally, some cases of IPTH might be due to viruses[20].  Hepatitis E virus 
(HEV) in particular has been linked to chronic hepatitis and fibrosis in some liver 
transplant recipients[177-178]. Most patients in the present study cohort had not been 
tested for hepatitis E virus, which only became part of the viral screening in specific 
cases in the last era.  At King’s College Hospital, up to present, there have been only 
a few individual liver recipients who showed allograft dysfunction and had positive 
RNA testing for hepatitis E virus in the post-transplant setting, and all of these were 
children. 
The present study on failed liver allografts showed that retransplantation for 
IPTH usually happened more than 8 years and 10 years after primary LT in children 
and adults, respectively. Most recipients had been asymptomatic, with stable liver 
function tests for many years. Biopsy was not performed until graft dysfunction 
became clinically evident. The biopsy then often revealed advanced fibrosis, in a 
background of non-specific chronic hepatitis of the graft.  
Previous studies have reported low sensitivity of standard liver biochemistry 
tests to predict allograft damage, and significant histological injury is frequent in 
protocol biopsies of recipients with normal liver function tests[13,23,120]. The role of 
histopathology in monitoring post-transplant long-term outcome therefore remains 
fundamental, particularly when considering immunosuppression minimization or 
withdrawal[176-178].  
In the current cohort, primary liver disease recurrence, particularly hepatitis C, 
represented the main reason for late retransplantation in adults. It is likely, however, 
that hepatitis C might decrease substantially due to the new generation of antiviral 
drugs that should become more widely available in the next years. Therefore, IPTH 
will possibly become the leading cause of late allograft failure in adults. Graft loss due 
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to hepatitis B recurrence has declined steadily since the start of antiviral therapy and 
immunoglobulin prophylaxis in the 1990’s.   
Increasing evidence indicates that AMR[182] is involved in the pathogenesis of 
liver graft damage and influences post-transplant outcome[21,57,90]. As mentioned in 
Chapter 1, acute AMR in the liver is frequently associated with acute TCMR[59,90]. In 
severe cases of acute AMR, the allograft presents early failure and a histological 
picture similar to marked preservation/reperfusion damage, infarction or haemorrhagic 
necrosis[55]. 
In the current series, 94.3% of the patients in the unknown category (whose 
allografts failed for unidentified reason) developed clinically an acute/subacute liver 
failure and showed histologically extensive areas of infarct or haemorrhagic necrosis. 
Acute TCMR was evident in almost half of these biopsies, and AMR was actually 
ventured by the pathologist in over a third of them. It is possible that AMR could have 
contributed to a proportion of these acute idiopathic graft failures. Furthermore, 
humoral rejection could have also triggered the original endothelial injury that initiated 
the immunological cascade resulting in hepatic artery thrombosis in some patients 
who underwent retransplantation for this reason. 
Unfortunately, DSA test is not routinely performed at KCH but is requested on 
a clinico-histological basis when AMR is suspected. To perform the DSA test 
retrospectively stored serum samples of the patients in this series were sought, but 
most did not have serum available. This lack of systematic DSA data and the 
retrospective nature of the analysis did not allow further comment on the role of AMR 
in the allograft losses in this study cohort. Because of the absence of DSA information, 
C4d immunohistochemistry in the histological specimens was also not performed, as 
C4d should always be interpreted in combination with DSA. The contribution of AMR 
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in cases of acute idiopathic graft loss and hepatic artery thrombosis could be better 
addressed by prospective studies correlating DSA and histology in these settings.  
Humoral mechanisms have also been linked to late idiopathic graft fibrosis, 
particularly in perivenular area in children[28,41,72]. In the present cohort, the review of 
biopsies preceding retransplantation showed perivenular fibrosis in 58% of children 
who had graft failure for IPTH. The diagnosis of chronic AMR in the liver graft is still 
under consideration, and the presence of DSA is a mandatory criterion[53,183]. 
Therefore, diagnosis of chronic AMR could not be confirmed or refuted in grafts that 
failed for chronic fibrosing idiopathic hepatitis. It is likely that graft failure in this group 
(CFH) was secondary to a slowly evolving form of rejection, possibly with a humoral 
component, which progressed throughout several years and eventually led to graft 
dysfunction and loss. 
In summary, by analysing the failed liver grafts explanted during almost three 
decades of KCH’s liver transplantation programme, a change was observed in the 
histological patterns of injury. Idiopathic posttransplant hepatitis, probably 
representing a slowly-progressing phenotype of rejection, represented the main cause 
for late retransplantation in children in the most recent era and was the second most 
likely cause in adults. This highlights the role of protocol biopsy in monitoring liver 
grafts in the long-term. AMR might contribute to the pathogenesis of unexplained 
inflammation and fibrosis, and this needs to be further clarified by studies correlating 
circulating antibodies, detailed histology including C4d immunostaining, and clinical 
parameters. Systematic testing for hepatitis E virus in instances of unexplained 
chronic hepatitis of the graft is recommended. 
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3 PAEDIATRIC PROTOCOL BIOPSIES 
3.1 RATIONALE FOR STUDYING PROTOCOL BIOPSIES 
 In the previous chapter (Chapter 2), the causes of allograft failure were 
investigated and the increasing relevance of IPTH and progressive fibrosis leading to 
allograft loss became evident, especially in the paediatric population. Many children 
had showed normalgraft function and so were not biopsied for many years after LT. 
Only when they presented with abnormal liver biochemistry did they undergo graft 
biopsy, which showed advanced liver fibrosis, and eventually they developed allograft 
failure. 
 This prompted a study of protocol biopsies of asymptomatic liver recipients to 
look for histological abnormalities, specially IPTH and fibrosis, which could be 
predictors of progressive graft injury. Histological features were compared with 
circulating DSA and C4d immunohistochemistry. This could improve understanding of 
the histological changes and of the pathogenic role of antibodies in long-term allograft 
injury, which could not be confirmed in the failed allograft group. 
 Possible associations between lymphocyte subsets and other histological signs 
of graft injury and antibody-mediated rejection were also investigated as well as 
expression of granzyme B by B cells and/or plasma cells. 
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3.2 MATERIAL AND METHODS 
3.2.1 Patients and Data 
Protocol biopsies of liver transplant recipients were located using the histology 
electronic database. Because liver protocol biopsies have not been routinely 
performed at KCH, there were no adult patients who had undergone liver allograft 
protocol biopsies.  In contrast, among the paediatric group, fifty-eight liver recipients 
had had one protocol biopsy several years post-transplant (from 8.6-15.6 years), as 
part of a historical clinical follow-up study. All children undergoing protocol biopsy were 
asymptomatic, and biopsy was performed to ensure that the normal clinical picture 
had a normal histological counterpart. No additional studies had been conducted in 
these specimens other than routine diagnostic assessment by a liver histopathologist.  
Clinical data retrieved for the paediatric patients consisted of: indication for liver 
transplantation; patient date of birth; age at transplantation and at biopsy; type of 
donation - donation after cardiac death (DCD), donation after brain death (DBD) or 
living-donor liver transplantation (LDLT); type of allograft received (whole, split, 
reduced); initial immunosuppressive regime and regime in use at time of biopsy; liver 
biochemistry; previous biopsy-proven episodes of rejection, clinical outcome and 
circulating autoantibodies at the time of biopsy. Liver biochemistry function tests 
included: aspartate aminotransferase (AST) and alanine aminotransferase (ALT); 
bilirubin; gamma-glutamyl transferase (GGT) and alkaline phosphatase (AP); platelet 
counts. 
In addition to histology and clinical data, the donor HLA information was found. 
Then recipient blood serum samples were retrieved to test for DSA; most children who 
underwent protocol biopsy had serum collected at the time of biopsy and stored in the 
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biobank for future research, although some samples had already been used and were 
no longer available. 
3.2.2 DSA testing 
 DSA testing was performed in the laboratory where routine diagnostic samples 
are analysed for antibodies, at Guy’s and St Thomas’s NHS Foundation Trust. 
Samples were retrieved, prepared and sent for analysis by the present author, who 
maintained personal contact with the pathologist responsible for the analysis. 
OneLambda mixed and single antigen bead kits (LABScreen, One Lambda, Canoga 
Park, CA) were used. Initially, a mixed test was performed to screen for the presence 
of antibodies. Then, the single-antigen test was carried out on cases that were positive 
in prescreening, in order to identify specific DSA types and MFI values, as specified 
in the manufacturer’s protocol. Antibodies to HLA A, B, C, DR, DQ and DP were 




 Two pathologists (A.Q. and L.N.S.) reviewed the original hematoxylin and 
eosin (HE)- and reticulin-stained biopsy slides together, made an overall assessment 
and scored a series of histological parameters. The scoring system (Table 7) was 
adapted from that designed for the assessment of long-term biopsies of liver transplant 
recipients participating in the multicentre Liver Immunosuppression Free Trial (LIFT), 
an immunosuppression withdrawal trial led by KCH. 
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Table 7. Histological score for grading and staging of HE and reticulin stained 
biopsies 
 Number of complete portal tracts 
 Number of central veins 
Lobular 
inflammation:   
0, none 
1, mild (sinusoidal cells and/or mild focal necrosis), 
2, moderate (multiple necro-inflammatory foci), 
3, marked (confluent or bridging necrosis);   
CP:   0, none 
1, mild (patchy, focal perivenular inflammation) 
2, moderate (affecting most central veins), 




1, mild (small groups of inflammatory cells in some/all portal tracts) 
2, moderate (expansive inflammatory infiltrate in some portal tracts) 
3, marked (severe inflammation expanding most or all portal tracts) 
Interface hepatitis: 0, none 
1, mild (focal, in few portal tracts) 
2, moderate (focal in most or continuous in a minority of portal tracts) 
3, severe (continuous around most portal tracts)   
Bile duct lesion: 0, none 
1, minimal (intraepithelial inflammatory cells or abnormal 
cholangiocytes) 
2, moderate (epithelial lesions in most portal tracts without 
destruction) 
3, marked (destructive lesions of bile ducts)   
Portal vein 
endotheliitis: 
0, absent  
1, mild (mild inflammation in a minority of portal tracts) 
2, moderate (mild inflammation in most portal tracts or moderate 
inflammation in a minority of portal tracts) 
3, marked (moderate to severe inflammation, in most/all portal 
tracts) 






1, focal at higher magnification (400x) 
2, centrilobular, obvious at 100x magnification 





Steatosis: 0, < 5% of hepatocytes 
1, 5-33% of hepatocytes 
2, 33-66% of hepatocytes 




1, fibrous expansion of a minority of portal tracts, 
2, fibrous expansion of most/all portal tracts without bridging 
3, fibrous expansion of most/all portal tracts with occasional portal-
portal bridging (fibrous septa) 
4, marked bridging fibrosis (portal-portal and/or portal-central) 
5, marked bridging fibrosis with occasional nodules 
6, cirrhosis 
Portal fibrosis 
(Venturi et al)[42]: 
0, none 
1, non-expanding fibrosis in <50% of portal tracts 
2, fibrosis in >50% of portal tracts and/or short periportal septa 
3, portal-portal or portal-central bridging fibrosis, with or without 
nodules   
Sinusoidal fibrosis 
(Venturi et al)[42]: 
0, none 
1, thin focal collagen deposits in <50% of sinusoids 
2, thin diffuse collagen deposits in >50% or thick fibrosis in <50% of 
sinusoids 
3, thick and diffuse fibrosis in >50% of sinusoids 
Centrilobular 
fibrosis (Venturi et 
al) [42]: 
0, none 
1, circular perivenular fibrosis in <50% of central veins without 
invasion into perivenular parenchyma 
2, circular perivenular fibrosis in >50% of central veins or expansion 
into short fibrous septa in perivenular parenchyma 








According to the overall assessment, the biopsies were categorized as 
“normal/minimal changes”, “chronic hepatitis of the graft” or “rejection”. Biopsies 
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classified as chronic hepatitis of the graft showed at least moderate (grade 2) portal 
inflammation, or mild (grade 1) portal inflammation associated with interface activity, 
central perivenulitis and/or with lobular inflammation ³2. Cases with isolated central 
perivenulitis were also considered as chronic hepatitis of the graft. Biopsies with only 
mild (grade 1) portal inflammation were considered normal/minimal changes. The 
diagnosis of rejection was established based on Banff criteria [143].  
Although both Ishak and Venturi et al. staging systems were used to score 
portal fibrosis, in the Results and Discussion sessions of this and the next Chapter 
(chapters 3 and 4), when referring to portal fibrosis, only the Ishak system will be 
considered (unless otherwise specified). Ishak was chosen for scoring portal fibrosis 
because this system provides more detailed information and considers a wider range 
of degrees of fibrosis. 
The threshold considered for portal fibrosis was Ishak ³ 2 (fibrous expansion of 
most portal tracts). Ishak stage 2 was selected instead of stage 1 because the latter 
corresponds to mild fibrosis affecting a minority of portal tracts. The differentiation 
between stage 1 and stage 0 (no fibrosis) can be very subtle, and the expansion of 
only a minority of portal tracts often corresponds to a patchy process, which might 
have no pathological significance and is more prone to sampling variability. 
In stage 2, on the other hand, the fibrous expansion is a more widespread 
process, involving >50% of portal tracts, and differentiation from stage 0 is clearer. 
Stage 2 was selected for cut-off instead of stage 3 also to facilitate the comparison of 
results with previous studies of paediatric protocol biopsies. Most of these studies 
used less detailed fibrosis scoring systems in which the first degree of portal fibrosis 
considered was portal fibrous expansion without bridging/fibrous septa[23,29]. Having 
an experienced liver pathologist performing the histological assessment, familiar with 
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the Ishak score, was essential to ensure consistency of the results. At some points in 
the current research, statistical associations were observed between higher degrees 
of fibrosis and other clinical or histological parameters. In such cases, the threshold of 
fibrosis is specifically stated. 
For sinusoidal and centrilobular fibrosis, Venturi stage ³2 was chosen as the 
threshold for similar reasons. In the sinusoidal fibrosis scoring, stage 1 corresponds 
to thin focal fibrosis in <50% of sinusoids. As with portal fibrosis, this often corresponds 
to a patchy process, more susceptible to sample variability, and of questionable 
significance. Stage 2 sinusoidal fibrosis represents a more widespread/significant 
process (diffuse thin fibrosis in most sinusoids or thick patchy fibrosis). For 
centrilobular fibrosis, stage 1 also refers to patchy fibrosis (in <50% of central areas), 
whereas stage 2 corresponds to a more diffuse/significant process with perivenular 
fibrosis in >50% of central veins and/or expansion into fibrous septa to adjacent 
parenchyma. 
Additional biopsy sections were obtained to perform Sirius Red staining, 
immunohistochemistry for C4d and combined immunostaining for quantifying 
inflammatory cells. 
3.2.3.2 Sirius	Red	
Sirius Red staining was performed by this thesis’ author (L.N.S.) following the 
method routinely used for diagnostic specimens in the Liver Histopathology Laboratory 
of King’s College Hospital. The protocol consisted of eight steps, detailed in Table 8. 
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Table 8. Protocol for Sirius Red staining 
 
*Weigert’s iron haematoxylin was prepared by mixing equal parts of Weigert’s A and Weigert’s 
B solution. Weigert’s A was composed of 0.4g of ferric chloride, 100mL of distilled water and 
0.75mL of hydrochloric acid and Weigert’s B comprised 1g of haematoxylin and 100mL of 
95% ethanol. **Picro-Sirius Red was made by adding 0.5g of Sirius red F3B to 500ml of 
saturated aqueous solution of Picric acid.  ***Acidified water consisted of 2.5ml of glacial acetic 
acid to 500ml of distilled water.  
 
Once staining was complete, the biopsies were digitalized using a brightfield 
slide scanner that produced high-resolution digital images (NanoZoomer-XR Digital 
slide scanner C12000-01, Hamamatsu Photonics, Hamamatsu, Japan). 
3.2.3.3 C4d	immunohistochemistry	
The wide range of protocols for C4d immunohistochemistry in FFPE liver tissue 
is probably responsible for the variability and inconsistency of this staining when 
comparing samples prepared at different times, in different laboratories or with 
different reagents (antibodies). The threshold employed to consider a staining as 
1. Deparaffinize with xylene for 10 minutes 
2. Rehydrate with 100% ethanol, then lower concentrations (70%, 30%), then distilled 
water  
3. Treat with Weigert’s iron haematoxylin* for 10 min to stain nuclei 
4. Wash in running distilled water for 10 min 
5. Treat with Sirius Red solution** for 1 hour 
6. Wash in acidified water*** 3 times 
7. Allow slides to dry, dip in xylene and mount with DPX 
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positive and the scoring system also vary between publications[91,97-98,100,103,140-142]. As 
the antibody initially used in the present research was not producing reliable results, 
a few different primary C4d antibodies were optimized to provide consistent staining. 
Some primary antibodies that showed consistent results in other centres were not 
available for purchase in the UK.  
In a multicentre study[98] including the Liver Histopathology Laboratory of the 
Institute of Liver Studies of King’s College Hospital, liver, kidney and heart allograft 
tissue samples were combined on a single paraffin block using tissue microarray 
(TMA), and the sections were stained for C4d and assessed by pathologists of each 
centre. Correlation between histology and a series of clinical parameters, including 
DSA and outcome, were used to identify the best C4d protocols. The most robust 
automated method identified in the multicentre study was selected for the present 
research.  
The automated immunostainer available to the Liver Histopathology Laboratory 
was a Leica Bond-Max (Leica Biosystems, UK). All reagents (except primary 
antibodies), were part of the recommended Leica Bond-max kit. The staining protocol 
is detailed below, in Table 9. The washing steps were done with TRIS buffered saline 
(Leica Bond wash, Leica Biosystems, UK), and Bond Polymer Refine Detection kit 
was used for detection (Leica Biosystems, UK). A biopsy section of a liver allograft in 
which AMR was diagnosed was included in each batch as a positive control. As all the 
histological procedures in this research, the C4d staining was conducted by L.N.S. 
 
Table 9. Protocol for C4d immunohistochemistry on FFPE liver tissue 
1. Deparaffinization with xylene for 10 minutes 
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2. Heat-induced epitope retrieval (HIER) for 30 minutes with ER2 solution (high pH) 
3. Wash 
4. Protein block for 5 minutes (standard time) 
5. Wash 
6. Incubation with a cocktail of two primary C4d antibodies for 30 minutes: a rabbit 
monoclonal (clone SP91, Cell Marque/Merck KGaA, Darmstadt, Germany), and a 
rabbit polyclonal (Cell Marque/Merck KGaA, Darmstadt, Germany), both diluted at 
1:50 in Leica primary antibody diluent solution 
7. Wash 
8. Incubation with secondary antibody with HRP (horseradish peroxidase) 
9. Wash 
10. Incubation with DAB (3,3' Diaminobenzidine) chromogen 
11. Wash 




Fifty out of the 52 study biopsies were stained for C4d (2 biopsies had too little 
tissue for analysis). The scoring system employed to evaluate the C4d staining was 
the same as that of the multicentre C4d study[98], which considered the distribution and 
intensity of C4d staining independently in each of the following compartments: portal 
vein; portal capillaries; hepatic artery; portal stroma; central vein and sinusoids. 
Because the Banff diagnostic criteria for AMR in the liver requires C4d+ in portal 
microvascular endothelium, which includes portal veins and portal capillaries, the 
category “portal microvascular endothelium” was included to the results. Positive 
staining in “any compartment” was added as a further category for C4d results. The 
system used for grading the distribution and intensity of C4d deposition in each 
compartment is specified in Table 10 below.  
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Table 10.  C4d scoring system 
Grade Distribution Intensity 
0 None None 
1 Minimal (<10%) Weak 
2 Focal (10-50%) Moderate 
3 Diffuse (>50%) Strong 
 
Outside the context of acute AMR, the sensitivity of C4d staining is lower, and 
diffuse C4d deposition is very rare. For this reason, all biopsies with at least focal C4d 
staining in a given compartment were considered as C4d+ (in that compartment). 
 
3.2.3.4 Quantum	dots	and	T	cell	immunostaining	
One of the objectives of this research was to study the inflammatory cell 
population, quantifying specific cell types. These data were to be correlated with other 
histological parameters, including C4d, DSA and clinical data. In particular, a possible 
link between B cells and/or plasma cells and fibrosis was investigated. Multiplex 
staining was used in order to quantify different cell phenotypes in the same tissue 
section.  
Quantum dots (Qdots) have advantages over conventional 
fluorophores/fluorescent dyes, with a narrow emission range allowing the combined 
use of multiple Qdots of different wavelengths for multiplex staining without signal 
overlap (Chapter 1). After studying the use of Qdots in histology, two different methods 
of immunostaining with Qdots were tested:  
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1. applying a conventional primary antibody followed by a Qdots-conjugated 
secondary antibody  
2. labelling the conventional primary antibody with Qdots.  
 The main advantage of the first option was the commercial availability of 
secondary antibodies conjugated with Qdots, and robust results using this method 
had been published[16]. The main disadvantages included the longer time required to 
perform sequential primary-secondary antibody staining (for multiple antigens) and 
the possibility of cross-reaction between antibodies. For instance, a secondary 
antibody could potentially bind to a non-target primary antibody from the same host 
species as its target primary antibody. Although in theory this cross-reaction could be 
eliminated by selecting primary antibodies from different host species and highly 
adsorbed secondary antibodies, when considering a panel of more than 3 antibodies, 
it becomes difficult to find primary antibodies from distinct host species. This is 
because most primary antibodies validated for use in FFPE sections are produced in 
rabbit or mouse. An antibody from a third species can sometimes be found, however, 
combinations with more than three antibodies are virtually impossible to find.  
The principal advantages of labelling primary antibodies with Qdots (option 2) 
were: elimination of the need for secondary antibodies and consequently, less cross-
reaction, and decreased total staining time. The detailed protocol for both methods of 
Qdots staining will be described in the next paragraphs. 
  For both Qdots immunostaining protocols, 4µm thick FFPE tissue sections were 
cut from training biopsy specimens of normal and cirrhotic liver obtained from the 
histology archive. For staining with Qdots-conjugated secondary antibody, a primary 
monoclonal mouse anti-human cytokeratin-7 antibody was chosen (clone OV-TL 
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12/30, Dako, Glostrup, Denmark) for its consistent results and a staining pattern easy 
to recognise.  
  In both staining protocols, all washing steps consisted of 3 washes of 5 minutes 
in PBS (phosphate-based saline) unless stated otherwise. The complete protocol for 
immunostaining with Qdot-conjugated secondary antibody is presented in Table 11 
below. The staining was assessed using a Leica DMR microscope, with a Leica 
DFC7000 T camera and a standard DAPI/blue, TRITC/red and FITC/green 





Table 11.  Protocol for immunostaining with Qdot-conjugated secondary 
antibody	
1.  Deparaffinization with xylene for 10 minutes 
2.  Rehydration with ethanol 100% for 15 min, followed by distilled water for 10 min 
3.  HIER with sodium citrate buffer (pH6.0) at 99°C for 20 min (in water bath) 
4.  After buffer/slides reach room temperature, wash 
5.  Protein block with 6% bovine serum albumin (BSA) in PBS for 1h at room 
temperature 
6.  Incubation overnight at 4°C with primary CK7 antibody (1:100 concentration) 
7.  Wash 
8.  Incubation with donkey anti-mouse Qdot655-conjugated secondary antibody 
(Invitrogen, Paisley, UK) for 1-hour at room temperature 
9.  Wash 
10.  Dehydration with ethanol 
11.  Dip slides in xylene and mount with Qmount™ Qdot Mounting Media (Invitrogen, 
Paisley, UK) 
 
  For immunostaining with Qdots-labelled primary antibody, the steps preceding 
the incubation with primary antibody were similar to the previous protocol 
(deparaffinization, rehydration, HIER, protein block).  In this case, however, the CK7 
primary antibody was labelled with Qdot655 using the SiteClick™ Antibody Labelling 
Kit (Life Technologies, Carlsbad, CA, USA), following the steps recommended by the 
manufacturer. The process involved modifying the antibody’s carbohydrate domain by 
removing terminal galactose residues in its Fc region, then attaching an azide-
containing sugar to the modified carbohydrate domain, and conjugating the antibody 
with Qdots nanocrystals. The reaction relies on 6 steps, the first five of which are 
depicted in Figure 7. The first step consists of antibody concentration and buffer 
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exchange, and is required if the chosen antibody has a concentration of less than 2 
mg/mL or contains azide or PBS. The primary antibody used fulfilled both criteria. 
 
Figure 7.  Workflow for primary antibody labelling with quantum dots  
The next steps were: modification of the antibody carbohydrate domain; azide 
attachment; purification and concentration of azide-modified antibody; conjugation 
with DIBO-modified Qdots label; and purification and concentration of antibody 
conjugate. Figure 7 was extracted from SiteClick™ Antibody Labeling Kits datasheet, 
available for download at 
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https://www.thermofisher.com/order/catalog/product/S10453. The protocol for 
immunostaining with Qdot-labelled primary antibody is detailed in Table 12. The 
staining results were assessed using the same fluorescence microscope previously 
mentioned (Leica DMR). 
 
Table 12. Protocol for immunostaining with Qdot-labelled primary antibody 
1. Deparaffinization with xylene for 10 minutes 
2. Rehydration with ethanol 100% for 15 min, followed by distilled water for 10 min 
3. HIER with sodium citrate buffer (pH6.0) at 99°C for 20 min (in water bath) 
4. After buffer/slides reach room temperature, wash 
5. Protein block with 6% bovine serum albumin (BSA) in PBS for 1h at room temperature 
6. Incubation overnight at 4°C with primary CK7 antibody labelled with Qdots* (1:5, 1:10, 
1:50 and 1:100 concentration) 
7. Wash 
8. Dehydration with ethanol 
9. Dip slides in xylene and mount with Qmount™ Qdot Mounting Media (Invitrogen, Paisley, 
UK) 
* The method used for labelling the primary CK7 antibody with Qdots is shown in Figure 7.  
 
The first immunostaining method, using a primary standard (CK7) antibody and 
a secondary Qdots-conjugated antibody produced a strong fluorescent signal with 





Figure 8. Normal liver stained with CK7 primary antibody + donkey anti-
mouse Qdot655 secondary antibody. Bile ducts in red. 
 
Figure 9.  Cirrhotic liver stained with CK7 primary antibody + donkey anti-
mouse Qdot655 secondary antibody. Bile ducts and ductular reaction in red. 
Despite the positive initial result of the first method (secondary Qdots-
conjugated antibody), after a week, the Qdots signal disappeared completely and no 
residual staining remained. The second protocol, with Qdot-labelled CK7 antibody was 
unsuccessful, and there was no staining of bile ducts, even at the highest 
concentration of antibody (1:5).    
It appeared that the setup of Qdot immunofluorescence was challenging and 
the results inconsistent in more than one laboratory (which I discovered after 
contacting pathologists from other centres). Further work with Qdots was developed 
	 71	
in the Division of Liver and Transplantation Pathology in the University of Pittsburgh 
Medical Centre (UPMC), where I was accepted by Dr A. J. Demetris as Visiting 
Research Fellow in Transplant Pathology. 
A robust method for multiplex Qdots staining, digital imaging and image 
analysis were developed in transplant pathology specimens. The mounting media 
provided and recommended by the manufacturer for Qdots staining was in fact 
responsible for the vanishing of the Qdots signal in my initial samples. Additionally, 
the use of biotin-conjugated secondary antibodies followed by streptavidin-conjugated 
Qdots, standard at UPMC, increased the final brightness. 
The equipment required to image slides with Qdots staining needs to have 
specialised excitation and emission filters. Normal fluorescence excitation filters are 
not suitable to analyse Qdots, as all Qdots will be excited and appear simultaneously. 
That is because although different Qdots have different emission wavelengths, most 
Qdots share an extremely similar spectrum of excitation, which is considerably larger 
than that of conventional fluorophores and, most importantly, corresponds to the 
excitation range of most standard fluorescence filters. Thus, if one assesses a triple 
staining containing Qdots 605, 655 and 705, for instance, with a conventional 
fluorescence filter, all three Qdots will be excited and emit signal simultaneously in any 
filter. As the emission colours do not have marked contrast with each other (orange, 
red and far red), then without appropriate Qdots filters it is not possible to distinguish 
and quantify the individual antigens. 
Figure 10 shows the specific excitation (dash lines) and emission (solid lines) 
wavelength for nuclear marker 4’,6-diamidino-2-phenylindole (DAPI) and for 3 of the 
most widely used Qdots: 605, 655 and 705 (whose emission peaks match their 
names). It is noticeable that the excitation range of Qdots overlaps with that of DAPI. 
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Figure 11 shows the range for the standard DAPI/blue, FITC/green and TRITC/red 
excitation filters, represented by the grey, blue and green areas, in addition to the 
Qdots and DAPI excitation and emission spectra. It can be observed that all filter 
ranges are within the excitation spectra of Qdots. Therefore, using a fluorescence 
microscope with a conventional filter set, the signal from all Qdots become visible 








Figure 11. Excitation filters, DAPI and Qdots excitation and emission spectrum 
In Pittsburgh, it was possible to use the image analysis software developed 
there: IAE-NearCYTE (http://nearcyte.org). This tissue cytometry software defines 
cells, enabling the delimitation of areas with different cell types depending on a user-
defined classification. The software also quantifies cells/antigen expression.  The area 
to be analysed can be selected regions or the whole biopsy area obtained from the 
whole, automatically scanned image. Whole biopsy images were used with the 
software tools to quantify cells. Tools used included: nuclei segmentation; channels 
overlay; compartments delimitation and cut-offs (of size, intensity of signal, etc.) for 
positive objects. 
Back in London, and based on the experience at Pittsburgh, new Qdots 
immunostaining protocols were designed for quantification of T cells and their 
subtypes (helper, cytotoxic and regulatory T cells) and for quantification of B cells, 
plasma cells and granzyme B (GrzB). Primary antibodies were used from different 
species in order to eliminate cross-reaction between secondary antibodies and non-
target primary antibodies.  Due to the limited range of host species of primary 
antibodies available for immunostaining in fixed tissue (essentially mouse and rabbit, 
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rarely rat), a three-antigen combination protocol was selected and multiplex staining 
of 4 or 5 antigens in one section was not possible. Biotinylated secondary antibodies 
were followed by streptavidin-conjugated Qdots, as this method generated stronger 
signal. 
The aim of the T cell staining was to quantify the following subtypes: helper, 
cytotoxic and regulatory T cells. For this, the following combination of primary 
antibodies were selected: CD4, CD8 and FoxP3. The B cell staining should allow 
quantification of B cells, plasma cells and expression of GrzB by these cells, thus 
CD20, CD138 and GrzB primary antibodies were chosen. The protocol was optimised 
for the following primary antibodies: CD4 (clone 4B12, Dako, Glostrup, Denmark), 
CD8 (clone C8/144B, Dako, Glostrup, Denmark), FoxP3 (clone PCH 101, 
eBioscience, San Diego, CA, USA), CD20 (clone L26, Dako, Glostrup, Denmark), 
CD138 (polyclonal, Atlas antibodies, Stockholm, Sweden) and GrzB (clone 496B, 
eBioscience, San Diego, CA, USA). 
First, Qdot immunostaining was optimised for each primary antibody 
individually by testing different antibody concentrations, incubation times and 
temperatures, antigen retrieval buffers (pH6, pH8, pH9) and antigen retrieval times. 
Then, the three antibodies and Qdots were combined in sequential staining. It was 
especially challenging and time consuming to optimize both triple staining, in particular 
to guarantee that all antibodies worked consistently with the same antigen retrieval. 
Because the CD4 antibody showed inconsistent results, other CD4 antibodies 
from different manufacturers were tested, and still yielded variable, non-reliable 
results. Other researchers also reported variable results with CD4 antibodies in FFPE 
liver tissue, because of variability in tissue fixation time and on paraffin block storage 
time. Since some of the selected research paraffin blocks had been in the archive for 
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many years, it was likely that fixation time was different among them (as these were 
real diagnostic biopsies). This could be the reason for the inconsistent results. 
Therefore, instead of CD4, a CD3 primary antibody was used in the triple panel. 
With CD3-CD8-FoxP3 combined staining, the total T cell population could be 
quantified, and the cytotoxic and regulatory subtypes separately labelled and 
quantified specifically. The selection of a Qdot with different wavelength to each 
antigen was made considering the following general rule of immunofluorescence/Qdot 
sstaining: the brightest Qdots, with strongest signal (for instance, Qdot 655, in the red 
emission spectra) were chosen to bind to the less expressed antigens.  
Because FoxP3 expression is nuclear, a Qdot to match this antigen had to have 
a specific wavelength to avoid overlap with the DAPI emission spectrum. Therefore, 
FoxP3 was assigned Qdot 705, which has a far-red emission signal that is distant from 
the DAPI blue emission wavelength (Figure 10). With this, the possibility of bleeding 
through from DAPI (which has the brightest signal of all) into the Qdot 705 acquisition 
filter was eliminated, so the signal captured by this filter would only reflect FoxP3 
expression. 
A nuclear marker is vital in most types of tissue staining, and is essential for 
identifying and quantifying most nucleated cells. DAPI is a fluorescent DNA stain in 
the blue spectrum widely used as nuclear counterstaining for fluorescence 
microscopy. It has high photostability (especially if stored with antifade mounting 
media) and its spectral characteristics allow its combination with other fluorophores 
for multiplexing[154-157]. 
During optimization of staining, positive and negative controls were used in 
each batch of slides, to evaluate the results. Tonsil and lymph node tissue were used 
as positive controls and results compared to the expected staining pattern depicted in 
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both the Human Protein Tissue Atlas[158-159] and the specification datasheet for the 
primary antibodies (when this information was available). Negative controls consisted 
of the same tissue as each of the positive controls (lymph node or tonsil) and test 
sample (liver) which were submitted to exactly the same staining steps except for 
addition of the primary antibody. It took several months to optimize individual and 
combined staining, and the protocol for the combination of primary antibodies and 
Qdots is specified in Table 13 and Table 14 below: 










































Table 14 (below). B cell CD20-CD138-GrB immunostaining with Qdots 
 
In each of the three-antigen combined immunostaining, the first primary 
antibodies applied were the least frequently expressed: FoxP3 for the T cell, and GrzB 
for the B cell staining. In the T cell staining, diluting the Foxp3 antibody in 1.5% bovine 
serum albumin (BSA) in PBS instead of just PBS resulted in less background. 
In regard to the Qdots, some technical aspects need to be considered when 
designing a staining protocol. Conventional hydrophobic/pap pens were avoided as 
they decreased the Qdot signal. A substitute histologic pen compatible with Qdots was 
used: Immedge (Vector laboratories, Burlingame, CA, USA).  Protein block was not 
done with casein, as it might cause quenching of Qdots conjugates. A serum-free 
protein block (Dako, Glostrup, Denmark), routinely used in Dr A.J. Demetris’ laboratory 
for Qdots staining, was chosen. Qdots were diluted in BSA in PBS. Different 
concentrations of BSA up to 6% were tested, and best results were achieved with 
1.5% BSA. Qmount™ Qdot Mounting Media (Invitrogen, Paisley, UK) was avoided, 




































(Biocare Medical, Pacheco, CA, USA). Serum from the host species was added to 
each secondary antibody and each Qdot to avoid nonspecific binding. Finally, 
biotinylated secondary antibodies and streptavidin conjugated Qdots were used. 
Avidin and biotin blocking was with an avidin/biotin blocking kit (Vector laboratories, 
Burlingame, CA, USA) used before adding each primary antibody to avoid nonspecific 
binding of streptavidin-conjugated Qdots to liver tissue, producing background 
staining. The complete protocol for the T cells immunostaining and B cells 
immunostaining are detailed below in Table 15 and Table 16, respectively. All washing 
steps consisted of 3 washes in PBS, each lasting 5 minutes. 
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Digital image analysis was necessary to quantify cell populations in whole 
tissue biopsies, and it requires digitalization of the slides. At the beginning of the 
current research, the liver histopathology laboratory at King’s College Hospital was in 
the process of acquiring a high-resolution histology slide scanner, which would have 
specific Qdots filters installed. However, the acquisition of the scanner could not be 
completed, thus an alternative needed to be found to analyse the research slides. 
As previously mentioned, Qdots are normally excited by any standard 
(excitation) filter on conventional fluorescence microscopes. Since a fluorescence 
microscope with standard blue/DAPI, green/FITC and red/TRITC filters was available, 
the results of single Qdot staining were evaluated using this equipment. Qdot 605 
(orange) or Qdot 655 (red) were selected for their brightness when staining for 
individual antigens. 
For combined three-antigen staining, besides not being able to differentiate the 
signal of the different antigens/Qdots, the microscope could not detect the third Qdot 
(Qdot 705) with an emission wavelength in the far-red spectrum. Therefore, when 
assessing the three-antigen staining in a conventional fluorescence microscope, I 
could only recognise two Qdots: Qdot 655 and Qdot 605, in red and orange, 
respectively. However, because these signals appeared concurrently, their colours 
were not very distinct from each other and the microscope did not have specific 
equipment to differentiate their wavelengths, the cells could not be quantified using 
this equipment. Furthermore, pictures could only be taken of individual fields of the 
slide, as the microscope did not acquire whole-slide images. 
In summary, the available equipment was sufficient to identify the signal of two 
of the three Qdots present in the staining. While this generally confirmed that the 
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respective antigen staining worked, no detailed evaluation/quantification could be 
performed. Suitable equipment to evaluate the results required a slide scanner or 
fluorescence microscope with Qdot filters. Dr A. J. Demetris in Pittsburgh, USA, kindly 
agreed to digitalize the slides.  
The Mirax MIDI WSI scanner, equipped with a Plan-Apochromat 40×/.95N.A. 
objective lens, AxioCam MRm digital CCD camera (Carl Zeiss, Jena, Germany) and 
specifically selected excitation/emission Qdot filters (Omega Optical, Battleboro, VT) 
was used. Test slides with each of the three-antigen Qdot immunostaining were 
digitalised and showed that both T cell and B cell staining had worked: the signal was 
strong, background was minimal, and the resulting images were suitable for digital 
analysis. Therefore, T cell staining was performed in all biopsies in the research cohort 
and the slides sent once more for imaging.  
When performing the Qdots protocol, each stained slide was checked using the 
fluorescence microscope to confirm that CD3-Qdot605 and CD8-Qdot655 signals 
were present and strong before being sent to Pittsburgh. Although it was not possible 
to assess the FoxP3-Qdot705 signal in the three-antigen combined staining, since it 
had worked on test samples submitted to the same protocol, it was assumed that this 
antigen staining also had worked. 
Nevertheless, after a few months, on receipt of the whole slide digitalized 
images, it was evident that the FoxP3 staining had not worked. This might have 
resulted from a problem with the batch of Foxp3 antibody. Consequently, instead of 
three-antigen immunostaining, a two-antigen CD3-CD8 staining was obtained. As 
turnaround time for further staining optimization was likely in the order of months, the 
experiments were not repeated for this thesis. 
	 83	
Furthermore, because the digital images had a particular extension format for 
Carl Zeiss equipment (.czi) instead of standard .tiff or .jpeg format, they could not be 
opened with a conventional image analysis software, such as Fiji/ImageJ. They could 
only be analysed with the bespoke software used in Pittsburgh: IAE-NearCYTE. 
Unfortunately, the software presented several recurring problems when used in 
London, which required several remote meetings with the software developer. 
Because of the problems with the software, the quantification of the CD3 and CD8 
cells was finally performed by the software developer. 
An additional limitation of the image analysis programme was that it could not 
separate anatomical areas in an automated fashion, such as portal tracts or 
centrilobular veins. It only showed the overall number of cells against the total surface 
area of the biopsy sample. Breakdown of the cell count according to the location of 
the cells in different areas would require constant manual input by a pathologist, which 
was not feasible.  
Considering the lack of proper equipment at the current centre for Qdots slide 
imaging, the time spent to have the slides with the T cell staining digitalized and the 
problems with the image analysis software, Qdots were not used for the B cell staining. 
Despite investing a large amount of time in developing protocols using a new, 
potentially better technology, apparently, London’s hospitals and Universities could 
not provide adequate facilities to continue with this state-of-the-art research. 
 
3.2.3.5 Conventional	immunofluorescence	and	B	cell	staining	
As all staining performed during this research, the B cell staining using 
immunofluorescence was conducted by the research author (L.N.S.). The aim of 
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performing the B cell immunostaining was to quantify B cells and plasma cells in 
different regions of the tissue and also to verify whether either of these cell types 
expressed GrzB. This expression could indicate a possible local role for B cells and/or 
plasma cells (Chapter 1). Although not as good as Qdots staining, conventional 
fluorescence is a good option for three-antigen staining, even in FFPE tissue, as long 
as appropriate fluorophores with compatible spectral characteristics are used. 
Immunofluorescence in FFPE tissue is not routinely performed and has classically 
been considered as not doable, essentially for problems with innate autofluorescence 
and tissue quality[143-144]. 
In the last decade, however, several groups have developed protocols and 
reported robust results using single, double and multiplex immunofluorescence of 
fixed human tissue, frequently using archival samples[143-148].  According to Robertson 
et al.[143], after staining and imaging, slides can be kept at -20°C for large periods of 
time, beyond 250 days, with negligible loss of quality. In fact, the optimization of 
multiplex immunofluorescence in FFPE tissue and the possibility of long-term storage 
of slides could enable numerous studies in archival diagnostic samples.  
Several aspects need to be considered to perform good quality, multiple antigen 
immunofluorescence staining with consistent results: 
1. Choice of fluorophores needs to be compatible with the filters of the microscope 
where samples are to be analysed. In the present research, with the available 
microscope with standard blue-green-red filter set, only two antigens could be 
analysed (with the green and red filters), besides the nuclear DAPI stain (blue). 
2. Fluorophores should have narrow emission wavelengths in order to avoid 
bleed-through (crossover) of a given fluorescent dye to the detection channel 
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of another (for instance, of a green fluorophore into the red channel). 
Fluorophores chosen should be spectrally different to (compatible with) the 
chosen nuclear counterstain. 
3. Secondary antibodies (labelled with fluorescent dyes) should ideally originate 
from a single host species. This, combined with the use of serum of this (host) 
species for the protein block, avoids nonspecific binding and reduces 
background staining. All secondary antibodies used were raised in goat, and 
goat serum was used for the protein block. 
4. Ideally, the secondary antibodies selected should have been pre-
adsorbed/cross-adsorbed against both the host species of the primary 
antibodies, and the species of the tissue sample. This prevents species cross-
reactivity of secondary antibodies and non-target primary antibodies and also 
minimizes background. Pre-adsorption is an additional step of purification 
performed to increase the specificity of a secondary antibody. The process 
consists of passing the solution of the secondary antibody through a column 
with serum proteins from possibly cross-reactive species. The non-specific 
antibodies are then retained in the column, while highly specific secondary 
antibodies pass through. Figure 12[149], shows a solution of secondary 
antibodies against rabbit IgG passing through a column with serum proteins of 
potentially cross-reactive species (sheep and bovine IgGs). Secondary 
antibodies with high specificity to the target (rabbit IgG) pass through the 
column, whereas those that show species cross-reaction (with either sheep or 
bovine IgG) stay bound to these proteins. This results in secondary antibody 
with high specificity for its target species. In the current protocol, I selected only 
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secondary antibodies which were cross-absorbed against the host species of 
non-target primary antibodies and the species of the liver samples[150]. 
 
 
Figure 12. Pre-adsorption of secondary antibodies 
 
Alexa Fluor (AF) fluorescent dyes (Invitrogen, Thermo Fisher Scientific, 
Carlsbad, California, USA) were chosen for their intense brightness, good stability in 
fluorescent mounting medium, and because they are the most used fluorophores in 

























low bleaching after an initial assessment in the microscope (including pictures), and 
this signal was maintained after a month of storage at -20oC (protected from light). 
Although not as stable in the long-term as Qdots, these dyes were a suitable 
alternative to Qdots for staining fixed tissue. DAPI was used for nuclear staining for 
the reasons previously explained. 
My aim in performing the B cell immunostaining was to quantify B cells and 
plasma cells and also to verify whether either of these cells expressed granzyme B 
(GrzB). This expression could indicate a possible local role for B cells and/or plasma 
cells (Chapter 1). The protocol previously designed for B cell and plasma cell staining 
with Qdots included 3 primary antibodies: CD20, CD138 and GrzB. However, because 
of the microscope filters available, only two antibodies could be chosen (besides the 
DAPI for the nuclei). 
Therefore, CD20, that marks B cells only, was substituted with CD79a (clone 
JCB117, Dako, Glostrup, Denmark), which recognizes both B cells and plasma cells. 
Therefore, if GrzB was expressed by only one of these cell types (plasma cells or B 
cells), double positive cells (CD79a+GrB+) would be seen amongst the CD79a+ cells. 
However, in case such CD79a+GrB+ cells were found, it would not be possible to 
differentiate between B cells and plasma cells with only two antibodies. So the CD138 
antibody was included in a three-antibody staining protocol, with a secondary antibody 
conjugated with a far-red Alexa fluorophore. If CD79a+GrB+ cells were found in an 
initial assessment, a fluorescence microscope equipped with a far-red excitation filter 
and acquisition camera would be located for further analysis of CD138 staining. 
I chose a fluorescent dye in the far-red spectrum for the additional antibody 
(CD138) for two reasons: 1) the far-red channel is a common filter in modern 
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fluorescence microscopes, and 2) it is compatible (shows low wavelength overlap) 
with the other selected fluorophores, in the blue, green and red spectra. I used the 
Fluorescence SpectraViewer tool[153] to select three Alexa Fluor dyes that could be 
combined in multiple antigen staining and were compatible with DAPI. The 
fluorophores and their respective excitation (dashed line) and emission (continuous 
line) wavelengths are depicted in Figure 13. The overlap between fluorophores is 
represented by the value of “Relative Intensity (%)” where the lines of different 
fluorophores meet.  
 
Figure 13. Excitation and emission wavelenghts of chosen fluorophores 
The compatibility of different AF dyes to be used in combination is shown in 
Figure 14[160]. Green, blue and red rectangles mean high, medium and low 
compatibility, respectively. High compatibility between a pair of fluorophores indicates 
no bleed-through between them; medium compatibility implies low bleed-through, and 





Figure 14. Compatibility between different Alexa Fluor dyes for multiple antigen 
immunostaining 
 
Although the emission spectrum of DAPI and AF 488 overlap (Figure 13), their 
excitation range is distinct, with virtually no overlap, so they can be used in 
combination.  Moreover, the fact that DAPI is a nuclear marker whereas GrzB is 
located in the cytoplasm helped evaluate possible bleed-through (which was not 
seen). The combination of AF 488 (used for GrzB) and each of the other fluorophores: 
AF594 (for CD79a) and AF 647 (for CD138) is highly compatible (Figure 14), with 
minimal spectral overlap (Figure 13). 
Thus, the combination of primary antibodies and fluorophores chosen for the B-
cell multiplex staining protocol was: GrzB-AF 488 (green), CD79a-AF 594 (red) and 
CD138-AF 647 (Table 17). There was some overlap between the excitation and 
emission spectrum of AF 594 (for CD79a) and AF 647 (for CD138), as seen in Figure 
13, which meant there could potentially be some bleed-through between their 
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respective channels (red and far-red). Despite that, there were other features that 
helped me to evaluate bleed-through between the respective fluorescent channels, 
the main being the distinct staining patterns of CD79a and CD138 antibodies. Besides 
plasma cells, CD138 stained the hepatocyte membranes across the biopsies, whereas 
CD79a only highlighted individual cells. The number of CD138+ cells was also 
considerably lower than that of CD79a+ cells, and CD138+ cells (plasma cells) had 
more cytoplasm than the other CD79a+ cells (namely, B cells).  Comparison between 
the single immunostaining of each of these antigens was done to validate multiplex 
staining.  
Table 17. Combination of antibodies for CD79a-CD138-GrzB 
immunofluorescence protocol 
 
Some considerations must be made regarding optimization of the staining 
protocol.  Different methods for protein block were attempted: skimmed milk (casein); 
BSA and serum-free protein block (Dako). The lowest background staining was 
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secondary antibody (goat). As to the order of antibodies, different methods were 
tested: 1) adding a primary antibody, then its corresponding secondary antibody, 
followed by another primary and secondary, in a sequence;  2) applying the primary 
antibodies simultaneously, followed by the secondary antibodies sequentially and  3) 
adding the primary antibodies simultaneously, then the secondary antibodies also 
concomitantly. The last method was less time consuming and produced similar results 
as the sequential approach, so was chosen. 
Although only two antibodies could be assessed simultaneously, not three (due 
to the lack of far-red filter/channel), using the available fluorescence microscope, I 
performed three double staining (all possible combinations of two primary antibodies: 
CD138-CD79a, CD138-GrzB, CD79a-GrzB) using secondary antibodies conjugated 
with green (488) and red (594) AF.  By performing double antigen stains with CD138-
CD79a and CD138-GrzB (plus DAPI), no cross-reaction was observed between 
CD138 and each of the other antigens/primary antibodies. The distinct pattern of 
CD138 staining was particularly useful for this evaluation. When performing the final 
three-antigen staining, both GrzB and CD79a could be assessed in the green and red 
channel, respectively. The hepatocyte membrane did not appear in the green or the 
red fluorescence channel (in which GrzB+ cells and CD79a+ cells were observed, 
respectively). Therefore, the absence of cross-reaction and bleed-through were 
confirmed. 
The fact that the primary antibodies chosen were from different species and the 
secondary antibodies were highly cross-adsorbed against the other primary antibody 
species (and the biopsy tissue species) allowed the simultaneous application of 
primary and secondary antibodies without cross-reaction. Details on the species 
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against which each secondary antibody had been cross-adsorbed are shown in Table 
18. Extensive washing was performed after incubation with primary antibodies, to 
ensure that any antibody not bound to the tissue was removed (decreasing 
background staining). 
Table 18.  Cross-adsorption of selected secondary Alexa Fluor-conjugated 
antibodies 







Goat anti-mouse AF594 (A-11032) 
 
Highly cross-adsorbed 
bovine IgG, goat IgG, 
rabbit IgG, rat IgG, 
human IgG and human 
serum 
 
Goat anti-rat AF488 (A-11006) 
 
Cross-adsorbed  
mouse IgG, mouse 
serum and human 
serum 
 
Goat anti-rabbit AF 647 (A-21245) 
 
Highly cross-adsorbed 
bovine IgG, goat IgG, 
mouse IgG, rat IgG and 
human IgG 
 
Significant autofluorescence was evident in the red channel, from both 
hepatocytes (mainly due to the presence of lipofuscin) and in some biopsies, red blood 
cells. Because the autofluorescence could interfere with the interpretation of the 
CD79a staining, slides were dipped in Sudan black at the end of the staining to 
decrease autofluorescent emission. This considerably decreased tissue 
autofluorescence without significant reduction of the fluorophore signal. Sudan Black 
has been used for this purpose by other researchers[161-163]. 
The final, detailed protocol after optimization is below (Table 19). Washing 
steps consisted of 3 washes in PBS each lasting 5 minutes, unless stated otherwise. 
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Table 19. Protocol for CD79a-CD138-GrzB immunofluorescence staining 
1. Deparaffinization in xylene for 10 min 
2. When tissue is dry, delimitation with Immedge pen  
3. Rehydration with ethanol 100% for 10 min, followed by distilled water for 10 min 
4. HIER with EDTA buffer (pH 9) for 25 min at 99oC in water bath 
5. When slides/buffer reach room temperature, wash in distilled water (3x 5 min each)  
6. Wash (PBS) 
7. Protein block with 5% BSA (in PBS) + 2% goat serum  for 1h 
8. Wash 
9. Primary antibodies:  CD79a (1:25) + GrzB (1:50) + CD138 (1:75) in 1.5%BSA 
overnight at 4oC 
10. Wash extensively in PBS  (6x 5 min each) 
11. Secondary antibodies: Goat anti-mouse AF 594 (to CD79a) + Goat anti-rat AF 488 
(to GrB) + Goat anti-rabbit AF 647 (to CD138) at 1:400 in 1.5%BSA + 1% Goat 
serum for 1h 
12. Wash  
13. DAPI for nuclear staining (3 uL DAPI in 100 ml PBS)  for 10 min 
14. Wash 
15. Wash in distilled water (3x 5min each) 
16. Dip slides in Sudan black for 5 seconds 
17. Wash in tap water 
18. Wash in distilled water (3x 5min each) 
19. Mount (Dako fluorescence mounting medium) 
 
 During the preparation of the slides, a fluorescence microscope capable of 
assessing all three fluorophores and DAPI (with far-red filter) was located at the Nikon 
Imaging Centre at Guy’s campus of King’s College London. This facility provides 
access to advanced imaging equipment and training in microscopy techniques. 
Confocal microscopy is commonly used for assessing multiplex fluorescence staining 
and was the original method of choice to analyse co-localization of GrzB on B cells 
and plasma cells. 
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 However, some modern microscopes are able to scan whole slide sections with 
exceedingly high precision by identifying several different focal planes through the 
tissue thickness, with results as accurate as confocal microscopy. This type of 
equipment has the advantage of imaging large areas of tissue instead of individual 
fields, which is essential for quantifying cells in whole biopsies. Slides were therefore 
digitalized using a motorised microscope for multi-dimensional imaging: the Eclipse 
Ti-2 inverted microscope (Nikon, Tokyo, Japan). This microscope can be used for both 
live cell imaging and fixed tissue biopsies. It captures an image from each microscope 
field, at the desired magnification, in each fluorescent channel.  Those images are 
combined into a final image file of the whole biopsy for each fluorescent channel: blue, 
green, red and far-red. 
Moreover, this microscope had a Perfect Focus System, which is a focal drift 
compensation mechanism that enables the equipment to stay on the correct focal 
plane despite the movement of the camera during the imaging of the whole slide. To 
generate the final in-focus image, the microscope captured several images at several 
focal planes/depths (“Z stacks”) throughout the sample. In each image, distinct areas 
of the tissue would be in focus. The microscope software automatically removed the 
out-of-focus signal captured in individual images, and blended the in-focus areas 
together, generating the final in-focus digital image of the whole biopsy 




Figure 15.  Z-stack analysis of human skin cells with fluorescence-staining of the 
cell membrane (red) and cell nuclei (blue) 
The one problem when using this microscope for whole slide imaging was the 
excessive amount of time required to create high quality whole biopsy digital images 
using 4 fluorescence channels, in some cases taking over an hour to scan a single 
biopsy specimen. Furthermore, the equipment was not capable of detecting the 
tissue/biopsy area automatically, as some slide scanners are, and the final image 
needed to be in a square or rectangle shape, so for biopsies with an irregular shape, 
the microscope spent a long time digitalising areas with no tissue. 
Additionally, each slide had to be manually positioned, and the equipment only 
accepted one slide at a time. The middle point of the biopsy was manually measured 
with a ruler for length and width, to place the exact centre of the tissue in the 
microscope field at the start of each digitalization. The microscope had to be set to the 
best focus for all fluorescent channels, so the equipment could maintain that exact 
focus through the Perfect Focus system. This process had to be repeated for each 
biopsy specimen. In summary, although very modern and able to digitalize three-
antigen fluorescence staining, the equipment was not practical for scanning large slide 
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sets of whole biopsy samples, as it required several manual steps and constant 
supervision. 
The 200x objective magnification was chosen for slide digitalization. This was 
accurate enough to allow quantification of cells and any higher magnification would 
demand an impracticable amount of time per scan. In addition, the Qdot  T-cell stained 
slides had been digitalized using the same magnification, and this was recommended 
by the image analysis software developer in Pittsburgh. 
 
3.2.4 Image Analysis 
3.2.4.1 Collagen	proportionate	area	
The digital quantification of fibrosis in Sirius Red stained biopsies was 
performed using NIH ImageJ software (available at http://rsb.info.nih.gov/ij/). The CPA 
(CPA) was calculated in percentage by dividing the area of fibrosis by the whole biopsy 
area. The steps for defining the CPA in ImageJ are specified in Table 20 below. 
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Table 20. Steps for measuring CPA using ImageJ 
1. Menu, select ‘Analyse’ à ‘Set Measurement’ à choose ‘Area’ and ‘Limit to 
threshold’ and unselect the other parameters à  ‘ok’ 
2. Menu, select ‘File’ à ‘Open’ à choose image file to be analysed 
3. Menu, choose ‘Image’ à ‘Type’ à ‘32-bit’ 
4. Menu, select ‘Image’ à ‘Adjust threshold’ à adjust the bottom pin until the whole 
tissue is selected (do not move the top pin) à ‘Apply’ à when the message about 
NaN appears, untick the box 
5. Menu, choose ‘Analyse’ à ‘Measure’ à ‘ok’.  The resulting number is the 
measurement of the whole tissue area in pixels. 
6. Close the image without saving 
7. Re-open the image (see step 2) 
8. Menu, choose ‘Image’ à ‘Adjust” à “Color threshold”.  Three parameters appear: 
Hue, Saturation and Brightness.  The first (top) pin of Saturation and Brightness 
should be adjusted until all the area stained with Sirius red is selected à ‘Select’  
9. Menu, choose ‘Analyse’ à then ‘Measure’ à ‘ok’.  The resulting number is the 
measurement of the area of collagen 
10. Calculate the CPA (percentage) by dividing the collagen area by the whole biopsy 
area and multiplying by 100. 
 
3.2.4.2 Qdots	cell	counts	
Digital images of Qdots slides were analysed in Pittsburgh. The IAE-NearCYTE 
software automatically calculated the biopsy area in mm2. The quantification of T cells 
was performed by software identification of all cells with a nucleus (positive DAPI) and 
CD3 cytoplasmic staining surrounding it. The threshold of staining/signal intensity for 
considering a cell positive for each antigen is determined by user input. Cells with 
nuclear staining that were double positive for CD3 and CD8 were considered cytotoxic 
T cells. Once the software showed positive cells for each antigen combination, further 
individualization, deletion or addition of cells could be done manually. For Qdots slides, 
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an automated quantification of cells that expressed each antigen was achieved by 
defining thresholds for brightness and contrast for each fluorescent channel, so the 
software would select positive cells and ignore background/autofluorescence. This 
worked for the Qdots stained slides because having a narrower emission spectra than 
conventional fluorescent dyes meant that the Qdots did not overlap significantly with 
liver autofluorescence. This was not the case of the biopsies stained with conventional 
fluorescence for B cells, though. 
Figure 16 and Figure 17 show the process of cell identification and 
quantification in one study biopsy specimen (small portal tract). Figure 16 is a biopsy 
field stained with DAPI (blue), CD3 (red) and CD8 (green). CD3+CD8+ (double 
positive) cells appear yellow. Figure 17 shows the same biopsy area with 
individualized cells/objects, classified using the IAE-NearCYTE image analysis 
software. DAPI+ objects are outlined in black, DAPI+CD3+CD8- are outlined in red; 
DAPI+CD3+CD8+ appear in yellow and DAPI+CD3-CD8+ in green. The CD3-CD8+ 
(green) cells correspond to natural killer and dendritic cells that express CD8 but not 
CD3. These cells were not the focus of the present study. 
Therefore, the total population of T cells included red (CD3+CD8-) and yellow 
(CD3+CD8+) cells.  To enable comparison of the number of cells in biopsies of 
different sizes, the total number of cells was divided by the biopsy area, thus resulting 
in number of cells per mm2. As previously mentioned, FoxP3 staining with Qdots did 
not work (Materials and Methods).  
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Figure 16. DAPI + CD3 + CD8 Qdots immunostaining 
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Figure 17. DAPI + CD3 + CD8 Qdots immunostaining - Cell identification and 
classification. Same biopsy field as Figure 16 showing the process of cell 
recognition for different antigens by the software IAE-NearCYTE 
 
3.2.4.3 Conventional	immunofluorescence	
Slides stained with DAPI + CD79a + CD138 + GrzB with immunofluorescence 
were analysed with Fiji/ImageJ software. The initial idea was to conduct automated 
quantification of cells by defining (brightness and contrast) thresholds for each 
fluorescent channel, similar to what was done for Qdots stained slides. Nonetheless, 
unlike Qdots staining, the sections stained with conventional fluorescent dyes still 
displayed autofluorescence even after treatment with Sudan Black. For this reason, 
despite numerous attempts, including the use of an alternate image analysis software 
(NIS-Elements - Nikon, Tokyo, Japan), the automated quantification was not possible, 
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particularly in the red (CD79a) channel. Figure 18 depicts one biopsy in the red 
fluorescence channel (CD79a staining). The autofluorescence is noticeably strong in 
red blood cells and also present in hepatocytes.  
 
Figure 18. CD79a staining in red channel displaying autofluorescence in red 
blood cells and hepatocytes 
When higher thresholds were imposed, to eliminate all background, real 
positive cells were overlooked (false negative), and when the threshold was lowered 
to incorporate all positive cells, it selected red blood cells (and sometimes 
hepatocytes) because of their autofluorescence (false positive). The possible option 
to quantify cells was then to manually select positive cells in Fiji/ImageJ. Despite the 
autofluorescence that prevented automated recognition and quantification of cells, 
CD79a+ cells could be easily recognised by human eye and differentiated from 
background. A tool in Fiji/ImageJ allowed the user to select each positive object, and 
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the software kept a record of labelled objects and displayed them, numbering them 
sequentially (Figure 19). 
The quantification of CD79a+ was conducted through assessing both the red 
(CD79a) and the combined blue + red (DAPI+CD79a) channel images simultaneously 
in the screen (Figure 19). Whilst positive cells were more easily spotted in the red 
channel, overlaying with the blue channel ensured that every cell included in the 
quantification was a nucleated cell. This partially manual process allowed the cell 
quantification in whole biopsies, despite exceptionally time consuming due to the size 
of samples analysed (whole biopsy specimens), resulting files (up to 4 gigabytes per 
sample) and number of positive cells (as much as one thousand per biopsy). 
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Figure 19. Manual selection of objects/cells on Fiji/Image. CD79a staining 
with (lower image) and without (upper image) nuclear staining. Each number represents a 
CD79a+ cell identified by the user’s manual selection in the software. 
Although no autofluorescence was observed in the far-red channel (CD138 




hepatocytes’ membranes and bile duct epithelial cells by CD138 antibody (Figure 20). 
Although this staining pattern prevented automated quantification of plasma cells, it 
was helpful to identify the architecture of the liver.  In many biopsies, the exact location 
of plasma cells could be determined (portal, central, lobular). In others, however, this 
was not possible because of liver architectural distortion in consequence of extensive 
fibrosis. Thus, the location of plasma cells was not considered in the results, only the 
number of cells per biopsy area, similar to that done for B cells. The CD138+ cells 
were also easily recognized by human eye, despite the hepatocyte membranous 
staining, as shown in Figure 21 and Figure 22. 
  
 
Figure 20.  CD138 staining highlighting the hepatocyte membranes. CV, central 







Figure 21. Two plasma cells in the lobule (CD138+), clearly differentiated from 
the background hepatocyte staining due to cell shape and signal brightness 
 
Figure 22. A group of plasma cells in a portal tract (inside circle). They can be 
differentiated from bile duct epithelial cells by their bigger size, more abundant 






The analysis of double-positive CD79a+GrzB+ cells was conducted in two 
ways: by assessing the slides in the original fluorescence microscope (with blue-
green-red filter set) and by examining the whole biopsy images acquired in the Nikon 
centre.  In the microscope, each biopsy specimen was viewed individually at 200x 
magnification, switching filters to spot double positive cells. Then at 400x, pictures 
were acquired of all CD79a+GrB+ cells. Finally, the microscope images were 
compared with the whole biopsy images from each specimen to confirm that the 
double positive cells also appeared as double positive in the images acquired with the 
other equipment. 
Because the whole biopsy images included an extra channel for the CD138 
(far-red), the images from both equipment were compared to verify whether the 
CD79a+ cells expressing GrzB observed in the microscope were also positive for 
CD138 in the scanned image. In other words, assessing the specimens on the 
microscope was the best method to spot B cells/plasma cells that expressed GrzB 
(CD79a+GrB+), whereas the whole biopsy scanned image was the only method able 
to differentiate whether those cells were plasma cells (CD138+) or B cells (CD138-). 
The image analysis of the biopsy slides required approximately two months. 
The total tissue area of each biopsy was calculated using similar method as that used 
to calculate the CPA in the Sirius red stained slides, above. The total number of 
CD79a+ cells and CD138+ cells in each biopsy was divided by the area of the biopsy, 
resulting in the number of cells per mm2, as previously done for the quantification of T 
cells in Qdots stained slides. This adjustment allowed the comparison of number of 
cells among biopsies of different sizes. Table 21 shows the steps followed to perform 
the quantification of cells in each channel using Fiji/ImageJ. 
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Table 21. Quantification of cells using Fiji/ImageJ 
1. In menu,  choose “File”,  choose “Import” and select  “Bio-Formats” 
2. When new window appears, in section stack viewing, choose hyperstack;  in color 
mode, choose default;  in memory management, select use virtual stack; in split into 
separate windows, select split channels. 
3. Once the 4 images are open (blue, green, red and far red fluorescence channel),  in 
menu, choose “Image”, then  “look up tables” and ascribe a different colour for each 
image. 
4. In menu, choose “Image”, then “adjust” and select  “brightness/contrast”. Adjust the 
parameters (brightness and contrast) for each layer/channel as appropriate. 
5. In menu, choose “Image”, then “color” and select “merge channels”. For counting the 
cells in each channel (each antibody staining), choose the channel desired and the 
DAPI channel. Tick “create composite” and “keep source images” and click “ok”. 
6. Once the composite image is open, select the “multi-point tool” in menu and identify 
each positive cell by clicking/adding a label to it. The software keeps record of the 
number of cells (objects) selected. 
 
3.2.5 Statistical analysis 
 Data were analysed statistically using SPSS version 23.0 (IBM Corp, 2015). 
Continuous variables were presented as median and range whilst categorical 
variables were presented as number and percentage. For most continuous variables, 
such as patient age at transplantation or number of inflammatory cells in a biopsy, the 
median was used to measure average tendency. The median is the middle number 
when the values of a given variable/parameter are put in order, and half of the samples 
will be below and half of the samples above that number.  It is a superior measure 
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compared to the mean for variables with a wide range of values and with outliers 
(extreme values) or else for small samples, as it is not as influenced by extremes as 
the mean[165]. 
 The mean (average) was used instead of the median when comparing degrees 
of inflammation or fibrosis between different groups. This choice was made because 
the scoring systems used to grade histologically inflammation or fibrosis incorporate a 
few discrete values with no extreme values/outliers. Most histological parameters 
scored had one of four possible values: 0, 1, 2 and 3 (corresponding to: absent, mild, 
moderate and severe intensity, respectively). 
 The Mann-Whitney (non-parametric) test was used to compare continuous 
variables between groups. The independent samples t test was not used because of 
the relatively small size of the sample.  
The Fisher’s exact test was used to compare categorical variables and validate 
differences in frequencies between different groups.  
The Person’s correlation test was used to correlate two continuous variables. 
For a significant p value, a correlation coefficient (r) from 0-0.3 was considered 
weak/no correlation; 0.3-0.5, moderate positive correlation (-0.3- -0.5, moderate 
negative correlation); and above 0.5, strong positive correlation (below -0.5, strong 
negative correlation). 
 For all tests, a p value of less than 0.05 was considered statistically significant. 
Throughout the tables in the Results sections, significant p values (<0.05) are 





3.3.1 Clinical data 
Five-hundred and thirty-nine children were transplanted between January 1989 
and March 2003 at King’s College Hospital. Fifty-eight of them were alive, under 
follow-up in the same centre, clinically asymptomatic, and consented to have a long-
term post-transplant protocol biopsy as part of a clinical follow up study. The biopsies 
had been performed between 8.6-15.6 (average 11.9) years post-transplant. Thirty 
patients were male and 28 were female. The recipients’ age at biopsy varied between 
8.5 to 17.1 (average 13.2) years. Organ donation types were: 90% DBD; 8.6% living-
relative liver transplant (LRLT) and one child (1.7%) DCD. Graft types were: 78% split 
graft, 19% whole, and 3.4% a reduced liver. 
 The indications for LT were: biliary atresia in 32 children;  acute liver failure  in 
6;  progressive familial intrahepatic cholestasis in 5;  Alagille syndrome in 4; 
hepatoblastoma in 4; cryptogenic cirrhosis in 2;  a1 anti-trypsin deficiency in 2; liver 
cystic fibrosis-related liver disease in 1; neonatal sclerosing cholangitis in 1 and 
cholestasis following total parenteral nutrition in 1 (Table 22). Average follow-up time 
after the protocol biopsy was 6.8 years (the range was 0-18.6 years). During this time, 
4 patients (6.9%) required retransplantation and one died 3 days after surgery.  
 
Table 22.  Indications for liver transplantation 
Indication for LT Number (%) 
Biliary atresia 32  (55.2%) 
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ALF 6 (10.3%) 
PFIC 5 (8.6%) 
Allagile syndrome 4 (6.9%) 
Hepatoblastoma 4 (6.9%) 
Cryptogenic cirrhosis 2  (3.5%) 
a1ATD 2  (3.5%) 
Cystic fibrosis 1  (1.7%) 
Neonatal sclerosing cholangitis 1  (1.7%) 
Cholestasis after TPN 1  (1.7%) 
Total 58 (100%) 
  * TPN, total parenteral nutrition 
Data on the initial immunosuppression was available for 31 patients: 23 (74%) 
received cyclosporine and prednisone, 20 of them with azathioprine (AZA), 1 with 
mycophenolate mofetil (MMF) and 2 without a third agent. The remaining 8 patients 
received tacrolimus and prednisone.  By the time of the protocol biopsy, 25 patients 
out of 58 (43%) used tacrolimus: 10 with prednisone + MMF, 12 with prednisone only,  
2 with MMF and one as monotherapy. Cyclosporine was the chosen calcineurin 
inhibitor (CNI) in 23 patients (39.6%): 10 patients received it with prednisone and AZA,  
4 with prednisone and MMF,  4 with MMF (no steroids), 2 with prednisone,  2 with AZA 
and one patient received cyclosporin as monotherapy. Additionally, 2 patients 
received prednisone with MMF (without CNI) and 2 patients were off 
immunosuppression at the time of biopsy (one for 8 months and one for 20 months). 
Details on these two patients without immunosuppression will be provided later in this 
chapter. Forty-five patients received steroids at the time of biopsy and 13 did not. 
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The average liver function tests (LFTs) at the time of protocol biopsy were: ALT 
29.55 (from 4 to 92, reference value 5-55), AST 35.05 (from 14 to 109, reference value 
10-50), bilirubin 15.00 (from 3 to 33, reference value 3-20), GGT 26.60 (from 5 to 134, 
reference value 1-55), AP 238.60 (from 75 to 516, reference value 30-130), platelets 
224.07 (from 72 to 372, reference value 150-450) and international normalised value 
(INR) was 1.07 (from 0.86 to 1.36, reference value 0.9-1.20). Out of the 58, 52 
recipients had AST within the normal range and only one had AST above 1.5 times 
the upper reference threshold at the time of protocol biopsy. Considering all LFTs, only 
13 patients had completely normal liver biochemistry. 
Regarding previous episodes of rejection, 62% of liver recipients had at least 
one biopsy showing rejection: 78% had early episode(s) of rejection, within 3 months 
post-transplant (most cases in the 1st month) and 22% had late rejection (which 
occurred between 4 months and 5 years after transplantation).  A fifth (19%) of patients 
who had early rejection also developed late episode(s) of rejection. 
Autoantibodies were present in 11 patients (19%) at the time of protocol biopsy: 
8 (14%) had antinuclear antibodies (ANA), 2 (3.4%) had anti-smooth muscle 
antibodies (ASMA), and 1 child had anti-gastric parietal cell antibodies (GPC). 
Considering the ANA titres, two patients had 1/20, one had 1/40, one had 1/80, two 
had 1/160 and two had 1/640, all in nucleolar pattern except one who had speckled 
pattern (at 1/20). The titres of ASMA were 1/20 and 1/160, and the patient with GPC 
had weak positivity (exact titre not specified). 
Anti-liver-kidney microsomal antibody (LKM) and mitochondrial antibodies were 
negative in all recipients. No patient with antibodies fulfilled the other criteria for de 
novo autoimmune hepatitis (AIH): raised immunoglobulins and raised AST. 
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3.3.2 Initial histological assessment (HE and reticulin staining) 
 
Three biopsy specimens had too little tissue for an appropriate assessment and 
therefore were excluded from the study. From the 55 HE biopsy specimens analysed, 
73% (40 biopsies) showed histological abnormalities. 40% (22) had unexplained 
chronic hepatitis of the graft (IPTH), in most cases (86%) associated with significant 
portal fibrosis (³2) and/or pericentral or sinusoidal fibrosis (³2); 20% (11) had 
significant portal fibrosis but no inflammation (7 were Ishak stage 3 or higher) and 
7.3% (4) had centrilobular fibrosis and/or sinusoidal fibrosis (³2) without inflammation 
or portal fibrosis; 1 patient had rejection (with active bile duct injury); 1 had a chronic 
cholangiopathy; and another, recurrent Hepatitis C virus (HCV). The two following 




Figure 23. Protocol biopsy 10 years post-transplant for biliary atresia. 
Fragmented biopsy showing bridging fibrosis with nodularity (Sirius Red, 40x) 
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Figure 24. HE staining depicting chronic inflammation associated with fibrosis 
(200x, same biopsy of Figure 23) 
 
Overall, 65.5% (36) of all protocol biopsies featured significant portal (³2), 
centrilobular (³2) or sinusoidal fibrosis (³2). Portal fibrosis (³2) was present in 56.4% 
(31), and bridging fibrosis or cirrhosis (³3), in 40% (22). Only 27.3% of the biopsies 
analysed displayed a normal/near normal histology. The general overview of the initial 
histological assessment is depicted in Table 23. 
Three patients were excluded from further histological assessment. One had 
histological signs of rejection, including bile duct damage and endotheliitis, so the 
diagnosis of late rejection was made. Another patient had cholangiopathy and a third 
had clinically recurrent HCV. Fifty-two biopsy specimens that showed no typical signs 
of rejection (no conspicuous bile duct damage/endotheliitis) or of other specific 
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aetiology for the histological findings were included in the study and submitted to 
additional staining and analysis. 
 




Number (%) of 
biopsies 
IPTH + fibrosis 
       Ishak 0/1 (CLF³2 + Sin³2) 
       Ishak 2 (+CLF ³2 in two patients, +Sin ³2 in one  
                       of them) 
       Ishak 3  (+CLF ³2 in two patients, no Sin) 
       Ishak 4 (+CLF ³2 in four patients, +Sin ³2 in three  
                       of them) 









Fibrosis only (Ishak ³2, CLF ³2 or Sin ³2) 
      Ishak 0/1 (+CLF ³2 in all, +Sin ³2 in one patient) 
      Ishak 2 (+CLF ³2 in two patients, no Sin) 
      Ishak 3 (+CLF ³2 in two patients, no Sin) 
      Ishak 4 (+CLF ³2, no Sin) 







Normal/near normal 15 (27.3%) 
IPTH (without fibrosis) 3 (5.5%) 
Rejection 1 (1.8%) 
Cholangiopathy 1 (1.8%) 
Recurrent HCV 1 (1.8%) 
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Total 55 (100%) 
CLF, centrilobular fibrosis;  Sin, sinusoidal fibrosis;  HCV, hepatitis C virus 
 
The number of complete portal tracts in each biopsy varied from 3-16 (average 
7.3) and the number of central veins, from 3-14 (average 5.9). The biopsy area varied 
from 3-20mm2 (average 8.6). As to the grade of inflammation in each compartment, 
portal inflammation was present in 53.8% of biopsies: mild (grade 1) in most (42.3%), 
moderate (grade 2) in 11.5%. Interface activity was evident in 17% of biopsies, and 
was mild in all except one. Some degree of lobular inflammation was present in 44% 
of biopsies: mild/grade 1 in 37% and moderate in 7.7%.  Central perivenulitis was 
present in 27% of patients and was typically mild (19%), although moderate in some 
cases (7.7%). A summary of the degree of inflammation in each compartment and 
other histological features assessed is presented in Table 24. 
 Only 11.5% of patients had bile duct injury on histology, which was mild in all 
cases. Bile duct loss and portal vein endotheliitis were not present in any biopsy 
specimen. Steatosis was conspicuous in 5.8% of biopsies, mild in all cases (affecting 
5-30% of hepatocytes).  
 
 
Table 24. Inflammation Grading in each site 
Histological parameters Number (%) of biopsies 
Portal Inflammation 
      Absent 
      Mild (grade 1) 







      Absent  
      Mild  (grade 1) 






      Absent  
      Minimal (grade 1) 






      Absent  
      Mild (grade 1) 





Bile duct lesion 
      Absent  
      Minimal (grade 1) 
      Moderate (grade 2) 






Bile duct loss 
       Absent 




Portal vein endotheliitis 
      Absent  
      Mild (grade 1) 
      Moderate (grade 2) 






Ductular reaction  
0 
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      Absent 
      Focal 




     Absent 
     Focal 
     Diffuse centrilobular 







      Absent 





      < 5% of hepatocytes 
       5-33% of hepatocytes (grade 1) 
       33-66% of hepatocytes (grade 2) 







The proportion of biopsies showing different degrees of portal fibrosis according 
to Ishak and Venturi scores is depicted in Figure 25 and Figure 26, respectively. There 
were no biopsies classified as Ishak 6. Centrilobular fibrosis (CLF) was present in two-
thirds of biopsies (67%): mild in 29%, moderate in 27% and severe in 12% (Figure 
27). Sinusoidal fibrosis was evident in 60% of biopsies: 44% were mild (stage 1), 10%, 
moderate (stage 2) and 6% severe (stage 3), as shown in Figure 28. In terms of the 





Figure 25 (above). Portal Fibrosis (Ishak) 
 
 


































Figure 27 (above). Centrilobular fibrosis 
 
 
Figure 28. Sinusoidal Fibrosis 
 
 The presence of IPTH was strongly associated with portal and sinusoidal 
fibrosis ³2, and also significantly associated with centrilobular fibrosis. Table 25 shows 


























patients with and without IPTH. The same table also compares the proportion of 
biopsies with fibrosis above specific thresholds between those with and without IPTH. 
Throughout this Result section, mean/average scores are displayed in light 
grey cells and proportion/number of samples above specified thresholds in white cells.  
 
Table 25. IPTH and fibrosis 
Fibrosis per compartment IPTH + IPTH - p value 
Portal (mean and range)  2.8 (0-5) 1.4 (1-4) 0.001 
Portal ³2 (% and number) 81.8% (18/22) 36.7% (11/30) 0.001 
Portal ³3 (% and number) 63.6% (14/22) 23.3% (7/30) 0.004 
Centrilobular (mean and range) 1.4 (0-3) 0.8 (0-3) 0.023 
Centrilobular ³1 (% and number) 86.4% (19/22) 53.3% (16/30) 0.024 
Centrilobular ³2 (% and number) 50% (11/22) 30% (9/30) 0.120 
Sinusoidal (mean and range) 1.0 (0-3) 0.6 (0-3) 0.039 
Sinusoidal ³1 (% and number) 72.7% (16/22) 50% (15/30) 0.196 
Sinusoidal ³2 (% and number) 31.8% (7/22) 3.3% (1/30) 0.007 
CPA (mean and range) 3.9% (0.7-9.1) 2.3% (0.33-9.7) 0.039 
 
The two patients who no longer received immunosuppression by the time of 
protocol biopsy were both 16-years old, had undergone liver transplantation for biliary 
atresia, had normal LFTs and no circulating autoantibodies at biopsy. One of them 
was tested for DSA and had circulating class II DSA with high MFI (23606), anti-DQ 
and anti-DR subtypes. The other recipient did not have a sample for DSA testing. 
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These two children showed advanced stage fibrosis on biopsy, central 
perivenulitis (grade 1 in one and grade 2 in the other), marked centrilobular fibrosis 
and sinusoidal fibrosis (stage 3 in one, stage 1 in the other).  The recipient who had 
DSA showed negative C4d staining (minimal weak staining in portal veins and stroma) 
and the second recipient showed focal moderate C4d deposition in portal capillaries 
and hepatic arteries. Clinical and histological details on these liver recipients, including 
histological findings, are shown in Table 26. 
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Table 26. Clinical and histological characteristics of two patients off 
immunosuppression 
 Patient 1 Patient 2 
Indication for LT Biliary atresia Biliary atresia 
Gender Male Female 
Age at LT 11 months 1 year 
Time off immunosuppression 20 months 8 months 
Age at protocol biopsy 16 years 16 years 
AST at protocol biopsy           
(normal range 10-50) 
38  26  
 
Circulating DSA (at biopsy) 






Isolated CP with advanced 
stage fibrosis 
Marked bridging and 
centrilobular fibrosis with mild 
CP and portal inflammation 
 
Inflammation grading 
CP 2;  Lobular 2;  Portal 0;  
Interface 0 
CP 1;  Lobular 1;  Portal 1;  
Interface 0 
Fibrosis staging Ishak 5;  CLF 3;  Sinusoidal 
3 




(Minimal weak + in portal 
veins and portal stroma) 
Positive in portal capillaries and 
hepatic arteries 
(focal moderate C4d+) 
 
Outcome 
Lost follow-up after protocol 
biopsy 
Stable without 
immunosuppression 6 years 
after protocol biopsy 
* CLF, centrilobular fibrosis; CP, central perivenulitis 
 
3.3.3 Comparison of fibrosis assessment: conventional and digital 
 
Overal, mean CPA was significantly higher in biopsies with more advanced 
centrilobular and sinusoidal fibrosis. Mean CPAs for the following stages of 
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centrilobular fibrosis (CLF) were: 1.9% for stage 0/1;  4.4% for stage 2  and 7.3% for 
stage 3 (p<0.001, Figure 29).  For sinusoidal fibrosis, median CPA was: 2.4% for stage 
0/1;  5.8% for stage 2 and 8.8% for stage 3 (p<0.001, Figure 30).  The CPA was not 
statistically associated with the degree of portal fibrosis.  
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Figure 29 (above). Median CPA and Centrilobular Fibrosis (p<0.001)
	
Figure 30. Median CPA and Sinusoidal Fibrosis (p<0.001) 
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3.3.4 Fibrosis, inflammation and clinical parameters 
  
 A strong statistical association was found between the presence of sinusoidal 
fibrosis and younger age at transplantation (p=0.009).  The median age at LT of 
children who showed some degree of sinusoidal fibrosis (³1) was 8.7 months versus 
22.0 months of children without sinusoidal fibrosis (Figure 31). Considering the 
threshold ³2 as significant sinusoidal fibrosis, the median age of patients with fibrosis 




Figure 31 (above).  Age at LT and Sinusoidal fibrosis ³1 (p=0.009) 
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 Portal fibrosis was significantly associated with steroid-free 
immunosuppression at the time of biopsy.  The average degree of portal fibrosis was 
lower in patients receiving steroid (1 versus 3), as was the frequency of portal fibrosis 
stage ³2 (48% versus 83% in patients not receiving steroid), as depicted in Table 27. 
Patients with steroid-free immunosuppression also had higher average scores of 
centrilobular fibrosis and CPA, but the differences were not statistically significant. 
 
Table 27.  Steroid and fibrosis per compartment 
Fibrosis per compartment Steroid + Steroid - p value 
Portal (mean and range) 1.7 (0-5) 2.9 (0-5) 0.023 
Portal ³2 (% and number) 47.5% (19/40) 83.3% (10/12) 0.046 
Portal ³3 (% and number) 32.5% (13/40) 66.7% (8/12) 0.048 
Centrilobular (mean and range) 0.9 (0-3) 1.5 (0-3) 0.221 
Centrilobular ³1 (% and number) 65% (26/40) 75% (9/12) 0.792 
Centrilobular ³2 (% and number) 35% (14/40) 50% (6/12) 0.500 
Sinusoidal (mean and range) 0.7 (0-3) 0.7 (0-3) 0.688 
Sinusoidal ³1 (% and number) 62.5% (25/40) 50% (6/12) 0.617 
Sinusoidal ³2 (% and number) 15% (6/40) 16.7% (2/12) 1.000 
CPA (mean and range) 2.8% (0.33-9.7)  3.8% (1.2-9.1) 0.221 
 
 
 Although all patients with poor outcome had portal fibrosis (³2) as against 53% 
of those with good outcome, this difference was not statistically significant (p=0.245), 
likely due to the scarce number of patients with poor outcome during follow-up (only 
3).  Poor outcome was defined as allograft loss during follow up (until March 2018). 
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Outcome was not significantly associated with fibrosis in other compartments or with 
CPA. 
 The following clinical parameters did not show statistical association/correlation 
with fibrosis in any compartment or with the CPA: time from transplant to biopsy, type 
of calcineurin inhibitor used for immunosuppression (tacrolimus or cyclosporine), type 
of graft (whole or split), type of donation (DBD or DCD or LRLT), previous episodes of 
rejection, autoantibodies, and liver biochemistry (ALT, AST, bilirubin, GGT, AP, 
platelets, INR).  
 Patients receiving steroid-free immunosuppression showed almost double the 
rate of IPTH than those using steroid (67% versus 35%, respectively), and this 
difference was extremely close to statistical significance (p=0.051). Considering 
inflammation in each compartment, only moderate portal inflammation was 
significantly linked to steroid-free immunosuppression. Two-thirds of the patients with 
moderate portal inflammation did not receive steroid versus only 18% of those with 
no/mild portal inflammation (p=0.021). Although not significant, patients receiving 
steroids had lower average scores of inflammation in portal, interface and centrilobular 
compartments. Table 28 shows a comparison of the average score of inflammation 
per compartment and of the proportion of biopsies above certain thresholds of 
inflammation between patients receiving or not steroid. 
 Inflammation in each compartment was not associated with other clinical 
parameters: age at transplantation, time from transplant to protocol biopsy, type of 
calcineurin inhibitor used for immunosuppression, type of graft, type of donation, 
previous episodes of rejection, presence of autoantibodies and liver biochemistry. 
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Table 28. Steroid and inflammation per compartment 
Inflammation per compartment Steroid + Steroid - p value 
Portal (mean and range) 0.6 (0-2)  1.0 (0-2) 0.104 
Portal ³1 (% and number) 50% (20/40) 75% (8/12) 0.510 
Portal ³2 (% and number) 5% (2/40) 33.3% (4/12) 0.021 
Interface (mean and range) 0.1 (0-1) 0.4 (0-2) 0.082 
Interface ³1 (% and number) 12.5% (5/40) 33.3% (4/12) 0.185 
Interface ³2 (% and number) 0 (/40) 8.3% (1/12) 0.231 
Lobular (mean and range)  0.5 (0-2) 0.5 (0-2) 0.825 
Lobular ³1 (% and number) 45% (18/40) 41.7% (5/12) 1.000 
Lobular ³2 (% and number) 92.5% (37/40) 91.7% (11/12) 1.000 
CP (mean and range) 0.2 (0-2) 0.6 (0-2) 0.061 
CP ³1 (% and number) 20% (8/40) 50% (6/12) 0.063 
CP ³2 (% and number) 7.5% (3/40) 8.3% (1/12) 1.000 
IPTH (% and number) 35% (14/40) 66.7% (8/12) 0.051 
 
3.3.5 DSA: general results 
 
DSA testing was performed in 34 (out of 52) liver recipients who had both donor 
HLA data and serum sample available for analysis. Twenty-four (71%) of them had 
circulating DSA at the time of protocol biopsy: 18 directed to class II, 2 to class I, and 
4 to both class I and class II HLA antigens (Table 29). For class II subtypes, 50% of 
patients with class II DSA had anti-DQ antibodies only, 27% had both anti-DQ and 
anti-DR, and 23% had anti-DR only. No children had anti-DP HLA antibodies. 
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Table 29. DSA test results 
DSA Number (%) 
Class II only 18 (52.9%) 
Class I and II 4 (11.8%) 
Class I only 2 ( 5.9%) 
No DSA 10 (29.4%) 
  
 
3.3.6 DSA and clinical parameters 
 
 There were no significant differences regarding clinical parameters between 
patients with and without DSA or DSA II.   Nonetheless, the median age at 
transplantation of patients with DSA II was younger (9.7 versus 22 months) compared 
to those without these antibodies, and this difference was extremely close to statistical 
significance (p=0.052).  Table 30 and Table 31 show clinical parameters in patients 
with and without circulating DSA and DSA II, respectively. 
	 131	
Table 30. Clinical data and DSA 
Clinical parameters DSA + DSA - p value 
Male gender (% and number) 50% (12/24) 30% (3/10) 0.247 
Age at LT (median and range in months) 11.6 (0.6-57.6) 19.7 (9.7-46.2) 0.088 
Time from LT to biopsy (median and range) 11.7 (9.6-15.4) 11.2 (8.6-13.1) 0.756 



















60% (6/10) 0.160 




























AST (median and range) 30.5 (15-76) 28.5 (14-109) 0.849 
Previous rejection (% and number) 62.5% (15/24) 70% (7/10) 0.346 
Autoantibodies (% and number) 16.7% (4/24) 30% (3/10) 0.088 
Poor outcome - death or graft loss (% and 
number) 
8.3% (2/24) 10% (1/10) 0.115 
LT, liver transplantation; CNI, calcineurin inhibitor;  TAC, tacrolimus;  CyA, cyclosporine;  DBD, 





Table 31. Clinical data and DSA II	
Clinical parameters DSA II + DSA II - p value 
Male gender (% and number) 50% (11/22) 33.3% (4/12) 0.285 
Age at LT, months (median and range in 
months) 
10.2  (0.6-57.6) 22.0 (9.7-46.2) 0.052 
Time from LT to biopsy (median and 
range) 
11.0 (9.6-15.4) 12.0 (8.6-14.3) 0.791 


















































AST (median and range) 31.5  (15-76) 29.5  (14-109) 0.859 
Previous rejection (% and number) 59.1% (13/22) 
 
75% (9/12) 0.256 
Autoantibodies (% and number) 18.2% (4/22) 
 
25% (3/12) 0.124 
Poor outcome - death or graft loss (% and 
number) 
9.1% (2/22) 8.3% (1/12) 0.137 
LT, liver transplantation; CNI, calcineurin inhibitor;  TAC, tacrolimus;  CyA, cyclosporine;  
DBD, donation after brain death;  DCD, donation after cardiac death; LRLT, living-related 
liver transplant.
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3.3.7 DSA, inflammation and fibrosis 
 
Of the 24 liver recipients with circulating DSA, 20 (83.3%) had abnormal 
histology. Nine had IPTH associated with fibrosis; 9 had simply fibrosis; and 2 had 
IPTH only. All patients with IPTH and fibrosis had portal fibrosis (³2), 6 also had 
significant centrilobular fibrosis (³2) and 3 of them also had sinusoidal fibrosis ³2 
(besides portal and centrilobular fibrosis).  As to the 9 patients with fibrosis only, 8 had 
portal fibrosis (³2) and 1 had just centrilobular fibrosis (³2). 
Regarding the 10 recipients without DSA, 3 (30%) showed both IPTH and 
fibrosis, 3 (30%) had fibrosis only and 4 (40%) had normal histology. Forty percent of 
patients without DSA had normal histology versus only 16.7% of those with DSA, but 
this difference was not statistically significant.  These results are depicted in Table 32.  
 
Table 32. Overal biopsy findings and DSA 
Histological findings DSA + DSA - p value 
IPTH + fibrosis 37.5% (9/24) 30% (3/10) 0.162 
Fibrosis only (Ishak³2, CLF³2 
or sinusoidal fibrosis³2) 
37.5% (9/24) 30% (3/10) 0.162 
IPTH (without fibrosis) 8.3% (2/24) 0 0.317 
Normal/near normal 16.7% (4/24) 40% (4/10) 0.151 
 
As to the 22 recipients with DSA II, 18 (81.8%) had abnormal biopsy: 8 had 
IPTH associated with fibrosis; 8 had fibrosis only and 2 had IPTH only. Table 33 
summarizes these findings. 
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Table 33. Overal biopsy findings and DSA II 
Histological findings DSA II + DSA II - p value 
IPTH + fibrosis 36.4% (8/22) 33.3% (4/12) 0.438 
Fibrosis only (Ishak ³2, CLF 
³2 or Sin ³2) 
36.4% (8/22) 33.3% (4/12) 0.438 
IPTH (without fibrosis) 9.1% (2/22) 0 0.212 
Normal/near normal 18.2% (4/22) 33.3% (4/12) 0.259 
 
The histological parameters in patients with and without DSA are shown in 
Table 34. The parameters are expressed in average and range or percentage and 
number of cases. Lobular inflammation was the only parameter significantly different 
between patients with and without DSA. On multivariate analysis, lobular inflammation 
was also the only parameter significantly associated with the presence of DSA 





Table 34. Detailed histological parameters and DSA 
Histological parameter DSA + DSA - p value 
Portal fibrosis Ishak (mean and range)  2.3 (0-5) 2.0 (1-4) 0.522 
Portal fibrosis Ishak ³2 (% and number) 70.8% (17/24) 50% (5/10) 0.221 
Portal fibrosis Ishak ³3 (% and number) 50% (12/24) 30% (3/10) 0.247 
CLF (mean and range) 1.1 (0-3) 1.1 (0-3) 0.737 
CLF present  (% and number) 70.8% (17/24) 70% (7/10) 0.633 
CLF ³2  (% and number) 41.7% (10/24) 30% (3/10) 0.406 
Sinusoidal fibrosis (mean and range)  0.8 (0-3) 0.5 (0-2) 0.205 
Sinusoidal fibrosis present (% and number) 66.7% (16/24) 40% (4/10) 0.145 
Sinusoidal fibrosis ³2 (% and number) 12.5% (3/24) 10% (1/10) 0.666 
CPA (mean and range) 2.3 (0.34-7.78) 3.1 (0.33-8.06) 0.331 
Portal Inflammation (mean and range) 0.7 (0-2) 1.0 (0-2) 0.247 
Portal inflammation moderate* (% and number) 8.3% (2/24) 30% (3/10) 0.138 
Interface activity (mean and range) 0.2 (0-1) 0.2 (0-2) 0.549 
Interface activity present (% and number) 20.8% (5/24) 10% (1/10) 0.416 
Interface activity moderate* (% and number) 0 (/24) 10% (1/10) 0.294 
Portal vein endotheliitis (mean and range)  0 (0) 0  (0) 1.000 
CP (mean and range)  0.3 (0-2) 0.2 (0-1) 0.369 
CP present (% and number) 33.3% (8/24) 20% (2/10) 0.367 
CP moderate* (% and number) 12.5% (3/24) 0 (/10) 0.338 
Lobular inflammation (mean and range) 0.6  (0-2) 0.1  (0-1) 0.018 
Lobular inflammation present (% and 
number) 
54.2% (13/24) 10% (1/9) 0.019 
Lobular inflammation moderate* (% and 
number) 
12.5% (3/24) 0 (/10) 0.338 
Bile duct injury (mean and range) 0.2 (0-1) 0.2 (0-1) 0.819 
Bile duct loss present (% and number) 0 (0) 0 (0) 1.000 
Canalicular cholestasis (mean and range) 0 (0) 0  (0) 1.000 
Ductular reaction present (% and number) 20.8% (5/24) 40% (4/10) 0.230 
CLF, centrilobular fibrosis 
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* No patients had grade 3 inflammation in any of these compartments: portal, interface, lobular and 
central veins 
Table 35. Detailed histological parameters and DSA II 
Histological parameter DSA II + DSA II - p value 
Portal fibrosis Ishak (mean and range) 2.4 (0-5) 2.0 (1-4) 0.470 
Portal fibrosis Ishak ³2 (% and number) 68.2% 
(15/22) 
58.3% (7/12) 0.084 
Portal fibrosis Ishak ³3 (% and number) 54.5% 
(12/22) 
25% (3/12) 0.098 
CLF (mean and range) 1.1 (0-3) 1.1 (0-3) 0.970 
CLF present  (% and number) 68.2 (15/22) 75% (9/12) 0.244 
CLF ³2  (% and number) 40.9% (9/22) 33.3% (4/12) 0.427 
Sinusoidal fibrosis (mean and range) 0.8 (0-3) 0.5 (0-2) 0.159 
Sinusoidal fibrosis present (% and number) 68.2 (15/22) 41.7% (5/12) 0.154 
Sinusoidal fibrosis ³2 (% and number) 13.6% (3/22) 8.3% (1/12) 0.275 





Portal Inflammation (mean and range) 0.7 (0-2) 1.0 (0-2) 0.397 
Portal inflammation moderate* (% and number) 9.1% (2/22) 25% (3/12) 0.111 
Interface activity (mean and range) 0.2 (0-1) 0.3 (0-2) 1.000 
Interface activity present (% and number) 18.2% (4/22) 16.7% (2/12) 0.486 
Interface activity moderate* (% and number) 0 (/22) 8.3% (1/12) 0.041 
Portal vein endotheliitis (mean and range) 0 (0) 0 (0) 1.000 
CP (mean and range) 0.3 (0-2) 0.3 (0-2) 0.752 
CP present (% and number) 27.3% (6/22) 33.3% (4/12) 0.346 
CP moderate* (% and number) 9.1% (2/22) 8.3% (1/12) 0.416 
Lobular inflammation (mean and range) 0.6 (0-2) 0.2 (0-1) 0.122 
Lobular inflammation present (% and number) 50% (11/22) 25% (3/12) 0.158 
Lobular inflammation moderate* (% and 
number) 
13.6% (3/22) 0 (/12) 0.193 
Bile duct injury (mean and range) 0.2 (0-1) 0.2 (0-1) 0.913 
Bile duct loss present (% and number) 0 (0) 0 (0) 1.000 
Canalicular cholestasis (mean and range) 0 (0) 0 (0) 1.000 
Ductular reaction present (% and number) 22.7% (5/22) 33.3% (4/12) 0.163 
CLF, centrilobular fibrosis 






Figure 32. Protocol biopsy 15 years post-transplantation for biliary atresia 
showing moderate (grade 2) lobular inflammation. The patient had circulating 




3.3.8 C4d immunohistochemistry 
 
Fifty out of the 52 biopsy blocks had enough tissue for additional staining and 
C4d immunohistochemistry was performed. The overall quality of C4d staining was 
good with little background in most samples, which did not interfere with the 
assessment (Figure 33).  Control samples stained appropriately. The association 
between C4d, DSA and other histological parameters are explored in the following 
sections of this chapter. Overall, 34% of biopsies had at least focal C4d deposition in 
one or more compartments and were considered C4d positive (C4d+). 
One-fourth of biopsies showed portal endothelial microvascular C4d+ (in portal 
veins or portal capillaries). This was included as a separate category/compartment 
because it was the criteria used for C4d+ in the Banff chronic AMR score[53]. The 
specific proportion of biopsies with at least focal C4d deposition in each individual 
compartment was: in portal veins, 16%;  portal capillaries, 16%;  portal stroma, 10%;  
hepatic arteries, 18%;  central veins, 4%; sinusoids, 2%. The results of the C4d 




Figure 33. Biopsy with strong diffuse C4d staining in vascular compartments 





Table 36. C4d deposition per compartment 
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3.3.9 DSA  and  C4d immunohistochemistry 
 
 Thirty-four patients had both DSA and C4d data.  Although overall patients with 
DSA had higher proportion of C4d+ in most compartments, particularly in portal veins, 
the differences were not statistically significant. Table 37 and Table 38 show the 
frequency of C4d+ per compartment in patients with and without circulating DSA and 
DSA II, respectively. 
 
Table 37. C4d deposition and circulating DSA 
 
Table 38. C4d deposition and circulating class II DSA 
C4d+ in DSA + DSA - p value 
Portal microvascular endothelium  16.7%  (4/24) 10%  (1/10) 0.535 
Portal vein 16.7%  (4/24)       0  (0/10) 0.296 
Portal capillaries 12.5%  (3/24) 10%  (1/10) 1.000 
Hepatic artery 20.8%  (5/24) 10%  (1/10) 0.644 
Portal stroma 16.7% (4/24) 10% (1/10) 0.535 
Central vein 4.2%  (1/24)      0  (0/10) 1.000 
Sinusoids 4.2%  (1/24)      0  (0/10) 1.000 
Any compartment 37.5% (9/24) 20% (2/10) 0.437 
C4d+ in DSA II + DSA II - p value 
Portal microvascular endothelium 13.6%  (3/22) 8.3%  (1/12) 1.000 
Portal vein 13.6%  (3/22) 8.3%  (1/12) 1.000 
Portal capillaries 9.1%  (2/22) 16.7%  (2/12) 0.602 
Hepatic artery 18.2%  (4/22) 16.7%  (2/12) 1.000 
Portal stroma 13.6%  (3/22) 16.7%  (2/12) 1.000 
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3.3.10 C4d and Inflammation 
 
 Central perivenulitis was significantly associated with C4d+ in portal vascular 
structures (portal microvascular endothelium and hepatic arteries). Lobular 
inflammation was also associated with C4d+ in hepatic arteries, as depicted in Table 
39. Patients with portal inflammation and interface activity also had higher proportions 
of C4d+ in most compartments, particularly portal capillaries, but this was not 
significant. 
 Considering the average inflammation score, C4d+ (in portal microvascular 
endothelium, portal veins and hepatic arteries) was linked to significantly higher 
degree of lobular inflammation (Table 40). Positive C4d staining in all portal vascular 
compartments was also associated with higher average score of central perivenulitis. 
 
 
Central vein 4.5% (1/22) 0  (/12) 1.000 
Sinusoids 4.5%  (1/22) 0  (/12) 1.000 
Any compartment 36.4% (8/22) 25% (3/12) 0.705 
	 143	
Table 39.  Frequency of C4d+ in each compartment versus inflammation in portal tracts, interface, lobule and central veins  
 
C4d+ in 


































































































































































Table 40. Average degree of inflammation in each compartment versus C4d positivity or negativity in each site 










Central vein (CP) 
C4d staining per 
compartment 



























 0.9 (0-2) 0.6 (0-2) 0.183 0.3 (0-1) 0.1 (0-2) 0.202 0.8 (0-2) 0.4 (0-2) 0.045 0.7 (0-2) 0.2 (0-2) 0.009 
Portal vein 0.9 (0-2) 0.6 (0-2) 0.323 0.4 (0-1) 0.1 (0-2) 0.084 0.9 (0-2) 0.4 (0-2) 0.031 0.7 (0-2) 0.2 (0-2) 0.013 
Portal capillaries 1.0 (0-2) 0.6 (0-2) 0.103 0.4 (0-1) 0.1 (0-2) 0.084 0.9 (0-2) 0.4 (0-2) 0.067 0.8 (0-2) 0.2 (0-2) 0.013 
Hepatic artery 0.8 (0-2) 0.7 (0-2) 0.579 0.2 (0-1) 0.2 (0-2) 0.607 0.9 (0-2) 0.4 (0-2) 0.037 0.7 (0-2) 0.2 (0-2) 0.031 
Portal stroma 1.0 (0-2) 0.6 (0-2) 0.256 0.4 (0-1) 0.2 (0-2) 0.140 0.8 (0-2) 0.4 (0-2) 0.259 0.6 (0-2) 0.2 (0-2) 0.375 
Central vein 1.0 (0-2) 0.7 (0-2) 0.663 0.5 (0-1) 0.2 (0-2) 0.199 0.5 (0-1) 0.5 (0-2) 0.955 1.0 (0-2) 0.2 (0-2) 0.272 
Sinusoids - 0.6 (0-2) - - 0.2 (0-2) - - 0.5 (0-2) - - 0.2 (0-2) - 
Any compartment 0.7 (0-2) 0.7 (0-2) 0.685 0.2 (0-1) 0.2 (0-2) 0.859 0.7 (0-2) 0.4 (0-2) 0.078 0.4 (0-2) 0.2 (0-2) 0.106 
*  Only one biopsy showed C4d+ in sinusoids. It was not possible to obtain mean inflammation scores and p value based on a single 
specimen
	 145	
3.3.11 C4d and fibrosis 
 
Centrilobular and sinusoidal fibrosis (³2) were individually associated with 
C4d+ in portal microvascular endothelium. Sinusoidal fibrosis was also strongly 
associated with C4d+ in portal veins, present in 57% of patients with and 9% of those 
without sinusoidal fibrosis (p=0.004). Patients with portal fibrosis had higher frequency 
of C4d+ than those without, particularly in portal capillaries (21.4% versus 9.1%), but 
this was not significant for any compartment. Table 41 shows the proportion of C4d+ 
in biopsies with and without significant fibrosis in each compartment. Considering the 
average score of fibrosis, patients with C4d+ in portal microvascular endothelium had 
higher degrees of sinusoidal and centrilobular fibrosis and of CPA, as depicted in 
Table 42.  
 Overall, considering both inflammation and fibrosis, C4d staining in portal 
microvascular endothelium was significantly associated with central perivenulitis, 







Table 41. Frequency of C4d+ in each compartment versus fibrosis in sinusoids, central veins and portal tracts  
 
C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p value ³2 0/1 p 
value 




57.1% (4/7) 14.0% (6/43) 0.022 36.8% (7/19) 9.7% (3/31) 0.048 25% (7/28) 13.6% (3/22) 0.738 
Portal vein 57.1% (4/7) 9.3% (4/43) 0.004 26.3% (5/19) 9.7% (3/31) 0.345 17.9% (5/28) 13.6% (3/22) 1.000 
Portal capillaries 28.6% (2/7) 14.0% (6/43) 0.178 26.3% (5/19) 9.7% (3/31) 0.345 21.4% (6/28) 9.1% (2/22) 0.629 
Hepatic artery 28.6% (2/7) 16.3% (7/43) 0.198 26.3% (5/19) 12.9% (4/31) 0.445 17.9% (5/28) 18.2% (4/22) 1.000 
Portal stroma 14.3% (1/7) 9.3% (4/43) 0.291 10.5% (2/19) 9.7% (3/31) 1.000 14.3% (4/28) 4.5% (1/22) 0.682 
Central vein 14.3% (1/7) 2.3% (1/43) 0.107 10.5% (2/19) 0 (/31) 0.269 7.1% (2/28) 0        (/22) 0.747 
Sinusoids 14.3% (1/7) 0   (/43) 0.058 5.3% (1/19) 0 (/31) 0.476 3.6% (1/28) 0        (/22) 1.000 




Table 42. Average degree of fibrosis in each compartment and CPA versus C4d positivity or negativity in each site 











C4d staining per 

























































Sinusoids - 0.7 (0-3) - - 1 (0-3) - - 1.9 (0-5) - - 2.9 
(0.3-9.7) 
- 





*  Only one biopsy showed C4d+ in sinusoids. It was not possible to obtain mean inflammation score and p value based on a single specimen
	 148	
 
3.3.12 C4d in combination with DSA and Inflammation 
 
Since circulating DSA and tissue C4d deposition are considered the traditional 
markers of AMR[182] and are both required for the diagnosis of chronic AMR and 
interpreted in association, I investigated whether the presence of both DSA and C4d+ 
(DSA+C4d+) was significantly related to other histological parameters. 
 DSA+C4d+ (in portal microvascular endothelium, and specifically in portal veins 
and portal capillaries) was associated with the presence of interface activity and 
central perivenulitis.  More in details, DSA+C4d+ in portal capillaries was present in 
50% of patients with interface and in none of those without interface (p=0.003). 
Similarly, DSA+C4d+ in portal veins was present in 40% of patients with central 
perivenulitis and in none of those without (p=0.007). The proportion of C4d positivity 
in biopsies with and without inflammation in each compartment is shown in Table 43. 
 Considering specifically class II DSA, the only significant association was 
observed between interface and C4d+ in portal capillaries (combined with DSA II), 
although the difference in proportions was narrower than for DSA overall (33% versus 
0 instead of 50% versus 0, respectively), as depicted in Table 44.
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Table 43.  DSA + C4d+  and inflammation in portal tracts, interface, lobule and central veins 
 
DSA+C4d+ in 
Portal Inflammation Interface activity Lobular Inflammation CP 






























































































































































Table 44. DSA II + C4d+  and inflammation in portal tracts, interface, lobule and central veins 
 
DSA II+ C4d+ 
in 
Portal Inflammation Interface activity Lobular Inflammation CP 
+ - p value + - p 
value 


















































































































































3.3.13  C4d in combination with DSA  and  fibrosis 
 
The only significant associations were observed between sinusoidal fibrosis 
and DSA/DSA II+C4d+ in portal veins (and portal vascular endothelium), as shown in 
Table 45 and Table 46. Half of patients with sinusoidal fibrosis (³2) showed DSA 
II+C4d+ in portal veins versus only 3.3% of those with no/mild sinusoidal fibrosis. 
Despite not significant, patients with fibrosis (³2) in each compartment showed higher 
proportions of DSA+C4d+ in almost every site. 
The three following figures show a protocol biopsy of a patient with circulating 




Table 45.  DSA + C4d+ and fibrosis in sinusoids, central veins and portal tracts 
 
 
DSA + C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 




50% (2/4) 6.7% (2/30) 0.039 23.1% (3/13) 4.8% (1/21) 0.344 18.2% (4/22) 0 (/12) 0.091 
Portal vein 50% (2/4) 6.7% (2/30) 0.039 23.1% (3/13) 4.8% (1/21) 0.344 18.2% (4/22) 0 (/12) 0.091 
Portal capillaries 25% (1/4) 6.7% (2/30) 0.322 15.4% (2/13) 4.8% (1/21) 0.544 13.6% (3/22) 0 (/12) 0.537 
Hepatic artery 25% (1/4) 13.3% (4/30) 0.429 15.4% (2/13) 14.3% (3/21) 1.000 13.6% (3/22) 16.7%(2/12) 0.226 
Portal stroma 25% (1/4) 10% (3/30) 0.379 15.4% (2/13) 9.5% (2/21) 0.913 18.2% (4/22) 0 (/12) 0.091 
Central vein 25% (1/4) 0 (/30) 0.068 7.7% (1/13) 0 (/21) 0.611 4.5% (1/22) 0 (/12) 0.141 
Sinusoids 25% (1/4) 0 (/30) 0.068 7.7% (1/13) 0 (/21) 0.611 4.5% (1/22) 0 (/12) 0.141 





Table 46 (below).  DSA II + C4d+ and fibrosis in sinusoids, central veins and portal tracts 
 
 
DSA II + C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 




50% (2/4) 3.3% (1/30) 0.016 23.1% (3/13) 0 (/21) 0.087 13.6% (3/22) 0 (/12) 0.094 
Portal vein 50% (2/4) 3.3% (1/30) 0.016 23.1% (3/13) 0 (/21) 0.087 13.6% (3/22) 0 (/12) 0.094 
Portal capillaries 25% (1/4) 3.3% (1/30) 0.225 15.4% (2/13) 0 (/21) 0.139 9.1% (2/22) 0 (/12) 0.529 
Hepatic artery 25% (1/4) 10% (3/30) 0.379 15.4% (2/13) 9.5% (2/21) 0.913 9.1% (2/22) 16.7%(2/12) 0.177 
Portal stroma 25% (1/4) 6.7% (2/30) 0.269 15.4% (2/13) 4.8% (1/21) 0.714 13.6% (3/22) 0 (/12) 0.094 
Central vein 25% (1/4) 0 (/30) 0.068 7.7% (1/13) 0 (/21) 0.611 4.5% (1/22) 0 (/12) 0.141 
Sinusoids 25% (1/4) 0 (/30) 0.068 7.7% (1/13) 0 (/21) 0.611 4.5% (1/22) 0 (/12) 0.141 









Figure 34. C4d staining showing positivity in portal vein branches (stars) and 
portal capillaries (arrows) 
 
 
3.3.14 Inflammatory cells: general results 
 Although 52 biopsies were included in the study, in a number of biopsy 
specimens the inflammatory cells could not be analysed. Some specimens were 
excluded because the sections obtained for B cell and T cell staining were too small 
(less than 3mm2) or because the final digitalised image showed artefacts that 
interfered with the cell count: time limitations prevented repeat staining. Thus, 40 
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biopsies were stained and analysed for B cells and plasma cells, while 42 were 
analysed for T cells and CD8+ T cells. 
 
For the specimens examined, the median biopsy area was 10.7 mm2 (ranging 
from 3 to 20); the median number of B cells per mm2 was 15.3 (range 4.5 - 45.4), and 
the median number of plasma cells per mm2 was 1.67 (range 0 to 10). The total 
number of T cells per mm2 varied extremely between biopsies, from 1.6 to 403.5 
cells/mm2 (median 91.2), and the number of cytotoxic T cells ranged from 1.4 to 193.2 
cells/mm2 (median 29.6). Table 47 shows the minimum, maximum and median 
number of inflammatory cells in the biopsy specimens. 
 
Table 47. Number of inflammatory cells in protocol biopsies 
Cell type Minimum Maximum Median 
B cells/mm2 4.5  45.4 15.3 
Plasma cells/mm2 0  10.0  1.7 
T cells/mm2 1.6 403.5 91.2 
CD8 T cells/mm2 1.4 193.2 29.6 
 
3.3.15  Inflammatory cells  and  Fibrosis 
 The number of plasma cells was strongly associated with sinusoidal fibrosis 
(p=0.008) and also significantly associated with centrilobular and portal fibrosis  
(p=0.043 and 0.041, respectively). Biopsies with portal fibrosis (³2) also had 
significantly higher numbers of B cells (p=0.010). The association between sinusoidal 
fibrosis (³2) and B cells was near significant (p=0.053). 
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Table 48. Median number of inflammatory cells and fibrosis in sinusoids, 





Sinusoidal fibrosis Centrilobular 
fibrosis 
Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 
³2  0/1 p 
value 
B cells 20.1 14.1 0.053 17.9 13.8 0.558 18.6 10.3 0.010 
Plasma cells 4.2 1.4 0.008 4.0 1.1 0.043 2.1 1.2 0.041 
T cells 220.8 64.9 0.353 105.2 64.9 0.808 95.7 47.0 0.513 
CD8+ T cells 83.3 20.0 0.273 30.2 20.0 0.729 35.1 12.0 0.363 
 
 
 The measured CPA showed a significant moderate positive correlation with the 
number of B cells (p=0.037 and r=0.344).  Although the Pearson’s correlation 
coefficient (r) between CPA and plasma cells was 0.310 (indicating a moderate 
positive correlation), it did not quite reach statistical significance (p=0.062). However, 
considering the small size of the sample, and the limited importance of p value in the 
Pearson’s correlation test, it is reasonable to assume that this result (r=0.310 and 
p=0.062) suggests a real, positive correlation between plasma cells and CPA. 
 There was no significant correlation between CPA and the number of T cells 
(r=0.068, p=0.681) or CD8+ T cells (r=0.191, p=0.243).  A Pearson’s correlation 
coefficient (r) from 0-0.3 was considered no/minimal correlation; 0.3-0.5, moderate 




3.3.16  Inflammatory cells  and  DSA 
 There were some differences in the numbers of B cells and T cells when 
biopsies were divided according to patients DSA (Table 49) and DSAII status (Table 
50), but these were not statistically significant and will not be considered any further. 
 
Table 49. DSA and inflammatory cells 
 DSA + DSA - P value 
B cells/mm2 18.7 16.2 0.426 
Plasma cells/mm2 2.3 1.4 0.265 
T cells/mm2 106.7 162.2 0.760 
CD8+ T cells/mm2 29.6 48.2 0.760 
 
Table 50 (below). DSA II and inflammatory cells 
 
 DSA II + DSA II - P value 
B cells/mm2 18.7 16.2 0.482 
Plasma cells/mm2 2.3 1.7 0.340 
T cells/mm2 113.1 66.6 0.737 
CD8+ T cells/mm2 31.7 18.3 0.666 
 
3.3.17 Inflammatory cells  and  C4d 
Positive C4d staining in portal microvascular endothelium was significantly 
associated with higher number of B cells and of plasma cells, but not of T cells or 
CD8+ T cells (Table 51). The median number of plasma cells per mm2 in biopsies with 
C4d+ in portal veins was more than double that of biopsies with negative C4d staining 
	 158	
in this compartment (3.9 versus 1.4, p=0.017). Interestingly, C4d+ in portal stroma was 
associated with significantly higher number of T cells (Table 51). 
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Yes No p value Yes No p value Yes No p value Yes No p value 
Portal microvascular 
endothelium  
18.7 13.8 0.037 2.9 1.3 0.035 80.3 70.9 0.915 30.2 28.0 0.963 
Portal vein 31.85 14.1 0.053 3.9 1.4 0.017 171.8 70.9 0.698 35.4 28.0 0.853 
Portal capillaries 18.6 13.9 0.037 2.9 1.3 0.035 80.3 70.9 0.601 30.2 28.0 0.673 
Hepatic artery 18.7 13.8 0.037 2.4 1.4 0.249 74.3 81.1 0.794 19.3 28.5 0.613 
Portal stroma 20.6 14.8 0.529 3.3 1.5 0.475 265.7 56.5 0.045 79.0 19.1 0.107 
Central vein* - 14.8 - - 1.7 - - 72.6 - - 24.4 - 
Sinusoids* - 14.8 - - 1.7 - - 72.6 - - 24.4 - 
Any compartment 18.6 13.8 0.107 2.2 1.3 0.186 105.2 56.5 0.534 33.1 19.1 0.517 
* No biopsy specimens stained for B cell and T cell had C4d+ in central veins or/and sinusoids (the 2 biopsies with C4d+ in these sites were too small and 
thus were excluded from the analysis). 
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3.3.18  Inflammatory cells and DSA combined with C4d 
 Although recipients with DSA/DSA II+C4d+ in almost all compartments had 
higher numbers of inflammatory cells of each subtype, these associations were not 
statistically significant (Table 52 and Table 53).  This lack of significance may be due 
to the combination of a relatively small number of patients (34) for whom DSA data 

















CD8+ T cells 
(median/mm2) 
 
DSA + C4d+ in 
Yes No p value Yes No p value Yes No p value Yes No p value 
Portal microvascular 
endothelium  
32.4 17.9 0.165 3.6 1.7 0.190 269.2 105.2 0.343 51.5 29.0 0.511 
Portal vein 32.4 17.9 0.165 3.6 1.7 0.190 269.2 105.2 0.393 51.5 29.0 0.511 
Portal capillaries 32.4 17.9 0.165 3.6 1.7 0.190 269.2 105.2 0.393 51.5 29.0 0.511 
Hepatic artery 26.4 17.7 0.065 3.0 1.8 0.453 103.4 106.7 0.741 26.2 29.6 0.741 
Portal stroma 26.5 17.8 0.339 3.4 1.8 0.195 203.7 89.6 0.237 56.1 29.1 0.393 
Central vein - 17.7 - - 2.1 - - 105.2 - - 33.1 - 
Sinusoids - 17.7 - - 2.1 - - 105.2 - - 33.1 - 















CD8+ T cells 
(median/mm2) 
 
DSA II + C4d+ in 
Yes No p value Yes No p value Yes No p value Yes No p value 
Portal microvascular 
endothelium  
30.1 18.2 0.405 3.9 1.8 0.308 285.7 89.7 0.220 67.4 28.5 0.281 
Portal vein 30.1 18.2 0.405 3.9 1.8 0.308 285.7 89.7 0.220 67.4 28.5 0.281 
Portal capillaries 30.1 18.2 0.405 3.9 1.8 0.308 285.7 89.7 0.220 67.4 28.5 0.281 
Hepatic artery 20.4 17.8 0.165 2.4 2.0 0.700 132.6 105.2 0.555 33.1 29.0 0.511 
Portal stroma 20.6 17.9 0.700 3.3 2.0 0.316 302.3 74.3 0.110 83.3 28.0 0.194 
Central vein - 17.9 - - 2.0 - - 105.2 - - 29.0 - 
Sinusoids - 17.9 - - 2.0 - - 105.2 - - 29.0 - 
Any compartment 19.1 18.2 0.641 2.3 1.8 0.683 200.9 72.6 0.186 42.3 23.6 0.170 
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3.3.19 Expression of granzyme B by B cells 
 The analysis of the B cell immunofluorescence staining (CD79a, CD138, DAPI) 
revealed expression of GrzB by B lymphocytes (CD79a+CD138- cells) in 12 out of the 
42 (28.6%) biopsies. In 11 biopsies, the double positive cells were observed in portal 
tracts and in one biopsy, in the lobular region.  There were few GrzB+ B cells per 
biopsy, ranging from 1 to 4 cells (average 1.5).  Because of the small number of 
biopsies with GrzB+ B cells, no statistical analysis was possible to correlate this with 
other parameters, such as degree of fibrosis and inflammation. 
 No double positive cells (CD79a+GrzB+CD138-) were present in the 
centrilobular/perivenular area and no plasma cells (CD79a+CD138+) were found to 
express GrzB.  Examples of B cells expressing granzyme B (CD79a+GrzB+CD138-) 
in portal tracts and lobule are shown in the next three figures. The red images 
correspond to CD79a, the green images to GrzB, and cyan images to CD138 staining. 




Figure 35. Portal tract with a CD79a+ (red) CD138- (cyan) cell expressing 










Figure 36. Lobular area with a CD79a+ (red) CD138- (cyan) cell expressing 






Figure 37. Large portal tract with a CD79a+ (red) CD138- (cyan) cell expressing 
granzyme B (green). The CD138 staining highlights a large portal bile duct at 












Analysis was conducted of 55 protocol biopsies obtained between 8.6-15.6 
years post-transplant from children who were clinically asymptomatic. The average 
time from LT to protocol biopsy was 11.8 years and average age of patients at biopsy, 
13.2 years. The most frequent indication for transplantation was biliary atresia. A high 
rate of abnormal histology was observed, consisting predominantly of chronic 
inflammation and fibrosis, in addition to a high prevalence of circulating DSA. 
Significant associations were found between clinical and histological parameters. 
At the time of the protocol biopsy, 43% of patients received tacrolimus, 40% 
received cyclosporine and 78% of children also had steroids as part of their 
immunosuppression regime. Although no patient had clinical evidence of graft 
dysfunction and most had normal liver biochemistry, a few recipients had mildly 
abnormal liver enzymes at the time of protocol biopsy. 
Two-thirds of children (66%) had at least one previous episode of acute 
rejection confirmed histologically, a frequency comparable to that found by Miyagawa-
Hayashino et al. (67%)[28] and higher than that reported by other centres[40,184-185]. 
Autoantibodies were present in 19% of patients, a lower rate compared to that reported 
by Evans et al. in their paediatric protocol biopsy study, in which autoantibodies were 
detected in 57% of children at 10 years post-transplant[23]. 
 Histological abnormalities were observed in the majority (73%) of biopsy 
specimens. Fibrosis was most common, affecting 60%, with 40% of biopsies already 
showing bridging fibrosis or cirrhosis. Unexplained chronic inflammation/IPTH was the 
second most frequent histological abnormality, present in 40% of transplant recipients 
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and typically accompanied by portal fibrosis (in 82% of cases). Fibrosis without 
inflammation was present in 27% of children. 
 Previous studies have reported high rates of abnormality in protocol biopsies of 
asymptomatic children, many of whom had normal liver biochemistry, and in some 
cases the biopsy findings led to a change in immunosuppression treatment[23,29,40,186]. 
This observation reinforces the relevance of protocol biopsies in monitoring allograft 
function and injury[13,19,96,120]. Currently, protocol biopsies are the only way of 
diagnosing hepatitis or fibrosis in paediatric liver recipients, since serum markers and 
non-invasive methods of fibrosis are still in need of further validation in children[187]. 
 Scheenstra et al.[29] and Evans et al.[23] reported comparable rates of 
histological abnormality in 10-year protocol biopsies of children (69% and 79%, 
respectively). In the former study, fibrosis was the commonest histological finding, 
present in 69% of 10-year protocol biopsies, with 49% showing bridging fibrosis or 
cirrhosis, a slightly higher frequency than that of the current cohort (60% fibrosis and 
40% bridging fibrosis or cirrhosis). Chronic inflammation, however, was a very unusual 
finding[29].  
 On the other hand, Evans et al. observed unexplained chronic hepatitis in 
almost two-thirds of protocol biopsies (64%)[23], a higher rate than found in the current 
study (40%).  This difference might be due to an important distinction between the 
cohorts: whilst in the Evans series, the patients did not receive steroid as part of the 
immunosuppression, in the current study, most children (78%) did. Use of steroid 
might also explain the lower rate of autoantibodies found in the present study, 
compared to that reported previously (19% versus 57%)[23]. Low-dose steroids are 
usually incorporated in paediatric post-transplant long-term immunosuppression at 
King’s College Hospital. 
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 Despite being lower than that reported by Evans et al.[23], the prevalence of 
IPTH was substantial in the current study cohort (40%). This is even more true 
compared to Scheenstra et al’s analysis[29], in which patients also received steroids. 
Chronic inflammation was not relevant in Scheenstra’s series, perhaps because the 
standard immunosuppressive regime consisted of triple therapy with cyclosporine, 
azathioprine and prednisolone, whereas in the current study cohort, most patients did 
not receive azathioprine, and 23% were under steroid-free immunosuppression by the 
time of biopsy.  
 In their study of late follow-up biopsies of paediatric recipients, Kosola et al.[188] 
found portal inflammation to be inversely associated with the use of steroid. Whilst 
only 14% of recipients receiving steroid had portal inflammation, almost half (47%) of 
those under steroid-free immunosuppression showed inflammatory activity in portal 
tracts (p=0.009)[188]. Another study of for cause post-transplant biopsies of paediatric 
patients also evidenced a link between the presence of fibrosis and steroid-free 
immunosuppression[50].  
 In the current analysis, steroid-free immunosuppression was individually 
associated with higher prevalence of IPTH (almost double), more severe portal 
inflammation and with portal fibrosis. Whereas only 5% of patients receiving steroid 
had moderate portal inflammation, one-third of those under steroid-free 
immunosuppression displayed this degree of inflammation (p=0.021, Table 28 on 
page 129). Other authors have reported an association between IPTH and steroid-
free immunosuppression, autoantibodies and previous episodes of rejection[23,28,189]. 
In the present series, IPTH or inflammation in each compartment were not associated 
with the presence of autoantibodies. For portal fibrosis, the mean Ishak score of 
patients receiving steroid was 1.7 versus 2.9 for patients under steroid-free 
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immunosuppression (p=0.023). The proportion of portal fibrosis (Ishak ³2) was 47% 
versus 83% (p=0.046) for patients receiving and not receiving steroid, respectively 
(Table 27 on page 127). 
 The rate of fibrosis was also slightly higher in Evans’ series compared to the 
current study: bridging fibrosis or cirrhosis was present in 50% of 10-year protocol 
biopsies[23], in comparison to 40% in the current study. This is probably a consequence 
of the higher prevalence of chronic inflammation, since fibrosis is a result of repeated  
or ongoing liver injury[33]. 
 Another study involving 10-year liver allograft biopsies of children transplanted 
for biliary atresia found abnormal histology in 73% of patients[40], a similar rate as the 
present study (73%). The main abnormalities in the published series, however, 
consisted of chronic rejection (41%) and mild centrilobular fibrosis (22%)[40]. The 
authors did not detail the histological features, including the criteria used to diagnose 
rejection. Thus, it is not possible to clarify whether biopsies with chronic inflammation, 
for instance, might have been classified as rejection[40]. 
Centrilobular/pericentral fibrosis was very common in the current series, being 
present in two-thirds (67%) of patients, moderate or severe (grade 2/3) in 38%. 
Previous publications have also reported considerable rates of centrilobular fibrosis in 
protocol biopsies, from 22.3% to 53.8%[40,-41]. Most studies on post-transplant protocol 
biopsies, however, used conventional fibrosis scoring systems, which did not take into 
consideration centrilobular fibrosis specifically. Scoring systems conventionally used 
to quantify liver graft fibrosis were intended to grade native liver biopsies with chronic 
viral liver diseases, in which the fibrogenic process targets primarily portal tracts[36-
37,39] (Chapter 1). Centrilobular fibrosis is not specifically considered in these systems.  
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It is possible that in some paediatric protocol biopsies with advanced fibrosis, 
the fibrogenic process might have begun in the centrilobular area. In the current series, 
no association was observed between fibrosis, including centrilobular, and the 
presence of autoantibodies, like reported by Venturi et al.[190] and Evans et al.[23].  
Sinusoidal fibrosis was also common in the current research cohort (present in 60% 
of biopsies), but was frequently mild/grade 1. Only 15% of patients had moderate-
severe sinusoidal fibrosis. 
In paediatric post-transplant long-term biopsies, the highest rate of fibrosis was 
reported by Ekong, at 97%[14]. Unlike the aforementioned studies, this involved 
clinically indicated biopsies as opposed to protocol, and the time interval post-
transplantation was broader (from 3-11 years)[14]. In the current research, fibrosis 
without associated inflammation was present in 27% of biopsy specimens. In such 
instances, fibrosis might be consequent to previous inflammatory flares, such as 
subclinical episodes of rejection, cholangitis or viral hepatitis, that later resolved. 
Although in the current study, a high frequency of previous episodes of rejection 
was observed (61.5%), no association was found between these (either early or late 
rejection) and fibrosis at protocol biopsy, unlike that previously reported[50]. Most 
biopsies showed inflammation in portal tracts (56%), frequently mild. Central 
perivenulitis was present in a quarter of biopsy specimens (27%), and interface activity 
in 15%. Other authors have reported comparable frequency of central perivenulitis in 
adult and paediatric liver allograft biopsies[111,191-192] (see below). 
 Considering the clinical parameters, patients who were younger at the time of 
transplantation showed a higher proportion of sinusoidal fibrosis (score ³1) at the 
protocol biopsy (p=0.009, Figure 31 on page 119). Scheenstra et al.[29] also found an 
association between younger age at transplantation and fibrosis on protocol biopsy of 
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paediatric liver recipients, although the fibrosis assessment did not include 
centrilobular or sinusoidal compartments specifically. 
 Increasing evidence emerging from studies of protocol biopsies of children 
suggests that fibrosis in this context might be the result of an immune-mediated injury, 
such as rejection or even AMR (see below). Considering this, the link observed in the 
current study, between fibrosis and younger age, could be due to age-related 
particularities of the human immune system that might predispose younger individuals 
to rejection post-transplant, such as a higher production of immune cells in the 
thymus[193]. It could also result from a distinctive response of the immature immune 
system to the immunosuppressive therapy. Likely, the association between younger 
age and long-term fibrosis is complex, and a more complete understanding requires a 
comprehensive study of children’s immune system development after transplantation, 
which is outside the scope of this research. 
 In the current cohort, fibrosis was not associated with other clinical parameters 
previously reported to be related, such as time since transplantation, the use of partial 
grafts, previous episodes of rejection or the presence of autoantibodies[28-29]. There 
was no difference in liver biochemistry between patients with and without fibrosis. The 
lack of correlation between fibrosis and liver function tests has been previously 
recognized[14,50,95,194-195]. 
Most cases of IPTH are thought to correspond to late rejection or chronic 
antibody-mediated rejection[19,21,53,170,187] (Chapter 2). Of note, the majority of patients 
in the current study were adolescents at the time of the protocol biopsy, and 
noncompliance is commonly observed in this age group, which shows a higher 
predisposition for developing late rejection[196]. 
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In the current study, significant association was observed between IPTH and 
concomitant fibrosis in each compartment, and between IPTH and CPA (Table 25 on  
page 121), consistent with previous reports of a strong link between IPTH and 
progression of fibrosis[19,197]. 
3.4.2 Value of collagen proportionate area 
In the present study, the digital quantitative measurement of fibrosis through 
CPA was significantly associated with sinusoidal and with centrilobular fibrosis. 
Interestingly, CPA was not statistically linked to portal fibrosis. During digital analysis 
of Sirius Red stained slides, the staining of the fibrous tissue in portal tracts frequently 
appeared lighter in colour compared to that of the perisinusoidal and pericentral 
fibrosis. Background staining of sinusoids with equivalent or stronger intensity 
compared to the portal tracts was frequently seen with Sirius Red staining.  
 Since the same threshold of colour and brightness had to be used for the 
analysis of the whole biopsy, usually some of the portal fibrous tissue was excluded 
from the selection in order to avoid false positive selection of other areas. These 
technical issues may explain the absence of statistical association between CPA and 
portal fibrosis in the current study. 
 CPA was significantly associated with IPTH (Table 25 on page 121) and 
strongly associated with C4d+ in portal microvascular endothelium (Table 42 on page 
147). The link with IPTH was also significant for sinusoidal and for centrilobular 
fibrosis, and the association with C4d+ was also significant for fibrosis in each 
compartment assessed conventionally. 
 These results showed that, for paediatric protocol biopsies, CPA was a good 
indicator of the degree of sinusoidal and centrilobular fibrosis.  Although the relevance 
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of the digital quantification of fibrosis has been well recognised in other settings, in the 
current study, CPA was not particularly useful when compared to the conventional 
semi-quantitative assessment of fibrosis in three compartments by a pathologist. 
Finally, despite being able to provide a continuous measurement of fibrosis, CPA does 
not provide information in terms of the location of fibrosis. This information is of 
particular relevance in the post-transplant setting, as fibrosis in different 
compartment(s) might result from distinct graft insults. 
 
3.4.3 DSA 
 In the current study, circulating DSA were present in 71% of liver recipients at 
the time of protocol biopsy (Table 29 on page 130), in most cases directed to HLA 
class II only (75%), or to both HLA class I and II (17%). The prevalence of DSA in the 
current study was higher than that found by Miyagawa-Hayashino et al.[28] in long-term 
protocol biopsies of children (48%). Both studies involved the same method of DSA 
detection: OneLambda mixed and single antigen bead kits. 
 Nevertheless, immunosuppression regimes differed between the two cohorts: 
in the latter, tacrolimus was the initial CNI[28], whilst in the current series, most children 
(74%) received cyclosporine in the first years post-transplant. This distinction might 
account for the different proportion of DSA, as cyclosporine is associated with a higher 
risk of developing DSA[84]. Low levels of CNI were also observed to constitute a risk 
factor for development of DSA in the long-term post-transplant[84,198]. Unfortunately, in 
the current research, information on CNI at the time of protocol biopsy were not 
available for most patients. 
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 Regarding the link between circulating DSA and other parameters: recipients 
with circulating class II DSA were younger at transplantation than those without these 
antibodies (median age 9.7 versus 22 months), and this difference was near significant 
(p=0.052, Table 31 on page 132).  Association between younger recipient’s age and 
DSA II has been previously reported[52,199-204]. As mentioned earlier about a similar 
association between younger age and fibrosis, this link is possibly related to 
immunological characteristics of young children. The physiological mechanism is not 
yet understood and has not been considered in these studies[52,199-104].  
 Although in the current cohort, patients with DSA/DSA II had higher proportions 
of fibrosis and higher average scores of fibrosis in portal tracts and sinusoids, the 
differences were not significant. Numerous studies have reported that liver recipients 
with circulating DSA, especially class II DSA, have higher degrees of 
fibrosis[28,50,198,205-207], which suggests that fibrosis in protocol biopsies might be related 
to antibody-mediated graft injury. 
 No significant association was found between DSA and previous episodes of 
rejection, autoantibodies, immunosuppression, graft type, donor type and LFTs, in 
contrast to previous reports[28,50,207]. Lack of significant association might be a 
consequence of the small number of patients in the current study for whom DSA data 
was obtained (34). Whereas Ruiz et al.[203] observed several liver recipients with DSA 
at high levels but with normal histology, in the current study, all except 2 patients with 
circulating DSA had abnormal histology (92%). 
 Ruiz et al.[203] also reported a higher incidence of inflammation in graft biopsies 
of children with circulating DSA compared to those without antibodies. In the current 
study, lobular inflammation was significantly associated with circulating DSA/DSA II. 
The frequency of lobular inflammation (scoring ³1) was 54% versus 10% in liver 
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recipients with and without DSA, respectively (p=0.019, Table 34 on page 135). The 
average score for lobular inflammation was also significantly higher in patients with 
DSA (mean 0.6 versus 0.1, p=0.018, Table 34 on page 135). 
 Although a significant association was observed between moderate interface 
activity and the absence of DSA II ( 
Table 35 on page 136), there was actually only one biopsy with moderate interface 
(and this patient had class I DSA only). For this reason, this association was 
disregarded as being clinically significant and will not be further considered. 
 Interestingly, in a 5-year follow-up study of operationally tolerant paediatric liver 
recipients, Feng et al.[119] found a subset of patients with persistent DSA II who did not 
display an increase in inflammation or progressive fibrosis after discontinuing 
immunosuppression. Their research suggests that some liver allografts maintain 
stable histology despite the presence of DSA. 
 Therefore, although required for the development of chronic AMR and 
associated with graft inflammation and fibrosis, the presence of DSA might not 
necessarily lead to antibody-mediated allograft injury.  This hypothesis is consistent 
with the current observation that recipients with DSA did not have significantly higher 
rates of fibrosis or inflammation in most compartments (except lobular), but those with 




 Focal, positive C4d staining was present in a third of biopsy specimens in the 
current cohort. In contrast to the study by O’Leary et al.[183], significant associations 
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between C4d+ and the presence of DSA or DSA II were not observed (Table 37 and 
Table 38 on page 141). Despite the insignificance, C4d+ in portal veins was only 
observed in patients with circulating DSA. The limited number of patients with DSA 
information, particularly concerning patients with no circulating DSA (10) and the low 
frequency of C4d positive staining in the current study might have contributed to the 
lack of statistical association. 
 A single patient without DSA had C4d+ in portal capillaries, portal arteries and 
portal stroma. In this instance, C4d activation might have been triggered by other (non-
HLA) antibodies reacting against donor antigens present in the allograft[57,208]. 
Although anti-HLA antibodies represent the majority of anti-donor antibodies and are 
classically associated with AMR, in some instances non-HLA antibodies, such 
as towards glutathione-S-transferase T1 (GSTT1) are expressed in the liver allograft 
and trigger antibody-mediated graft dysfunction[208]. 
 Recently, Dao et al.[209] reported C4d+ in 58% of 10-year paediatric liver 
biopsies, a considerably higher prevalence than that of the current series. However, 
the authors included C4d staining in <10% of each given compartment/structure as 
positive, whereas in this thesis such degree of C4d deposition was considered 
negative/non-significant, similar to the threshold considered in the Banff criteria for 
chronic AMR[53]. 
 Taner et al.[57] suggest that C4d is a better marker of chronic tissue injury than 
DSA.  In this study, significant associations were found between C4d+ in portal 
microvascular endothelium and each central perivenulitis and lobular inflammation. 
Association was also found between C4d+ and fibrosis in sinusoids, centrilobular area 
and CPA (Table 39 to Table 42 on pages 143 to 147).  Besides having a higher 
proportion of fibrosis and central perivenulitis, patients with C4d+ in portal vascular 
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structures also had significantly higher numbers of plasma cells and B cells in their 
biopsies, but not T cells (Table 51 on page 159). This finding further supports the idea 
of tissue C4d deposition as a marker of antibody-mediated graft injury. Although C4d+ 
in portal stroma was associated with higher number of T cells, staining in this 
compartment is regarded as less specific and not considered as a diagnostic criterion 
for AMR[53,183]. 
 The current findings confirm that C4d deposition in portal microvascular 
endothelium in protocol biopsies is linked to chronic and active graft injury (manifested 
as fibrosis and inflammation) and to a humoral inflammatory cell profile. DSA was only 
associated with lobular inflammation. This supports the idea that C4d might be a better 
marker of chronic tissue injury than DSA[57]. Nevertheless, the lack of significant 
association between DSA and fibrosis or inflammation in other sites might be simply 
a reflection of the small number of recipients who had known DSA status. 
 In kidney transplantation, tissue C4d staining is a better predictor of graft failure 
than circulating DSA[210].  In liver transplantation, Fayek et al.[140] found that C4d 
deposition in portal veins was associated with a tendency to poorer outcome. In the 
current cohort, C4d+ was not significantly associated with poor outcome. However, 
the follow-up period of most recipients was short and only 3 patients had poor outcome 
during this time. 
 In the liver graft, the significance of C4d deposition in different compartments 
in fixed tissue is still in question. A recent global, multicentre study evaluated the 
quality of C4d immunostaining in FFPE liver grafts[98] and found that despite being a 
good marker for typical, florid cases of acute AMR, C4d might be negative or weak in 
less intense cases of acute AMR. In chronic AMR, the frequency of C4d positive 
staining is not established. In fact, the diagnosis of chronic AMR in the liver graft itself 
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is still under study, has gone through changes in recent years and is in need of 
histological criteria refinement[96,98,209].  
The pathogenic role of DSA in chronic AMR is obscured by numerous 
confounding factors, including indolent evolution, immunosuppression and vast range 
of DSA MFI levels[53]. It is relevant to stress that liver function tests are often normal 
in recipients with chronic AMR, despite ongoing injury[53,95,104,202]. 
3.4.5 AMR and DSA in combination with C4d 
 In 2016, the Banff group on liver graft pathology made a list of criteria to 
diagnose probable chronic active AMR in liver allografts[53]: the presence of DSA, at 
least focal C4d deposition in portal microvascular endothelium, unexplained 
inflammation (portal or centrilobular with interface and/or perivenular necro-
inflammatory activity) and fibrosis, and exclusion of other aetiologies. When the other 
criteria are met but C4d is negative or minimal, possible AMR is the diagnosis[53]. 
Considering these criteria, 4 out of the 34 patients in the current study who had known 
DSA status (12%) fulfilled the criteria of probable chronic active AMR, and other 5 
patients (14.7%), of possible AMR. 
 Although most studies associate portal endothelial C4d staining with presumed 
chronic AMR lesions, the C4d deposition in the chronic setting is usually more focal in 
distribution and weaker in intensity compared to acute AMR lesions[53,97-98]. 
Furthermore, C4d deposition is more problematic in paraffin blocks that have been 
stored for several years[98]. In the current series, 8 biopsies that underwent 
immunostaining for C4d had been archived for more than 10 years. Seven of these 
were completely negative for C4d, and one biopsy had focal, moderate C4d+ staining 
in portal veins and portal capillaries. Because of such considerations, most authors 
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recommend that C4d staining should always be interpreted together with DSA[53,57-58]. 
In fact, the presence of DSA with C4d deposition is considered the traditional marker 
for humoral immunity[209] and both elements are required for diagnosis of AMR in the 
liver graft[53]. Nevertheless, because of this lower sensitivity of C4d staining, the mere 
lack of C4d+ does not exclude the possibility of chronic active AMR. 
Considering the combination of DSA+C4d+ and DSA II+C4d+ in relation to 
other histological parameters, DSA+C4d+ in portal microvascular endothelium was 
statistically linked to a higher frequency of interface activity and central perivenulitis 
(Table 43 on page 149). In fact, the combination of DSA+C4d+ in portal capillaries 
was exclusive of patients with interface activity (p=0.003), and DSA+C4d+ in portal 
veins was only present in patients with central perivenulitis (p=0.007). 
 O’Leary[104,211] previously found that interface activity was associated with 
circulating post-transplant DSA and higher risk of liver graft loss, and included this 
feature in the proposed criteria for chronic AMR in the liver graft. In their recent study 
on chronic AMR, Dao et al.[209] found portal inflammation to be associated with both 
DSA and C4d+.  Although in the current series DSA+C4d+ in portal veins or portal 
capillaries was only present in patients with portal inflammation, association was not 
significant. 
 Although lobular inflammation is not currently considered in the Banff criteria 
for the diagnosis of AMR[53], in the current cohort, this was the only histological 
parameter that was significantly associated with circulating DSA, and it was also 
associated with C4d+ in portal microvascular endothelium. Moreover, patients with 
lobular inflammation showed four times the proportion of DSA+C4d+ compared to 
those without inflammation in this compartment, although this difference was not 
statistically significant (Table 43 on page 149).  
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 Interestingly, the finding of lobular inflammation in long-term post-transplant 
liver biopsies is often considered an indication of possible viral infection. The patients 
in the current cohort, however, had negative viral screening. Lobular inflammation has 
been associated with graft loss in O’Leary et al’s cohort and this parameter was 
included in the authors’ proposed criteria for chronic AMR[183]. Hübscher et al.[212] 
suggest that diffuse lobular inflammation could represent a transitional phase between 
acute and chronic rejection. 
 In their study of 103 biopsies of 10 liver allografts that failed due to  chronic 
ductopaenic rejection (CR), Quaglia et al.[213] discovered that lobular hepatitis 
preceded CR in 9 cases, and in the remaining patient, it became evident after 
diagnosis of CR. Since humoral mechanisms might be involved in the development of 
CR, it is tempting to hypothesize that lobular inflammatory activity could possibly be a 
phenotype of graft damage caused by circulating DSA. The relationship between 
lobular inflammation and AMR needs further study.  
 In regard to fibrosis, only sinusoidal fibrosis was significantly associated with 
DSA+C4d+ in portal veins in the current study (Table 45 on page 152). Association 
was stronger for class II DSA+C4d+ (Table 46 on page 153), and the rate of DSA 
II+C4d+ in portal veins in patients with and without sinusoidal fibrosis was 50% versus 
3.3%, respectively (p=0.016). Previous research has suggested that fibrosis in 
paediatric protocol biopsies might be the result of chronic subclinical AMR[53,104,187,209]. 
Sinusoidal fibrosis has been associated with DSA and with allograft loss and therefore 
included in O Leary et al’s criteria for chronic AMR[183]. The Banff group suggested 
that atypical patterns of fibrosis might represent chronic AMR or mixed T-cell mediated 
and antibody mediated rejection[53]. In their recent review on humoral rejection in the 
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liver graft, Koo et al.[96] recommended that chronic AMR should always be included in 
differential diagnosis of unexplained graft fibrosis.   
 Dao et al.[209] recognised centrilobular fibrosis as a feature of chronic AMR in 
late protocol liver biopsies of children, linked to DSA+C4d+.  In the current study, 
DSA+C4d+ in portal veins was more frequent in patients with centrilobular fibrosis 
(23% versus 0), but this contrast was not significant (Table 46 on page 153), possibly 
due to the small number of patients who had DSA information in the current cohort. 
This may account for the lack of significance between DSA+C4d+ and fibrosis in 
central and possibly portal areas. 
   
3.4.6 Central perivenulitis and centrilobular fibrosis 
 Cumulative evidence considers that central perivenulitis is an indicator of late 
rejection[21,24,27]. Perivenular/centrilobular areas have effective (donor-derived) 
antigen-presenting cells, which make such regions susceptible to alloimmune 
response and subsequent graft injury[214]. In T-cell-mediated rejection (TCMR), the 
presence of central perivenulitis denotes higher severity of the rejection episode, 
which is less likely to respond to conventional immunosuppression than classical 
portal-based TCMR and has higher probability to evolve to chronic rejection[212]. 
 Some authors believe that central perivenulitis represents an intermediate 
stage between acute and chronic rejection, normally preceding the irreversible loss of 
bile ducts[212,215-216]. In a study of 54 liver recipients, Nakazawa et al.[217] observed 
centrilobular injury in over two-thirds of patients who developed chronic rejection. 
Another study of protocol biopsies of 100 adult liver recipients verified that late central 
perivenulitis, which frequently appeared isolated (without concomitant portal features 
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of rejection), was linked to long-term graft injury[191]. The frequency of isolated central 
perivenulitis was shown to increase with time post-transplant[34]. The long-term 
outcome of recipients with isolated central perivenulitis and of those with central 
perivenulitis accompanying portal based TCMR was comparable, so it seems that the 
outcome is more dependent on the central injury than the portal[27,111]. 
 In the current analysis, there was a strong association between central 
perivenulitis and DSA+C4d+ in portal microvascular endothelium (particularly in portal 
veins, Table 43 on page 149). Central perivenulitis and centrilobular fibrosis were also 
individually associated with C4d+ in portal microvascular endothelium (Table 39 and 
Table 41 on pages 143 and 146, respectively). This combination suggested that, 
besides a feature of late (T-cell-mediated) rejection, the presence of perivenular injury 
in protocol biopsies of children is likely to represent AMR. 
 Centrilobular injury as a possible phenotype of AMR could explain why CP is 
linked to more severe rejection episodes, poorer response to immunosuppression and 
a higher chance of progression to CR. The Banff group recently acknowledged that 
perivenular inflammation is one of the most frequent histological patterns of injury 
linked to chronic AMR, and it is currently incorporated to the histological criteria for the 
diagnosis of chronic active AMR[53]. In fact, each interface, portal and perivenular 
inflammation are currently included in the histological criteria for chronic AMR[53]. 
 Yamada et al.[41] suggest that antibody-mediated immunity is involved in the 
development of centrilobular fibrosis. This pattern of fibrosis results from previous 
ongoing or repeated episodes of central perivenulitis. Interestingly, centrilobular 
fibrosis is not unusual in long-term biopsies of paediatric liver transplant recipients with 
circulating DSA, and might be reverted with increased immunosuppression[28,57]. 
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 An immunosuppression withdrawal study of 158 children 10 years post-
transplant concluded that centrilobular fibrosis in long-term biopsies can be a marker 
of insufficient immunosuppression and might be related to antibody-mediated 
immunity[194]. Moreover, biopsies with centrilobular fibrosis have stronger C4d staining 
and higher numbers of B cells on immunohistochemistry, suggesting 
that humoral immunity is involved in the development of fibrosis in this site[41]. 
 
3.4.7 Quantification of inflammatory cells 
 The analysis of the inflammatory cells revealed that B cells and plasma cells 
were significantly associated with portal fibrosis and with C4d staining in portal 
microvascular endothelium (Table 48 and Table 51 on pages 156 and 159, 
respectively). Plasma cells in particular were associated with fibrosis in each 
compartment, the strongest link being with sinusoidal fibrosis. For instance, the 
median number of plasma cells in biopsies with centrilobular fibrosis ³2 was almost 
four times higher than in biopsies with no/mild sinusoidal fibrosis (Table 48 on page 
156). 
 T cells typically represent the majority of inflammatory cells in the liver, and are 
approximately 10 times more common than B cells[106]. In the current study, the 
median number of T cells in protocol biopsies was about six-times larger than that of 
B cells (Table 47 on page 155). Despite that, T cells (and CD8+ T cells) were not 
significantly associated with the presence of fibrosis in any given compartment, unlike 
B cells and plasma cells. 
 The association between fibrosis and a humoral inflammatory profile (B cells 
and plasma cells), in addition to the significant link found between fibrosis in most sites 
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and C4d+, and between sinusoidal fibrosis and DSA+C4d+, support the idea that 
unexplained fibrosis in protocol biopsies of children is likely a result of chronic 
subclinical AMR. 
 
3.4.8 Local role of B cells 
 B cells are required for the development of liver fibrosis in mice, and this effect 
is antibody-independent and T cell-independent, therefore likely mediated by local 
roles of B cells[110] (Chapter 1). In humans, B cell activation has been associated with 
fibrosis in skin and lungs of patients with systemic sclerosis[112-113].  GrzB (granzyme 
B) is expressed by human B cells and plasma cells upon stimulation with viral 
antigens[114,118]. GrzB is a cytolytic granule protein with proapoptotic role, and is 
classically associated with cells with cytolytic function, such as NK cells and CD8 T 
cells, and had not been described in B lymphocytes before the study by Hagn et al.[114]. 
Granzyme molecules also seem to play alternative roles, besides the apoptotic, such 
as matrix degradation and remodelling[114-116]. 
 In the present study of long-term post-transplant protocol biopsies, combined 
multiplex immunofluorescence was used to demonstrate that B cells express GrzB in 
human liver allografts, which has not yet been reported. Expression was seen in 28.6% 
of liver recipient’s biopsies. Interestingly, the number of B cells that expressed GrzB 
in each biopsy was tiny (average 1.5 cells/biopsy) and these cells were typically 
located in portal tracts. No plasma cells were found to express GrzB. These GrzB-
expressing B lymphocytes might be involved in matrix remodelling following 
inflammation, leading to allograft fibrosis. This expression of GrzB adds more 
complexity to the interpretation of B cell infiltrates in liver allograft biopsies.  B cells are 
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usually considered part of the adaptive immune system, maturing into plasma cells 
that produce and secrete antibodies which act remotely. The expression of a molecule 
such as GrzB by B cells, however, endorses the theory that B cells also play a local 
role. This could change the way injuries/diseases in which these cells predominate are 
regarded, such as de novo autoimmune hepatitis/plasma cell hepatitis of the liver 
allograft.  
 Because the number of B cells showing GrzB expression in each individual 
biopsy was so small, it would be interesting to repeat the multiplex staining in serial 
sections of each biopsy specimen to identify other positive cells. It could also be valid 
to look for B cells and perhaps plasma cells expressing GrzB in larger histological 
specimens, such as failed liver allografts. 
 Interestingly, in the current analysis, T cells, despite representing the majority 
of the inflammatory population, were not associated with fibrosis in any compartment. 
Although T cells have a central role in cellular rejection in the transplantation setting, 
it seems that in protocol biopsies with chronic subclinical lesions, the pathologists 
should pay special attention to B cells and plasma cells, bearing in mind that they 
might have additional roles besides the production of antibodies. It is possible that 
specific subpopulations of T cells, particularly FoxP3, could be associated with 
histological findings and clinical parameters. Although the study of FoxP3 was 





 In summary, the present study of long-term paediatric protocol biopsies 
confirmed a high prevalence of relevant histological abnormalities in biopsies of 
asymptomatic children, consistent with previous reports by other centres. A high 
frequency of circulating DSA was detected, mainly directed to class II HLA, and these 
antibodies were associated with active graft injury in the form of lobular inflammation. 
Children who were younger at transplantation were more likely to have sinusoidal 
fibrosis and class II DSA by the time of protocol biopsy. The reasons behind these 
links are not clear.  
 In the context of protocol biopsies, portal microvascular C4d staining appeared 
to be an indicator of antibody-mediated graft injury. It was significantly associated with 
a humoral inflammatory cell profile (B cells and plasma cells), with central perivenulitis 
and lobular inflammation, and with higher frequency of fibrosis in sinusoids and in 
central/pericentral regions.  The combination of circulating DSA and tissue C4d+ in 
portal microvascular endothelium was also associated with central perivenulitis and 
sinusoidal fibrosis, and additionally, to interface activity. B cells and plasma cells were 
independently linked to fibrosis (in portal tracts and in all compartments, respectively). 
 These findings suggest that unexplained inflammation (particularly interface 
activity, central perivenulitis and lobular inflammation) and fibrosis (especially in 
sinusoids and centrilobular area) in protocol biopsies of children probably represent 
chronic AMR that might lead to allograft loss, consistent with what was observed in 
Chapter 2 (Failed Liver Allografts). Considering the Banff criteria for chronic AMR, over 
a fourth (26%) of paediatric protocol biopsies fulfilled criteria for either probable or 
possible AMR. 
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 The current observations reinforce the crucial role of the histological 
assessment of liver allograft biopsies in the diagnosis of subclinical but potentially 
harmful pathological conditions, such as chronic AMR, and in management of 
immunosuppression. Chronic AMR, a recently acknowledged condition in liver 
transplantation, might cause progressive fibrosis in patients who are clinically well with 
normal liver function tests.  Finally, the expression of GrzB by B cells in human liver 
allografts could mean a potential local role for B cells in the development of fibrosis, 
which needs to be further investigated. 
 In Chapter 2, the reasons for retransplantation over the years were explored, 
and a rising frequency of unexplained chronic hepatitis associated with fibrosis leading 
to allograft failure was found.  In the current chapter, protocol biopsies and the 
association between histology, including subclinical inflammation and fibrosis, and 
circulating DSA, tissue C4d deposition, clinical parameters and inflammatory cell 
phenotype were analysed. Evidence for chronic AMR being involved in long-term graft 
damage, including inflammation and fibrosis in most compartments was found, and 
C4d revealed to be a useful marker of humoral injury in liver biopsies, although not 
sensitive. 
 Based on these findings, I decided to study liver allograft biopsies with 
diagnosis of TCMR to see whether in this distinct context, the presence of DSA and 




4   FOR CAUSE BIOPSIES WITH REJECTION 
4.1 RATIONALE FOR STUDYING FOR CAUSE BIOPSIES WITH 
REJECTION 
In this study cohort, an analysis of for cause biopsies with a diagnosis of rejection 
was performed and the histology was correlated with circulating DSA and with gene 
expression. In the literature review, no previous research has compared all these 
parameters together. Therefore, a pathogenic role was sought for DSA by comparing 
the histological and transcriptional characteristics of liver biopsies with rejection.  
4.2 MATERIAL AND METHODS 
4.2.1 Patients and Data 
 All liver recipients who underwent a for cause allograft biopsy in which the 
diagnosis of (T-cell mediated) rejection had been made, and who were tested for DSA 
within two weeks of the biopsy were selected. Patients whose biopsy specimens were 
no longer in the hospital’s archive and one patient with possibly recurrent hepatitis C 
were excluded from the study. When several biopsies had been performed for the 
same rejection episode, that selected was one obtained before starting treatment for 
rejection. In King’s College Hospital, patients with suspected rejection normally 
undergo biopsy prior to treatment. 
In total, 44 biopsy specimens corresponding to 44 liver recipients were included 
in the research. Patient demographic and clinical information was collected, including 
age, primary liver disease, baseline immunosuppression, time from transplant to 
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biopsy, liver biochemistry (AST, bilirubin, AP, GGT, INR) and clinical outcome. 




Two pathologists (A.Q. and L.N.S.), blinded to all clinical and serological data, 
assessed 44 biopsy slides originally stained for HE and reticulin, and graded a series 
of histological parameters using the same scoring system as Chapter 3 (Table 7 on 
page 57). Quality of staining was appropriate in all biopsy specimens.   
 The threshold for significant portal/periportal fibrosis was defined as Ishak 
stage ³2 (fibrous expansion of most portal tracts), and for sinusoidal/subsinusoidal 
and centrilobular fibrosis, as Venturi stage ³2, as previously done for protocol biopsies 
(Chapter 3, section 3.2.3.1, page 56).  Because digital analysis of Sirius Red stained 
biopsies in the previous study cohort did not add value to the conventional scoring, it 
was not used here. 
Immunohistochemistry for C4d was performed using precisely the same 
protocol as for the protocol biopsies (Chapter 3, section 3.2.3.3, page 61). 
Unfortunately, during this study, the C4d antibodies employed became unavailable to 
be ordered from the supplier. For this reason, only 21 out of the 44 study biopsy 
specimens were stained for C4d. 
The assessment of C4d immunostaining was conducted using the same 
scoring system specified in Chapter 3 (section 3.2.3.3, page 61). The C4d positive 
threshold in a given compartment was defined as at least focal C4d staining in that 
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compartment (as used above for the protocol biopsy cohort). Minimal C4d deposition 
(<10%) was considered negative. 
 
4.2.3 DSA testing 
 In this group of patients, DSA testing had previously been performed close to 
biopsy date (this was an inclusion criteria for the cohort selection). The diagnostic kits 
and protocol employed for DSA detection were as described in Chapter 3 (section 
3.2.2, page 56). 
 
4.2.4 RNA extraction 
 RNA was obtained from liver biopsies using RNeasy FFPE kit (Qiagen, UK).  
Firstly, excessive paraffin was removed from the biopsy blocks with a blade and eight 
5µm sessions were cut from each block with a microtome and placed in 2 ml sterile 
plastic tubes. The tissue underwent the following steps according to the 
manufacturer’s protocol: deparaffinization, incubation with lysis buffer, DNase 
treatment, ethanol addition and RNA elution through RNeasy MinElute spin column. 
Finally, sterile, RNAse-free distilled water was added to remove the RNA from the 
column membrane. Concentration and purity of resulting RNA were measured with 
Nanodrop (ThermoScientific). RNA samples were stored at -80°C until analysis. 
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4.2.5 RNA sequencing and analysis of gene expression data 
The RNA extracted from the biopsies was sent for sequencing (RNASeq) at the 
Bioinformatic Platform of the Biomedical Research Center in Hepatic and Digestive 
Diseases (CIBEREHD), Instituto de Salud Carlos III, Spain. The sequencing protocol 
used was similar to that reported in a recent paper on molecular profiling of adult liver 
recipient biopsies, in which the current author participated[138]. A small amount of RNA 
(50ng) was used to generate sequencing libraries (with Ion AmpliSeq™ Transcriptome 
Human Gene Expression Kit, Thermo Fisher). Sequences were then compared to 
reference sequences that include over 20,000 genes in the AmpliSeq Human Gene 
Expression panel. The correlation patterns among genes were analysed with 
Weighted Gene Correlation Network Analysis (WGCNA) software.  
Statistical significance for previously recognised groups of genes associated 
with biological pathways were computed with Quantitative Set Analysis for Gene 
Expression, and an FDR<0.10 was considered significant. Gene sets were 
incorporated from both the transplantation-related Pathogenesis-Based Transcript 
(PBT) from the Alberta Transplant Applied Genomics Centre (available at 
atagc.med.ualberta.ca/Research/GeneLists) and the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway databank. 
4.2.6 Statistical analysis 
 The data were analysed using SPSS version 23.0 (IBM Corporation, 2015). 
Categorical variables are presented as number and percentage. Continuous variables 
are presented as median and range or mean/average and range. For most continuous 
variables, such as liver enzymes and patients age, the median was used to measure 
central tendency, as for the protocol biopsies (Chapter 3). For histological variables 
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with few possible discrete values, such as degree of fibrosis and inflammation, 
however, the mean (average) was used instead of the median (detailed explanation 
in section 3.2.5, page 107). 
 The Mann-Whitney (non-parametric) test was used to compare continuous 
variables between groups. Fischer’s exact test was used to compare categorical 
variables and validate differences in frequencies between different groups. A p value 
of less than 0.05 was considered statistically significant. 
 
4.3 RESULTS 
4.3.1 Demographic Data 
 Between January 2012 and December 2015,  44 liver recipients had a clinically 
indicated graft biopsy with TCMR confirmed on histology, had undergone DSA testing 
within 2 weeks and had no evidence of recurrent disease. Although most patients had 
the biopsy performed before starting treatment for rejection, 7 patients underwent liver 
biopsy after the start of empirical treatment for rejection. The recipients’ ages ranged 
from 9 months to 66.5 years (median 24.1 years), 68% (30) were adults and 32% (14) 
were children. 
 The biopsy was obtained between 6 days and 5.9 years after liver 
transplantation (median 164 days or 5.5 months). In most cases, the biopsy was 
performed later than the typical time when T-cell mediated rejection is diagnosed 
(usually the first month posttransplantation). This difference could be explained 
through the selection criteria, since only patients with rejection who were also tested 
for DSA were included, thus patients in which AMR was suspected. As patients with 
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typical TCMR that promptly resolves with conventional treatment are not usually tested 
for DSA, these were not included in the study. The indications for transplantation (LT) 
are specified in Table 54. 
 
Table 54. Indications for liver transplantation 
Indication for LT Number (%) 
Biliary atresia 9 (20.5%) 
ALF 7 (15.9%) 
AIH 5 (11.4%) 
PBC 5 (11.4%) 
PSC 4 ( 9.1%) 
NASH 3 ( 6.8%) 
HCV + HCC 3 ( 6.8%) 
AIH/PSC 2 ( 4.5%) 
Cryptogenic cirrhosis 2 ( 4.5%) 
ALD 1 ( 2.3%) 
HBV 1 ( 2.3%) 
a1AT deficiency 1 ( 2.3%) 
BSEP deficiency 1 ( 2.3%) 
ALF, acute liver failure; AIH, autoimmune hepatitis;  PBC, primary biliary cholangitis;  PSC, primary 
sclerosing cholangitis;  NASH,  non-alcoholic steatohepatitis;  HCV, hepatitis C virus;  HCC, 
hepatocarcinoma;  ALD, alcoholic liver disease;  HBV, hepatitis B virus;  a1AT, alpha-one anti-
trypsin;  BSEP, bile salt export pump 
 
 For baseline immunosuppression, 41 patients (93%) received tacrolimus: 18 
combined with MMF, 17 on its own and 6 with sirolimus. Two patients received 
cyclosporine and MMF and 1 patient everolimus and MMF (Table 55). In addition, 33 
recipients (75%) received steroid as part of the immunosuppression prior to the 
biopsy/rejection episode. 
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Table 55.  Baseline immunosuppression 
Baseline immunosuppression Number (%) of patients 
 Tacrolimus 17 (38.6%) 
Tacrolimus  and  MMF 18 (40.9%) 
Tacrolimus  and  sirolimus 6 (13.6%) 
Cyclosporine  and  MMF 2 ( 4.5%) 
Everolimus  and  MMF 1 ( 2.3%) 
 
 The median and range of liver biochemistry tests at biopsy were: AST 201 IU/L 
(35 - 2642);  bilirubin, 93 µmol/L (4 - 431); GGT 506 IU/L (34 - 2181);  AP 422 IU/L 
(144 - 1796);  INR 1.13 ratio (0.84 – 2.81, Table 56). 
 
Table 56. Liver biochemistry at biopsy 
Test Patients Results 
(median and range) 
Reference value 
(units) 
AST 201 (35 - 2642) 10-50  IU/L 
Bilirubin 93 ( 4 -    431) 3-20  µmol/L 
GGT 506 ( 34 - 2181) 1-55  IU/L 
AP 422 (144 - 1796) 30-130  IU/L 
INR 1.13 (0.84 - 2.81) 0.9-1.2  ratio 
 
 In regard to clinical follow-up, median follow-up time after the biopsy was 3 
years (from 7 days to 6.5 years).  During this period, 25 patients (57%) were alive and 
had the same graft; 18 patients (41%) had poor outcome with graft loss and/or death, 
and 1 patient (2.3%) was lost to follow-up. From the 18 patients with poor outcome, 7 
(16%) underwent retransplantation and survived, and 11 patients died (25%), 7 of 
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them as direct consequence of graft failure, 2 due to infection, 1 for acute respiratory 
distress syndrome after transplantation, and 1 in consequence of carotid haemorrhage 
following self-inflicted injuries in the context of steroid-induced psychosis during 
rejection treatment. Patient outcome is shown in Table 57. 
 Considering the 14 allograft losses (7 of which resulted in death), 10 allografts 
failed for chronic ductopaenic rejection (CR), 1 for recurrent PSC and rejection, 1 for 
acute TCMR with hepatic artery thrombosis, 1 for non-thrombotic infarction with 
rejection, and 1 for subacute liver failure which cause was not clear. The reasons for 
allograft loss are specified in Table 58. Therefore, in 13 out of 14 patients who lost 
their allografts (93%), rejection played a recognizable role in the organ failure. In the 
remaining patient with subacute liver allograft failure, it is not possible to confirm or 
exclude a role for rejection (including AMR) in the allograft loss. 
 
Table 57.  Patient outcome 
Outcome % and number 
Alive with same graft 57% (25) 
Graft failure and death 16% (7) 
Graft failure, retransplantation and survived 16% (7) 
Death (not directly linked to graft failure)  7% (4) 
Lost to follow-up 2.3% (1) 
Total 100% (44) 
 
	 197	
Table 58. Reasons for graft failure 
Causes of graft loss % and number 
CR 71.4 %   (10) 
Recurrent PSC + TCMR 7.1 %   (1) 
TCMR + HAT 7.1 %   (1) 
Non-thrombotic infarction + 
rejection 
7.1 %   (1) 
Subacute liver failure 7.1 %   (1) 
Total 100  % (14) 
* CR, chronic rejection; PSC, primary sclerosing cholangitis; 
TCMR, T-cell mediated rejection; HAT, hepatic artery thrombosis 
4.3.2 DSA: overall results 
 
 In this series, 29 patients (66%) had circulating DSA: 27 had class II (19 in 
isolation, 8 combined with class I) and 10 recipients had class I DSA (8 combined to 
class II, 2 in isolation, Table 59). For DSA subtypes: most patients with class II DSA 
had both anti-DQ and anti-DR antibodies (14 out of 27,  52%), and 13 recipients had 
anti-DQ antibodies only (48%, Table 60). Anti-DP antibodies were not detected in any 
liver recipient.  
Table 59.  DSA test results 
DSA class Number (%) of 
patients 
II 19  (43.9%) 
I and II 8  (18.2%) 
I 2  ( 4.5%) 
No DSA 15  (34.1%) 
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 For class I DSA: 6 patients (60%) had anti-A and anti-B antibodies, and one of 
them also had anti-Cw antibodies. Two patients (20%) had anti-B antibodies only, 1 
(10%) had Anti-A only and 1 (10%) had anti-Cw only (Table 61). The minimum, 
maximum and average MFI of DSA I, DSA II and total DSA are detailed in Table 62. 
 
Table 60. DSA II subtypes 
DSA II subtype Number (%) of 
patients with DSA II 
DQ and DR 14 (51.9%) 
DQ only 13 (48.1%) 
DR only - 
DP - 
 
Table 61 (below). DSA I subtypes 
DSA I subtype Number (%) of 
patients with DSA I 
A and B 5 (50%) 
A, B and Cw 1 (10%) 
B 2 (20%) 
A 1 (10%) 
Cw 1 (10%) 
 
Table 62 (below). DSA total MFI 
DSA type Sum of MFI (median and 
range) 
Class I   8,163  (2,047-18,854) 
Class II 17,655  (1,800-71,676) 
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4.3.3 DSA and clinical parameters 
 There was no significant association between clinical parameters and DSA, 
except for INR, which was lower in patients with these antibodies (1.04 versus 1.28). 
However, the median INR was inside the normal range in both groups of patients 
(DSA+ and DSA-). The median AP was higher in patients with DSA (518 versus 306, 
Table 63) and this difference was near statistical significance (p=0.057). 
 
Table 63. Clinical parameters and DSA 
Clinical parameter DSA + DSA - p value 
Age in years (mean and range) 21.6 (0.7-66.2) 33.9 (1.4-53.7) 0.325 
Steroid use prior to rejection 
episode (% and number) 
72.4% (21/29) 80% (12/15) 0.722 
AST (median and range) 199 (44-762) 250 (35-2642) 0.068 
Bilirubin 137 (3-514) 135 (6-397) 0.394 
GGT 466.5 (34-2052) 533 (63-2181) 0.703 
AP 518 (169-1796) 306 (144-963) 0.057 
INR 1.04 (0.84-2.21) 1.28 (0.97-2.75) 0.004 
Poor outcome - death or graft loss 
(% and number) 
31% (9/29) 60% (9/15) 0.139 
 
 The presence of circulating DSA II at >10,000 mean fluorescence intensity 
(MFI) was strongly associated with younger recipient age (p=0.007). The median age 
of patients with DSA II above that threshold was 14.8 years versus 38.7 years of those 
with no/lower DSA II (Figure 38).  Considering age groups: children accounted for 56% 
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of patients with DSA II >10,000 versus only 15% for those with no/lower DSA II 
(p=0.008, Table 64).  Analysing both age and DSA II as continuous variables, there 
was significant negative moderate correlation between these parameters (Pearson’s 
correlation coefficient, r=-0.339, p=0.024). In the scatter plot in Figure 39, it is possible 
to visualise that older liver recipients overall tended to have lower DSA II MFI than 
younger patients. 
 
Figure 38 (above). DSA II and patient age at biopsy (p=0.007) 
Table 64 (below).  Liver recipient age group and DSA II (p=0.008) 
Age group DSA II >10,000 DSA II – or <10,000 
Paediatric 56% (10/18) 15% ( 4/26) 





Figure 39. Correlation between patients’ age and DSA II MFI 
 
 The presence of DSA II above 10,000 MFI was also statistically associated with 
lower proportion of poor outcome: 17% versus 60% for those with no/lower DSA II 
(p=0.005).  At first glance, this association seems contradictory, since the presence of 
DSA II in high titres is classically linked to worse outcome. Nonetheless, because most 
patients with DSA II >10,000 were children (and those who were adults also tended to 
be younger), the association between good outcome and DSA II might simply reflect 
better health condition of younger patients. 
 Circulating DSA at the time of biopsy (regardless of type or MFI) were not 
associated with prior use of steroid, type of primary liver disease (autoimmune versus 





Considering all biopsies: the median rejection activity index (RAI) was 6 (range 
3 to 9). Bile duct lesion was conspicuous in all specimens, and of moderate or severe 
degree (grade 2/3) in 82%.  A quarter of biopsies already displayed bile duct loss 
(27%), which was advanced (loss of >50% of bile ducts) in one patient only. Bile duct 
loss was only considered significant when >10% of portal tracts lacked bile duct and 
the remaining showed obvious bile duct injury. This confirmed that bile duct loss was 
the result of pathogenic damage, and not merely due to sample variability[218]. Portal 
vein endotheliitis was moderate or severe in 43% of patients. Central perivenulitis was 
observed in 80% of biopsies, and was moderate/severe in 59%. Most patients had 
moderate or severe portal (75%) and moderate or severe lobular (55%) inflammation. 
 Overall, 32% of biopsies displayed significant fibrosis, either portal (³2), 
centrilobular (³2) or sinusoidal (³2). Portal fibrosis was present in a fourth of 
specimens, and 6.9% had at least bridging fibrosis (Ishak ³3).  Significant centrilobular 
and sinusoidal fibrosis were present in 16% and 6.8% of patients, respectively.  
Table 65 displays the detailed histological assessment of HE and reticulin stained 
biopsies. Figure 40, Figure 41 and Figure 42 show the degree of fibrosis in portal, 
centrilobular and sinusoidal compartment, respectively. 
 
Table 65. Overall histological scoring (HE and reticulin staining) 




   1 (  2.3%) 
 10 (23   %) 
 24 (55  %) 
   9 (21    %) 





 17 (39   %) 
 10 (23   %) 
   4 (  9.1%) 




   0 
 20 (46   %) 
 19 (43   %) 
   5 (11   %) 




   6 (14  %) 
 19 (43  %) 
 17 (39  %) 





   9 (21   %) 
   9 (21   %) 
 16 (36   %) 
 10 (23   %) 




    0 
  8 (18   %) 
 19 (43   %) 
 17 (39   %) 
Bile duct loss: Absent 
Loss of <50% 
Loss of >50% 
  32 (73   %) 
  11 (25   %) 
    1 (  2.3%) 
Ductular reaction: Absent 
Present 
 32 (73   %) 
 12 (27   %) 




 24 (55   %) 
 13 (30   %) 
   3 (  6.8%) 
   4 (  9.1%) 






 33 (75   %) 
   8 (18   %) 
   1 (  2.3%) 
   1 (  2.3%) 
   1 (  2.3%) 
   0  




  30 (68   %) 
    7 (16   %) 
    4 (  9.1 %) 
    3 (  6.8 %) 




  35 (80   %) 
    6 ( 14  %) 
    1 (   2.3%) 




Figure 40 (above). Portal Fibrosis staging 
 






















Figure 42. Sinusoidal Fibrosis staging 
 Significant portal fibrosis (Ishak ³2) was associated with longer time from 
transplant to biopsy: 4.2 years versus 93 days for those without portal fibrosis 
(p=0.001). Sinusoidal and centrilobular fibrosis were not statistically associated with 
time from transplant to biopsy. Outcome was not significantly associated with any 
histological finding, including fibrosis or inflammation in each compartment or bile duct 
loss. The proportion of patients who had poor outcome was similar for recipients with 
and without bile duct loss: 46% versus 41%, respectively (p=0.333).  
 
4.3.4.2 C4d	immunohistochemistry	
The quality of C4d immunostaining was good, as in the previous study group 
(protocol biopsies). C4d positivity (C4d+) in at least one compartment was observed 
in 86% (18/21) of biopsies stained for C4d. Positive C4d staining in portal 
microvascular endothelium (portal veins or portal capillaries) was present in 52% 










veins, 38.1%; portal capillaries, 14.3%;  portal stroma, 52.4%;  hepatic arteries, 28.6%;  




Table 66. C4d positivity per compartment 








Focal and weak 
Focal and moderate/strong 
Diffuse 
 7 (33.3%) 
 6 (28.6%) 
  1 (4.8%) 
 4 (19.1%) 






Focal and weak 
Focal and moderate/strong 
Diffuse 
16 (76.2%) 
  2 (9.5%) 
0 







Focal and weak 
Focal and moderate/strong 
Diffuse 
13 (61.9%) 
  2 (9.5%) 
0 
  5 (23.8%) 






Focal and weak 












Focal and weak 
Focal and moderate/strong 
Diffuse 
15 (71.4%) 
 4 (19.1%) 
0 
 1 (4.8%) 






Focal and weak 




  1 (4.8%) 
  1 (4.8%) 
  1 (4.8%) 
 
 
4.3.5 DSA and Histology (HE and reticulin) 
 
 Out of all the histological parameters assessed on HE and reticulin stained 
slides, only two parameters were significantly associated with the presence of 
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DSA/DSA II: bile duct loss and portal fibrosis. The presence of bile duct loss was 
strongly associated with DSA and with DSA II (p=0.003 and p=0.001,  
Table 67 and Table 68, respectively). In fact, all 12 patients whose biopsies displayed 
bile duct loss had circulating class II DSA (all had anti-DQ isotype). One-quarter of 
them had concomitant class I DSA. Table 69 and Table 70 depict the DSA class and 
DSA subtype present in patients with bile duct loss.  
 Regarding fibrosis, the presence of portal fibrosis (³2) was associated with 
circulating DSA II (p=0.031). The proportion of patients with and without DSA II who 
had portal fibrosis was 37% versus 6% respectively (Table 68). The remaining 
histological parameters assessed showed no significant association with DSA or DSA 
II. Figure 43 shows the proportion of patients with and without portal fibrosis who had 
circulating DSA II. 
 
Table 67. DSA and histological parameters (HE and reticulin) 
Parameter DSA + DSA - p value 
Portal fibrosis - Ishak (mean and range) 1.07 (0-4) 0.67 (0-5) 0.090 
Portal fibrosis ³2 (% and number) 34.5% (10/29) 6.7% (1/15) 0.067 
CLF – Venturi (mean and range) 0.52 (0-3) 0.60 (0-3) 0.822 
CLF present  (% and number) 31% (9/29) 33.3% (5/15) 1.000 
CLF ³2  (% and number) 13.8% (4/29) 20% (3/15) 0.675 
Sinusoidal fibrosis – Venturi (mean and range) 0.31 (0-3) 0.33 (0-3) 0.972 
Sinusoidal fibrosis present (% and number) 20.7% (6/29) 20% (3/15) 1.000 
Sinusoidal fibrosis ³2 (% and number) 6.9% (2/29) 6.7% (1/15) 1.000 
RAI (mean and range) 6.03 (3-9) 6.07 (3-9) 0.990 
Portal Inflammation (mean and range) 1.9 (1-3) 2.0 (1-3) 0.722 
Portal inflammation moderate-severe (% and 
number) 
75.9% (22/29) 73.3% (11/15) 1.000 
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Portal inflammation severe (% and number) 17.2% (5/29) 26.7% (4/15) 0.464 
Interface activity (mean and range) 1.0 (0-3) 1.33 (0-3) 0.369 
Interface activity present (% and number) 69% (20/29) 73.3% (11/15) 1.000 
Interface activity moderate-severe (% and 
number) 
27.6% (8/29) 40% (6/15) 0.501 
Portal vein endotheliitis (mean and range) 1.31 (1-3) 1.40 (1-3) 0.728 
Portal vein endotheliitis present (% and 
number) 
82.8% (24/29) 80% (12/15) 1.000 
Portal vein endotheliitis moderate-severe (% 
and number) 
41.4% (12/29) 46.7% (7/15) 0.759 
CP (mean and range) 1.62 (0-3) 1.60 (0-3) 0.949 
CP present (% and number) 79.3% (23/29) 80% (12/15) 1.000 
CP moderate-severe (% and number) 58.6% (17/29) 53.3% (8/15) 0.759 
Lobular inflammation (mean and range) 1.62 (1-3) 1.73 (1-3) 0.744 
Lobular inflammation present (% and number) 100% (29/29) 100% (15/15) - 
Lobular inflammation moderate-severe (% 
and number) 
51.7% (15/29) 53.3% (8/15) 1.000 
Bile duct injury (mean and range) 2.24 (1-3) 2.13 (1-3) 0.630 
Bile duct injury severe 41.4% (12/29) 33.3% (5/15) 0.748 
Bile duct loss present (% and number) 41.4% (12/29) 0 (/15) 0.003 
Canalicular cholestasis (mean and range) 0.72 (0-3) 0.67 (0-3) 0.978 
Canalicular cholestasis present 44.8% (13/29) 46.7% (7/15) 1.000 
Canalicular cholestasis ³2 17.2% (5/29) 13.3% (2/15) 1.000 
Ductular reaction present (% and number) 24.1% (7/29) 33.3% (5/15) 0.722 
CLF, centrilobular fibrosis;  RAI, rejection activity index 
 
Table 68 (below). DSA II and histological parameters (HE and reticulin) 
Parameter DSA II + DSA II - p value 
Portal fibrosis - Ishak (mean and range) 1.07 (0-4) 0.71 (0-5) 0.156 
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Portal fibrosis ³2 (% and number) 37% (10/27) 5.9% (1/17) 0.031 
CLF – Venturi (mean and range) 0.44 (0-3) 0.71 (0-3) 0.539 
CLF present  (% and number) 30% (8/27) 35% (6/17) 0.748 
CLF ³2  (% and number) 11.1% (3/27) 24% (4/17) 0.402 
Sinusoidal fibrosis – Venturi (mean and range) 0.26 (0-3) 0.41 (0-3) 0.631 
Sinusoidal fibrosis present (% and number) 19% (5/27) 24% (4/17) 0.716 
Sinusoidal fibrosis ³2 (% and number) 3.7% (1/27) 12% (2/17) 0.549 
RAI (mean and range) 6 (3-9) 6.12 (3-9) 0.893 
Portal Inflammation (mean and range) 1.9 (1-3) 2.0 (1-3) 0.689 
Portal inflammation moderate-severe (% and 
number) 
74% (20/27) 77% (13/17) 1.000 
Portal inflammation severe (% and number) 19% (5/27) 24% (4/17) 0.726 
Interface activity (mean and range) 1 (0-3) 1.29 (0-3) 0.396 
Interface activity present (% and number) 67% (18/27) 76% (13/17) 0.735 
Interface activity moderate-severe (% and 
number) 
30% (8/27) 35% (6/17) 0.748 
Portal vein endotheliitis (mean and range) 1.26 (0-3) 1.47 (0-3) 0.349 
Portal vein endotheliitis present (% and number) 82% (22/27) 82% (14/17) 1.000 
Portal vein endotheliitis moderate-severe (% and 
number) 
3.7% (10/27) 53% (9/17) 0.359 
CP (mean and range) 1.56 (0-3) 1.71 (0-3) 0.643 
CP present (% and number) 78% (21/27) 82% (14/17) 1.000 
CP moderate-severe (% and number) 59% (16/27) 52% (9/17) 0.760 
Lobular inflammation (mean and range) 1.59 (1-3) 1.76 (1-3) 0.605 
Lobular inflammation present (% and number) 100% (27/27) 100% (17/17) - 
Lobular inflammation moderate-severe (% and 
number) 
52% (14/27) 53% (9/17) 1.000 
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Bile duct injury (mean and range) 2.26 (1-3) 2.12 (1-3) 0.482 
Bile duct injury severe 44% (12/27) 29% (5/17) 0.360 
Bile duct loss present (% and number) 44% (12/27) 0 (/17) 0.001 
Canalicular cholestasis (mean and range) 0.74 (0-3) 0.65 (0-3) 0.947 
Canalicular cholestasis present 44% (12/27) 47% (8/17) 1.000 
Canalicular cholestasis ³2 19% (5/27) 12% (2/17) 0.689 
Ductular reaction present (% and number) 22% (6/27) 35% (6/17) 0.489 
CLF, centrilobular fibrosis;  RAI, rejection activity index 
 
  Table 69 (below). DSA class in patients with bile duct loss 
DSA class  Number (%) 
Class II only 9 (75%) 
Class I and II 3 (25%) 
 
Table 70 (below). DSA subtype in patients with bile duct loss 
DSA subtype Number (%) 
DQ only 7 (58.3%) 




Figure 43 (above). Portal fibrosis and DSA II (p=0.031) 
4.3.6 DSA and C4d immunohistochemistry 
 
 In this cohort, the presence of circulating DSA / DSA II was strongly associated 
with tissue C4d+ in portal microvascular endothelium and specifically in portal veins. 
The difference in proportions was even higher for DSA II than DSA overall (Table 71 
and Table 72).  Whereas 92% of patients with DSA II had C4d+ in portal microvascular 
endothelium, none of those without DSA II showed this positivity (p<0.001).  
Conversely, DSA II was present in all liver recipients with C4d deposition in portal 
endothelium versus just 10% without (Figure 44). 
 Although C4d positivity in other compartments was not significantly associated 
with DSA/DSA II, all patients with C4d positivity in any vascular compartment 

















Table 71. DSA and C4d positivity per compartment 
C4d+ in DSA + DSA - P value 
Portal microvascular 
endothelium 
84.6% (11/13) 0 (/8) <0.001 
Portal vein 69.2% (9/13) 0 (/8) 0.002 
Portal capillaries 27.1% (3/13) 0 (/8) 0.117 
Hepatic artery 30.8% (4/13) 0 (/8) 0.096 
Portal stroma 30.8% (4/13) 37.5% (3/8) 0.824 
Central vein 15.4% (2/13) 0 (/8) 0.311 
Sinusoids 15.4% (2/13) 0 (/8) 0.311 





Table 72 (below). DSA II and C4d positivity per compartment 
C4d+ in DSA II + DSA II - P value 
Portal microvascular 
endothelium 
91.7% (11/12) 0 (/9) <0.001 
Portal vein 75% (9/12) 0 (/9) <0.001 
Portal capillaries 25% (3/12) 0 (/9) 0.133 
Hepatic artery 33.3% (4/12) 0 (/9) 0.065 
Portal stroma 33.3% (4/12) 33.3% (3/9) 0.860 
Central vein 16.7% (2/12) 0 (/9) 0.260 
Sinusoids 8.3% (1/12) 11.1% (1/9) 0.840 





Figure 44 (above).  C4d+ in portal microvascular endothelium and DSA II 
(p<0.001) 
4.3.7 C4d and inflammation 
 
 Inflammation was present in all biopsies and inflammation scores were higher 
than in the protocol biopsy group (Chapter 3), as these patients had a diagnosis of 
rejection. For this reason, a threshold of 2 was deemed “significant” inflammation in 
each compartment (as opposed to 1 in Chapter 3). 
 Overall, inflammation in no individual compartment was statistically associated 
with C4d+. Despite being non-significant, patients with each interface or lobular 
inflammation (³2) had higher proportions of C4d+ in most compartments, including 
portal vascular structures (Table 73). Biopsies with central perivenulitis also displayed 
a higher proportion of C4d+ in portal veins. Considering the degree of inflammation in 
each site as a continuous variable, patients with C4d+ in portal vascular structures 
also showed slightly higher scores of interface inflammation than those with negative 
















Table 73.		Frequency of C4d+ in each compartment versus inflammation in portal tracts, interface, lobule and central veins	
 
C4d+ in 
Portal inflammation Interface Lobular inflammation CP 

























































































Central vein 15.4% 
(2/13) 













































Table 74. Average degree of inflammation in each compartment versus C4d positivity or negativity in each site 










C4d staining per 
compartment 



























1.9 1.9 0.912 1.4 1.1 0.650 1.8 1.9 0.940 1.0 1.3 0.481 
Portal vein 2.0 1.8 0.737 1.4 1.1 0.516 1.9 1.8 0.762 1.1 1.2 0.765 
Portal capillaries 2.0 1.9 0.673 1.3 1.2 0.914 1.7 1.9 0.707 1.0 1.2 0.711 
Hepatic artery 2.5 1.8 0.158 1.5 1.2 0.665 1.8 1.9 0.848 1.0 1.2 0.777 
Portal stroma 2.0 1.9 0.784 1.0 1.4 0.521 1.6 2.0 0.232 1.0 1.2 0.753 
Central vein 2.5 1.5 0.345 2.0 1.16 0.367 2.0 1.8 0.701 1.5 1.1 0.753 
Sinusoids 2.5 1.8 0.345 1.5 1.2 0.747 2.5 1.8 0.224 3.0 0.95 0.032 
Any compartment 1.9 1.7 0.597 1.2 1.7 0.482 1.8 2.0 0.748 1.2 0.7 0.428 
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4.3.8 C4d and fibrosis  
 C4d+ in portal microvascular endothelium (p=0.024) and in portal veins 
(p=0.032) were significantly linked to portal fibrosis (³2), as shown in Table 75. Whilst 
88% of biopsies with portal fibrosis had C4d+ in portal microvascular endothelium, 
only 31% of those without fibrosis showed C4d deposition in this compartment. 
Centrilobular and sinusoidal fibrosis showed no significant association with C4d+ in 
any compartment. 
 Considering the degree of fibrosis in each compartment as a continuous 
variable, the mean/average degree of portal fibrosis was significantly higher in patients 
with C4d+ in portal microvascular endothelium (p=0.030, Table 76). 
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Table 75. Frequency of C4d+ per compartment versus fibrosis in sinusoids, central veins and portal tracts 
 
C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 




33.3% (1/3) 55.6% (10/18) 0.586 20% (1/5) 62.5% (10/16) 0.149 87.5% (7/8) 30.8% (4/13) 0.024 
Portal vein 33.3% (1/3) 44.4% (8/18) 1.000 20% (1/5) 50% (8/16) 0.338 75% (6/8) 23.1% (3/13) 0.032 
Portal capillaries 0 (/3) 16.7% (3/18) 1.000 0 (/5) 18.8% (3/16) 0.549 12.5% (1/8) 15.4% (2/13) 1.000 
Hepatic artery 0 (/3) 22.2% (4/18) 1.000 0 (/5) 25% (4/16) 0.532 37.5% (3/8) 7.7% (1/13) 0.253 
Portal stroma 33.3% (1/3) 33.3% (6/18) 1.000 20% (1/5) 37.5% (6/16) 0.624 50% (4/8) 23.1% (3/13) 0.364 
Central vein 0 (/3) 11.1% (2/18) 1.000 0 (/5) 12.5% (2/16) 1.000 0 (/8) 15.4% (2/13) 0.505 
Sinusoids 33.3% (1/3) 5.6% (1/18) 0.271 20% (1/5) 6.3% (1/16) 0.429 0 (/8) 15.4% (2/13) 0.505 





Table 76. Average degree of fibrosis per compartment versus C4d positivity or negativity per site 












C4d staining per 
















0.5 0.6 0.825 0.6 1.1 0.489 1.8 1.0 0.030 
Portal vein 0.6 0.5 0.755 0.7 1.0 0.587 1.8 1.2 0.088 
Portal capillaries 0 0.6 0.256 0 1.0 0.100 1.0 1.5 0.637 
Hepatic artery 0 0.7 0.177 0.3 1.0 0.241 1.8 1.4 0.350 
Portal stroma 0.4 0.6 0.425 0.7 0.9 0.684 1.9 1.2 0.276 
Central vein 0 0.6 0.366 0 1.0 0.191 0.5 1.5 0.235 
Sinusoids 1.0 0.5 0.452 1.5 0.8 0.601 0.5 1.5 0.235 
Any compartment 0.6 0.3 1.000 0.9 0.7 0.701 1.6 0.3 0.067 
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4.3.9 C4d and other histological parameters 
 
 The following parameters did not have a statistically significant association with 
C4d in any compartment scored: RAI, portal vein endotheliitis, bile duct lesion, bile 
duct loss, cholestasis and ductular reaction.  
 Despite not statistically significant, patients with bile duct loss had more than 
double the proportion of C4d+ in portal microvascular endothelium than those without 
bile duct loss: 83% versus 40% (p=0.149, Figure 45). The lack of statistical 
significance could be due to the tiny number of patients with bile duct loss who had 
C4d immunohistochemistry performed (only 6 patients). 
 
 
Figure 45. Bile duct loss and C4d in portal microvascular endothelium 
(p=0.149) 
 
4.3.10 C4d with DSA and inflammation 
 There was no significant association between inflammation in any compartment 
















78, respectively. Nonetheless, patients with interface and those with lobular 




Table 77.  DSA + C4d+  and inflammation in portal tracts, interface, lobule and central veins 
 
DSA+C4d+ in 
Portal Inflammation Interface Lobular Inflammation Central perivenulitis 



























































































Central vein 15.4% 
(2/13) 
0 (/8) 0.505 18.2% 
(2/11) 
0 (/10) 0.476 15.4% 
(2/13) 







































Table 78 (below). DSA II + C4d+  and inflammation in portal tracts, interface, lobule and central veins 
 
DSA II+ C4d+ 
in 
Portal Inflammation Interface Lobular Inflammation Central perivenulitis 















































































































































4.3.11 C4d with DSA and fibrosis 
 
 The combination of DSA/DSA II and C4d positivity in portal microvascular 
endothelium and specifically in portal veins was significantly associated with portal 
fibrosis.  The frequency of DSA/DSA II+C4d+ in portal microvascular endothelium was 
88% for patients with portal fibrosis versus 23% for those without fibrosis (p=0.024), 






Table 79.  DSA + C4d+ and fibrosis in sinusoids, central veins and portal tracts 
 
 
DSA + C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 




0 (/3) 27.8% (5/18) 0.549 0 (/5) 31.3% (5/16) 0.278 37.5% (3/8) 15.4% (2/13) 0.325 
Portal vein 33.3% (1/3) 44.4% (8/18) 1.000 20% (1/5) 50% (8/16) 0.338 75% (6/8) 23.1% (3/13) 0.032 
Portal capillaries 0 (/3) 16.7% (3/18) 1.000 0 (/5) 18.8% (3/16) 0.549 12.5% (1/8) 15.4% (2/13) 1.000 
Hepatic artery 0 (/3) 22.2% (4/18) 1.000 0 (/5) 25% (4/16) 0.532 37.5% (3/8) 7.7% (1/13) 0.253 
Portal stroma 0 (/3) 22.2% (4/18) 1.000 0 (/5) 25% (4/16) 0.532 37.5% (3/8) 7.7% (1/13) 0.253 
Central vein 0 (/3) 11.1% (2/18) 1.000 0 (/5) 12.5% (2/16) 1.000 0 (/8) 15.4% (2/13) 0.505 
Sinusoids 33.3% (1/3) 5.6% (1/18) 0.271 0 (/5) 6.3% (1/16) 0.429 0 (/8) 15.4% (2/13) 0.505 





Table 80 (below).  DSA II + C4d+ and fibrosis in sinusoids, central veins and portal tracts 
 
 
DSA II + C4d+ in 
Sinusoidal fibrosis Centrilobular fibrosis Portal fibrosis 
³2 0/1 p 
value 
³2 0/1 p 
value 




0 (/3) 27.8% (5/18) 0.549 0 (/5) 31.3% (5/16) 0.278 37.5% (3/8) 15.4% (2/13) 0.325 
Portal vein 33.3% (1/3) 44.4% (8/18) 1.000 20% (1/5) 50% (8/16) 0.338 75% (6/8) 23.1% (3/13) 0.032 
Portal capillaries 0 (/3) 16.7% (3/18) 1.000 0 (/5) 18.8% (3/16) 0.549 12.5% (1/8) 15.4% (2/13) 1.000 
Hepatic artery 0 (/3) 22.2% (4/18) 1.000 0 (/5) 25% (4/16) 0.532 37.5% (3/8) 7.7% (1/13) 0.253 
Portal stroma 0 (/3) 22.2% (4/18) 1.000 0 (/5) 25% (4/16) 0.532 37.5% (3/8) 7.7% (1/13) 0.253 
Central vein 0 (/3) 11.1% (2/18) 1.000 0 (/5) 12.5% (2/16) 1.000 0 (/8) 15.4% (2/13) 0.505 
Sinusoids 0 (/3) 5.6% (1/18) 1.000 0 (/5) 6.3% (1/16) 1.000 0 (/8) 7.7% (1/13) 1.000 




 The following parameters did not show significant association with DSA/DSA 
II+C4d positivity in any compartment: RAI, portal vein endotheliitis, bile duct lesion, 
bile duct loss, cholestasis and ductular reaction. Despite not statistically significant, 
patients with bile duct loss had more than double the proportion of DSA/DSA II+C4d+ 
in portal microvascular endothelium than those without bile duct loss (83% versus 
40%, p=0.220). The lack of statistical significance of this last association could be due 
to the small number of patients with bile duct loss who had C4d staining performed 
(only 6 patients). 
4.3.12 Criteria for acute AMR 
 
 The Banff study group on allograft pathology[53] considers a series of criteria to 
establish the diagnosis of acute AMR in liver allografts (Chapter 1). These consist of: 
compatible histology, circulating DSA, diffuse C4d in portal microvascular endothelium 
and reasonable exclusion of other possible aetiologies that might produce a similar 
pattern of liver injury.  
 In the current cohort of rejection biopsies, 21 patients could be assessed using 
the Banff criteria to diagnose acute AMR (these were the patients who had C4d 
immunostaining performed).  Thirteen out of these 21 had circulating DSA, and 5 
(24%) fulfilled all the criteria for definite acute/active AMR, including presence of DSA, 
diffuse portal microvascular C4d deposition and compatible histology. The Banff 
criteria for the diagnosis of acute AMR are specified in  
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Table 81 and the C4d-scored and h-score which are part of the criteria are detailed 
in  
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Table 81. Banff criteria for diagnosing acute AMR in liver grafts 
Definite for acute/active1 AMR (all four criteria required): 
(1) Histopathological pattern of injury consistent with acute AMR, usually including the 
following: portal microvascular endothelial cell hypertrophy, portal capillary and inlet 
venule dilatation, monocytic, eosinophilic, and neutrophilic portal microvasculitis, 
portal edema, ductular reaction; cholestasis is usually present, but variable; edema 
and periportal hepatocyte necrosis are more common/prominent in ABO-incompatible 
grafts; variable active lymphocytic and/or necrotizing arteritis 
(2) Positive serum DSA 
(3) Diffuse (C4d score = 3) microvascular C4d deposition1 on frozen or formalin-fixed, 
paraffin-embedded tissue in ABO-compatible tissues or portal stromal C4d deposition 
in ABO-incompatible grafts. 
(4) Reasonable exclusion of other insults2 that might cause a similar pattern of injury (see 
text). Most cases will score (C4d-score: 3+ h-score = 5 or 6; see below). 
Suspicious for AMR (both criteria required): 
(1) DSA is positive (see definitions). 
(2) Non-zero h-score with: C4d-score + h-score of 3 or 4. 
Indeterminate for AMR (requires 1+2 and 3 or 4): 
(1) C4d-score + h-score is  2. 
(2) DSA not available, equivocal, or negative. 
(3) C4d staining not available, equivocal, or negative. 
(4) Co-existing insult might be contributing to the injury. 
 
AMR, antibody-mediated rejection; DSA, donor-specific antibody. 
1Optimized C4d staining including positive control is critical for proper evaluation. 
2Thrombocytopenia, low serum complement levels, persistence of DSA early after transplantation, 









(0) No C4d deposition in portal microvasculature 
(1) Minimal (<10% portal tracts) C4d deposition in >50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries) 
(2) Focal (10–50% portal tracts) C4d deposition in >50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries) - usually without extension into 
periportal sinusoids 
(3) Diffuse (>50% portal tracts) C4d deposition in >50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries)—often with extension into inlet 
venules or periportal sinusoids 
h-(histopathology)-score
3,4,5 
(1) Portal microvascular endothelial cell enlargement (portal veins, capillaries, and inlet 
venules) involving a majority of portal tracts with sparse microvasculitis defined as three 
to four marginated and/or intraluminal monocytes, neutrophils, or eosinophils in the 
maximally involved capillary with generally mild dilation (Figure 1). 
(2) Monocytic, eosinophilic, or neutrophilic microvasculitis/capillaritis, defined as at least 5–
10 leukocytes marginated and/or intraluminal in the maximally involved capillary 
prominent portal and/or sinusoidal microvascular endothelial cell enlargement involving 
a majority of portal tracts or sinusoids, with variable but noticeable portal capillary and 
inlet venule dilatation and variable portal edema (Figure 2). 
(3) As above, with marked capillary dilatation, marked microvascular inflammation (10 or 
more marginated and/or intraluminal leukocytes in the most severely affected vessels), 
at least focal microvascular disruption with fibrin deposition, and extravasation of red 
blood cells into the portal stroma and/or space of Disse (subsinusoidal space) (Figure 3). 
AMR, antibody-mediated rejection; PAS, periodic acid-Schiff; RBC, red blood cells. 
1Formalin-fixed, paraffin-embedded tissues are known to show weaker staining than fresh-frozen 
tissues, but interpretation of frozen tissues can be more difficult because of background/nonspecific 
staining and poor preservation of morphology. Sinusoidal staining should be localized to sinusoidal 
endothelial cells; false positive staining of connective tissue fibers can occur in livers with subsinusoidal 
fibrosis. 
2Ideally the C4d positive control should be a liver graft, but peritubular capillary staining of a kidney graft 
is an acceptable alternative. 
3Special stains that help identify capillaries, such as CD31, CD34, and/or PAS are often needed to help 
identify involved portal-based capillaries. 
4Other features commonly seen, but not necessarily associated with severity include ductular reaction 
and cholestasis. 




 All five liver recipients with definite AMR had class II DSA (three also had class 
I) and all had DQ (three also had DR). The total sum of MFI in each of these patients 
was above 10,000, ranging from 13,441 to 54,626. The sum of MFI of class II DSA 
varied from 7,081 to 45,583. 
 Table 83 details clinical parameters of the 5 patients with definite AMR. The 
following figures show biopsy sections of one of the patients who had diagnosis of 
definite acute AMR. 
 
 
Table 83. Clinical data of patients with definite AMR 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Age (years) 52 13 27 30 22 
Indication for LT Autoimmune 
hepatitis 











12 days 5 years 3 years 10 days 5 years 
Baseline 
immunosuppression 
Tacrolimus Cyclosporine + 
Mycophenolate 




108 104 236 44 173 
Bilirubin (µmol/L, 
reference 3-20) 
247 13 311 241 18 
AP (IU/L, reference 
30-130) 




638 34 351 651 183 
INR (ratio, reference 
0.9-1.2) 
2.21 1.05 1.33 1.28 0.97 
DSA class I and II II I and II I and II II 
DSA type A, DR, DQ DQ A, DQ A, B, Cw, 
DQ, DR 
DQ, DR 
DSA I MFI 18854 - 6360 9043 - 
DSA II MFI  18359 27328 7081 45583 24267 
DSA total MFI  37213 27328 13441 54626 24267 











Figure 46. Patient with diagnosis of acute AMR. Portal tract with mild/moderate 
inflammation and capillary dilatation with microvasculitis (intraluminal 
leukocytes, arrows)(HE, 400x) 
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Figure 47. Same biopsy as above, different area. Portal tract with oedema and 
severe inflammation (HE, 200x)		
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Figure 48. Same portal tract as Figure 47, higher magnification. Dilated portal 
capillaries with numerous intraluminal leukocytes (arrows).  Endothelial cell 
enlargement is also noticed (stars) (HE, 400x). 
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Figure 49. Same portal tract as Figure 48, C4d immunostaining. Diffuse C4d 
positivity in portal microvascular endothelium (portal vein branches and portal 
capillaries, arrows).  Intraluminal inflammatory cells can be visualised (star) 
(400x). The inset (top right) shows endothelial cell hypertrophy in a capillary in 





Figure 50. Same biopsy section as Figure 49, different biopsy field. Diffuse 
microvascular C4d+. Vascular dilatation and intraluminal inflammatory cells 
are conspicuous (arrows) (C4d immunohistochemistry, 400x). 
4.3.13 Gene expression 
 Forty-two patients had enough tissue in their respective biopsy specimens for 
RNA analysis. Following the RNA sequencing and analysis of the gene expression 
patterns using the gene libraries (section 4.2.5, page 192), a comparison was made 
between patients with and without DSA as well as with or without DSA II. Analysis of 
gene expression and of inflammatory pathways known to be upregulated/activated in 
specific liver conditions, including TCMR and recurrent HCV, and in AMR in kidney 
allografts was conducted. Since gene expression patterns of AMR are still not 
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established for the liver allograft, as the diagnosis of AMR in liver itself has only 
recently been recognised, there are no libraries including gene signatures of AMR in 
the liver. In fact, recognising gene signatures linked to AMR in liver was the reason 
why the RNASeq was conducted in the present study. No significant difference was 
observed between the groups analysed (DSA+ versus DSA-  and DSA II+ versus DSA 
II-) in terms of expression of genes or pathways. 
 It was not possible to compare patients with and without C4d+ or DSA+C4d+ 
since the number of liver recipients with C4d staining available was too small to 
generate significant results for the molecular analysis. 
4.4 DISCUSSION 
4.4.1 Overview 
 This chapter presented the study of 44 liver allograft biopsies with TCMR and 
DSA testing who had no evidence of recurrent disease. In the Results section above, 
the histological assessment, including HE and reticulin staining and C4d 
immunohistochemistry, and the correlation between histology, circulating DSA and 
gene expression were presented. In the current section, the findings are discussed in 
view of relevant up-to-date literature. 
 In terms of the histological assessment of HE and reticulin staining, a third 
(32%) of biopsies had fibrosis scoring ³2 in one or more compartments analysed. A 
fourth had portal fibrosis (³2), 16% showed centrilobular fibrosis (³2) and 6.8%, 
sinusoidal fibrosis (³2) (see  
Table 65 and Figure 40 - Figure 42, page 203). This rate of fibrosis was almost half of 
that found in long-term paediatric protocol biopsies (Chapter 3), despite the greatly 
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shorter time post-transplant of the biopsies of the present cohort (median 5.5 months). 
Fibrosis was observed to be linked to a longer time from transplantation to biopsy, as 
expected, and it reflects some degree of ongoing graft injury or previous flares of acute 
injury, such as episodes of rejection.  
 It is important to consider that the histological analysis of portal fibrosis, 
especially when no bridging/fibrous septa is present (Ishak stages 1 and 2), is more 
difficult in biopsies with portal oedema, which is typical of acute rejection. Therefore, 
the diagnosis of portal fibrosis in this group is potentially less reliable than in the long-
term protocol biopsies. Whereas liver fibrosis is well documented in post-transplant 
graft protocol biopsies, studies on acute rejection do not normally involve evaluation 
of fibrosis. 
 Another interesting finding in the present study cohort was the presence of bile 
duct loss in over a fourth of the biopsies. Bile duct loss was considered significant 
when more than 10% of portal tracts lacked bile ducts, and the residual interlobular 
ducts displayed obvious damage. This not unusual finding of bile duct loss denotes a 
severe nature to the rejection episode, which is progressing towards CR. Since the 
bile duct loss in all but one patient involved <50% of bile ducts, it could be potentially 
reversible through appropriate changes in immunosuppression. In fact, most patients 
(55%) who showed bile duct loss on histology did have good outcome (allograft 
preservation) during follow-up. Musat et al.[90] found a comparable rate of bile duct loss 
in for cause biopsies of patients with TCMR, 21%. 
 Compared to the protocol biopsy study group, the for-cause biopsies with 
rejection showed less fibrosis and more inflammation in all compartments assessed, 
as shown in Table 84. The biopsies with rejection also had higher proportion of bile 
duct lesion, canalicular cholestasis and bile duct loss. This higher degree of 
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inflammation and bile duct injury was expected, since these biopsies were diagnosed 
as rejection (which requires inflammation and bile duct injury). In contrast, the protocol 
biopsies belonged to asymptomatic recipients with normal or nearly normal LFTs. 
 
Table 84. Overall biopsy assessment (HE and reticulin staining) of two study 





For cause biopsies with 
rejection 
Portal Inflammation 
      Absent 
      Mild (grade 1) 
      Moderate (grade 2) 












      Absent  
      Mild  (grade 1) 
      Moderate  (grade 2)     












      Absent  
      Minimal (grade 1) 
      Moderate (grade 2) 












      Absent  
 
73.1% 
    
21% 
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      Mild (grade 1) 
      Moderate (grade 2) 







Bile duct lesion 
      Absent  
      Minimal (grade 1) 
      Moderate (grade 2) 











Bile duct loss 
       Absent 
       Present <50% 










Portal vein endotheliitis 
      Absent  
      Mild (grade 1) 
      Moderate (grade 2) 













      Absent 








     Absent 
     Focal 
     Diffuse centrilobular 



















       5-33% of hepatocytes (grade 1) 
       33-66% of hepatocytes (grade 2) 







Portal fibrosis (Ishak) 
     Stage 0/1 
     Stage 2 
     Stage 3 
     Stage 4 













































 On C4d immunohistochemistry, over half of the patients showed positivity in 
portal microvascular endothelium (portal veins and/or portal capillaries). Overall, 
incidence of positive C4d staining in the present for-cause cohort was substantially 
higher than in the previous protocol biopsy group, in which only 28% of patients had 
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C4d staining in portal microvascular endothelium. Table 85 shows a comparison of 
the frequency of C4d positivity per compartment in each of the two study groups. 
 
Table 85. C4d staining per compartment in two study groups: protocol 
biopsies and for cause biopsies with rejection 
C4d+ in Paediatric protocol 
biopsies 
For cause biopsies 
with rejection 
Portal endothelium 28% 52.4% 
Portal vein 16% 38.1% 
Portal capillaries 16% 14.3% 
Hepatic artery 10% 28.6% 
Portal stroma 18% 52.4% 
Central vein 4% 9.6% 
Sinusoids 2% 14.4% 
Any compartment 34% 85.7% 
 
The higher frequency of C4d positivity observed in biopsies with acute 
rejection in comparison to long-term protocol biopsies is consistent with previous 
research reporting lower sensitivity of C4d staining in the context of chronic graft 
injury/chronic AMR[53,97-98].  The shorter storage time of the paraffin blocks in the 
current study group biopsies can also have influenced the frequency of C4d 
positivity[98]. Finally, acute AMR frequently occurs in combination with TCMR, which 
will be further discussed. 
4.4.2 DSA 
 
DSA were present in almost two-thirds of patients in this cohort, and 93.1% 
of these had class II DSA. High prevalence of DSA was expected in this group, in 
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which DSA test was clinically indicated, thus AMR was suspected (prior to or after the 
biopsy result). Compared to the previous study group (protocol biopsies), the patients 
with rejection had a slightly lower prevalence of circulating DSA: 66% versus 71%. 
The higher proportion of DSA in children undergoing protocol biopsy might be related 
to the longer time between transplantation and biopsy in that group. Another reason 
for the higher prevalence of DSA in the protocol biopsy group could be the patients’ 
age: all patients in that cohort were children at transplantation, whereas in the rejection 
group, both children and adults were included.  As to DSA class, the frequency of class 
II DSA was similar in both cohorts: 64.7% and 62.1% in the protocol and rejection 
groups, respectively. In both cohorts, class II was the most prevalent type of DSA, as 
shown in Table 86.  
 
Table 86. DSA in two study groups: protocol biopsies and for cause biopsies 
with rejection 
DSA in Paediatric protocol 
biopsies 
For cause biopsies 
with rejection 
Class II only 52.9% 43.9% 
Class I and II 11.8% 18.2% 
Class I only 5.9% 4.5% 
No DSA 29.4% 34.1% 
 
Previous studies showed an association between both pretransplant and de 
novo DSA and higher risk of developing acute rejection[90,207].  Conversely, previous 
episodes of acute rejection seem to be the main predictor for the development of de 
novo DSA post-liver transplant[57,218]. A likely explanation is that continued or recurrent 
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tissue injury secondary to rejection leads to alloantigen exposure, causing 
upregulation of expression of HLA molecules and resulting in the production of DSA[57]. 
More class II than class I DSA were present, and in particular anti-DQ, in 
both protocol and for cause cohorts. This is consistent with previous publications 
showing that anti-HLA II of DQ subtype is the most frequent de novo DSA in the liver 
allograft[83,95]. The high rate of DSA against DQ might be due to the higher 
polymorphism of the genes encoding DQ antigens, which happens for α chain as well 
as for the b[85] (Chapter 1). Del Bello et al.[202] found that class II DSA accounted for 
92% of post-transplant DSA in adult liver recipients, and 73% of them were against 
DQ. In another series, 95% of liver recipients developed class II DSA, with 85% 
against DQ isotype[84]. In yet another series, 92% of DSA were towards class II HLA 
and over two-thirds of these (70%) were directed to DQ[207].  
 As to DSA and clinical parameters, a strong association was found between 
DSA II >10,000 MFI and younger recipient age (p=0.007, Figure 38 on page 201).  
Most patients (56%) with DSA II above that threshold were children, in comparison to 
only 16% of those with lower or no DSA II (Table 64 on page 201). In the protocol 
biopsy group, patients with circulating DSA II were younger at transplantation and this 
was close to statistical significance (p=0.052). In both cohorts, DSA were not 
associated with the time from transplantation to biopsy. Other authors have also found 
younger liver recipient age to be related to post-transplant DSA II[52,199-204] (Chapter 
3). Despite the frequency of this association, the physiological mechanisms that make 
younger patients more prone to develop de novo DSA is not understood. 
 There was a relationship between circulating antibodies and histology: DSA II 
were associated with each portal fibrosis, bile duct loss and C4d deposition, 
particularly in portal microvascular endothelium. Patients with DSA II had higher 
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proportion of portal fibrosis (³2) than those without (p=0.031, Table 68 on page 210) 
and vice-versa (Figure 43). Higher prevalence of fibrosis in recipients with circulating 
DSA, particularly class II DSA, has been repeatedly reported[28,50,95,198,200,205-207]. 
 This association between fibrosis and DSA has been mostly observed in 
protocol or long-term post-transplant biopsies, and suggests that antibody-mediated 
mechanisms play a role in the process of unexplained graft fibrosis. In recent study of 
adult liver recipients by Vandevoorde et al.[207], DSA were associated with portal 
fibrosis (and with TCMR) at 1-year after LT. 
 Another interesting finding in the present study was the strong statistical 
association between circulating DSA II and bile duct loss (p=0.001). In fact, bile duct 
loss was exclusively found in patients with circulating class II DSA (Table 68 on page 
210). In the 80’s and 90’s, studies reported an association between preformed 
antibodies against donor HLA and the development of CR in the liver allograft[219-221].  
These studies did not consider de novo DSA, and the method used for antibody 
detection (cell-based cytotoxic assays) was limited compared to current solid-phase 
immunoassays. However, the mechanism of bile duct destruction proposed then is still 
valid in the present context.  More recently, other authors have corroborated the 
association between DSA and ductopenia/chronic rejection[75,79,90,222-223].  
 The liver graft has classically been considered to be greatly spared from the 
pathogenic effects of preformed HLA antibodies, for reasons previously stated 
(Chapter 1 and Figure 1 on page 171). Currently, it is known that whereas the hepatic 
parenchyma is notably protected from humoral damage, the biliary tree works in a 
similar way to kidney and heart allografts, due to its purely arterial circulation and its 
arteriolar and capillary network. As a consequence, sustained antibody-mediated 
injury to the arterioles and peribiliary plexus can potentially lead to bile duct loss[221]. 
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 The pathogenic cascade of antibody-mediated injury starts with the binding of 
DSA to endothelial cells in the portal microvasculature. This triggers complement 
activation, leading to destruction of the portal microvascular endothelium, including 
the arteries from which the periductal vascular plexus arises. The consequence is bile 
duct ischemia and subsequent loss[90,221].  Morphometric studies in human liver 
allografts have confirmed that the destruction of the portal microvasculature (including 
peribiliary small vessels) precedes bile duct destruction in CR. These findings support 
the role of antibody-mediated damage and of ischemia in chronic rejection[224-225]. 
 On the other hand, in a retrospective study of 268 successive liver transplants, 
Muro et al.[226] did not find difference in the frequency of CR between liver recipients 
with positive and negative crossmatch. However, the authors only considered 
preformed antibodies, not de novo DSA. As mentioned in Chapter 1, most preformed 
anti-HLA antibodies disappear from the recipient’s circulation after liver 
transplantation[57,222].  Grabhorn et al.[227] observed that all DSA present in liver 
recipients with CR were in fact de novo DSA. O’Leary et al.[67] found an association 
between high MFI DSA and CR, and suggested that AMR can manifest as CR. For 
DSA subtype, all 12 liver recipients with bile duct loss in the current series had anti-
DQ DSA (Table 70). Wosniak et al.[52] found DQ DSA specifically to be strongly 
associated with late TCMR and with CR. 
 Interestingly, in the failed allografts cohort (Chapter 2), despite its decrease 
over the years as a cause of retransplantation, CR still accounted for over 10% of 
allograft losses in both adult and paediatric liver recipients in the most recent era. 
Considering the link between bile duct loss and antibody-mediated injury, it is possible 
that tacrolimus prevents the development of CR resulting from pure TCMR or from 
TCMR associated with mild forms of AMR, but it might not be able to treat more severe 
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cases of AMR.  Therefore, the allograft failures due to CR at present might be a 
consequence of active AMR rather than an evolution of pure TCMR. 
 Strong statistical association was also found between the presence of DSA II 
and C4d staining in each vascular compartment, the strongest being portal 
microvascular endothelium and portal veins (p<0.001). The proportion of patients with 
and without portal vascular C4d+ who had DSA II was 100% versus 10%, respectively 
(Figure 44 on page 215).  Thus, C4d was a highly specific (exclusively present in 
patients with DSA II) and reasonably sensitive indicator of the presence of circulating 
DSA in the present cohort. The consistency of the results means that the protocol for 
C4d immunohistochemistry employed in this research has potential to be applied to 
clinical practice.  
 Although in the protocol biopsy cohort (Chapter 3) C4d was not significantly 
associated with DSA, C4d+ in portal veins was only present in patients with these 
circulating antibodies (Table 37 on page 141). The lack of statistical association is 
likely due to a combination of limited sample size (only 34 patients with DSA data) and 
the low occurrence of C4d positivity in that population, due to the lower sensitivity of 
this staining in the chronic setting and to longer tissue storage times. 
4.4.3 C4d and DSA combined with C4d 
 
 Regarding the link between C4d and other histological parameters, I observed 
that patients with C4d positivity in portal microvascular endothelium had a significantly 
higher proportion of portal fibrosis. They also had higher frequency of interface and 
lobular inflammation, but these were not significant.  
 Portal fibrosis was not only linked to DSA II, but also to C4d+ in portal 
microvasculature (p=0.024, Table 75 on page 219) and to the combination of 
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DSA+C4d+. Considering the latter, patients with portal fibrosis (³2) showed 
significantly higher proportion of DSA+C4d+ in portal microvascular endothelium (88% 
versus 23%, p=0.024, Table 79, page 226).  Considering its association with DSA and 
C4d individually and in combination, the presence of portal fibrosis in biopsies with 
rejection should be viewed as a warning sign of ongoing antibody-mediated damage. 
Thus, unexplained fibrosis in both long-term post-transplant and acute rejection 
settings might be a sign of AMR[96,183]. 
 Although not significant, patients with interface and lobular inflammation ³2 
showed higher proportion of C4d+ in portal microvascular endothelium and of 
DSA+C4d+ in this compartment. Recipients with central perivenulitis also displayed 
higher frequency of C4d+ in portal veins and of DSA+C4d+ in the same location (Table 
77 on page 223). A link between DSA+C4d+ in portal microvascular endothelium and 
each interface and central perivenulitis was also observed in the protocol biopsy cohort 
(Table 43 on page 149). 
 Currently, interface is included in the histological criteria of chronic AMR but not 
of acute AMR in the liver allograft[53]. Since acute AMR often occurs in combination 
with TCMR, some of the criteria traditionally considered to be features of TCMR might 
be in fact related to the antibody-mediated component[58,59,228]. Therefore, the 
presence of moderate/severe interface in biopsies with rejection should be regarded 
with particular attention as a possible marker of concomitant AMR. In Musat’s series, 
54% of patients with TCMR also showed signs of simultaneous humoral rejection 
(characterised as DSA with diffuse C4d staining).  
 Interestingly, whilst in the protocol biopsies central perivenulitis was associated 
with DSA+C4d+ (and with C4d+) in portal microvascular endothelium, in the current 
group of rejection biopsies, central perivenulitis was not significantly associated with 
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any parameter of humoral activation: DSA, C4d or their combination. Nevertheless, 
patients with central perivenulitis ³2 showed considerably higher proportion of C4d+ 
in portal veins and of DSA+C4d+ in the same site (Table 73 and Table 77 on pages 
216 and 223, respectively). Based on the current results and considering the limited 
size of the present cohort (21 patients with C4d data), it is not possible to confirm or 
refute an association between central perivenulitis and AMR in the context of rejection.  
 Furthermore, patients with lobular inflammation ³2 had more than double the 
proportion of C4d+ and of DSA+C4d+ in portal veins than those with no/grade 1 lobular 
inflammation (53.9% versus 25%), although this difference was not significant (Table 
73 and Table 77 on pages 216 and 223, respectively). Even though not significant, 
this higher proportion of C4d+/DSA+C4d+ in patients with more prominent lobular 
inflammatory activity is consistent with the findings of the protocol biopsy group, in 
which lobular inflammation was significantly linked to DSA and C4d+ individually. 
 In regard to bile duct loss, the frequency of DSA+C4d+ in portal microvascular 
endothelium in patients with bile duct loss was more than double that of patients with 
preserved number of bile ducts (83.3% versus 40%), although not statistically 
significant (p=0.220). This lack of significance is probably due to the tiny number of 
patients with bile duct loss who had C4d immunohistochemistry performed (6 patients 
only). Five (83.3%) of these 6 recipients had both circulating DSA (class II in all) and 
C4d+ (at least focal) in portal vascular endothelium. The other patient had circulating 
class II DSA but no C4d deposition in any compartment.  Combined to the strong 
association I found between bile duct loss and DSA, these findings support the 
hypothesis that bile duct loss in the context of rejection is likely consequence of AMR. 
 Other authors have found C4d deposition in 8-57.9% and 17-100% of liver 
allograft biopsies with acute and CR, respectively[141,229-231]. This wide range is 
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consistent with the diversity of C4d immunostaining methods. In a study by Musat et 
al.[90] of for cause liver allograft biopsies with rejection, all patients with bile duct loss 
had both DSA and diffuse tissue C4d staining. In the current study, overall only 3 
patients showed diffuse C4d staining: thus, the current C4d staining seems to be less 
sensitive than that of the mentioned study. Nevertheless, considering focal (as 
opposed to only diffuse) C4d deposition as positive, the C4d immunohistochemistry in 
the current study showed good statistical links with several relevant histological 
parameters, as aforementioned. 
 Considering the current Banff diagnostic criteria for acute AMR[53], five of the 
21 patients for which C4d was available (24%) fulfilled all conditions for definite acute 
AMR: circulating DSA, diffuse endothelial C4d deposition, compatible histology and 
no other injury that could justify the histological findings. This is a significant proportion 
of patients previously diagnosed with purely TCMR. Of note, 3 out of the 5 patients 
with definite AMR had their biopsies performed years after transplantation. This 
contrasts with the classical reports of acute AMR, which typically occur in the early 
post-transplant period (within weeks). 
 
4.4.4 Summary 
 In the current analysis of post-transplant biopsies with rejection, C4d positivity 
in portal microvascular endothelium was a highly specific and sensitive indicator of the 
presence of DSA II (present in 92% of patients with DSA II and in none of the patients 
without, p<0.001). Portal fibrosis (³) was associated with antibody-mediated injury, as 
it was significantly linked to C4d+ and circulating DSA, both separately and in 
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combination. Bile duct loss was also strongly linked with DSA, and was present 
exclusively in patients with circulating class II DSA.  
 Furthermore, patients with more severe interface and lobular activity also 
showed higher rates of C4d+ and DSA+C4d+ in portal microvascular endothelium, 
which could indicate a potential link with AMR, but due to the lack of statistical 
significance of these associations, this is simply a speculation. Similarly, an 
association between central perivenulitis and humoral activation in the present context 
could not be confirmed (as it was in the protocol biopsy cohort). A fourth of patients 
with TCMR also fulfilled the Banff criteria for definite acute AMR. 
 These findings showed that, in the context of TCMR, C4d is a good marker of 
AMR and a specific indicator of circulating DSA and that portal fibrosis and bile duct 
loss should be regarded as potentially linked to AMR. This is consistent with the 
hypothesis that some findings classically considered to be part of the T cell-mediated 
rejection spectrum might be the consequence of an overlapping antibody-mediated 
component.   
 In comparison, in paediatric long-term protocol biopsies, the sensitivity of C4d 
staining was very low. Although not significant, in that context, C4d+ in portal veins 
was exclusively found in patients with DSA. Additionally, C4d+ was associated with 
higher numbers of B cells and plasma cells. In the same group, sinusoidal fibrosis, 
interface, central perivenulitis and lobular inflammation were related to AMR (the first 
3 parameters were linked to DSA+C4d+, and lobular inflammation was associated with 
DSA and C4d separately).  
 In for cause biopsies with rejection, essentially the portal features (and perhaps 
lobular inflammation) were associated with AMR. In contrast, in the protocol biopsies, 
injury of the central/lobular region also showed significant links with potential chronic 
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AMR, including sinusoidal and centrilobular fibrosis, central perivenulitis and lobular 
inflammation.  
 In the RNA sequencing analysis, no difference in the expression of genes 
related to known pathological conditions of the liver was observed between patients 
with and without DSA or class II DSA. Due to the relatively small number of patients 
who had C4d staining performed, it was not possible to compare gene signatures in 
patients with and without C4d+ or DSA+C4d+.  It is important to stress that gene 
expression patterns were evaluated by comparing the patterns from samples with 
recognized pathologies of the liver graft, such as recurrent HCV, AIH and TCMR.  
Since TCMR often occurs intertwined with AMR, it is possible that some of the gene 
signatures which are currently considered to be markers of the former could actually 
also include the latter. This could explain the lack of differentiation of patients with and 
without DSA in the molecular level.  
The results highlight the role of histological analysis, since a detailed 
microscopic assessment of biopsies with basic staining to evaluate liver structures, 
inflammation and fibrosis, combined to C4d immunohistochemistry, could greatly help 
in recognising cases of AMR. In this assessment, the technical aspects of C4d staining 
should be considered. Particular attention should be given to the recognition of 
histological findings considered in the Banff diagnostic criteria of acute AMR, some of 
which are not routinely scored by liver pathologists (such as microvasculitis). Biopsies 
with TCMR should also be assessed for the presence of concomitant AMR. In 
particular, the presence of bile duct loss in the context of rejection should always raise 
the possibility of antibody-mediated injury and prompt to tissue C4d staining and 




5   CONCLUSION 
The current work consisted of a histopathological study of liver allografts, with 
particular emphasis on idiopathic post-transplant chronic hepatitis (IPTH) and 
antibody-mediated injury. Three groups corresponding to three distinct post-
transplantation settings were analysed: failed allografts removed at retransplantation;  
long-term protocol biopsies of asymptomatic paediatric liver recipients, and for cause 
biopsies with a diagnosis of TCMR. 
In Chapter 2 (Failed Liver Allografts), a histological review of 460 explanted liver 
allografts through almost three decades showed a steady increase in the proportion 
of allograft loss for IPTH associated with fibrosis.  In the last era, IPTH with fibrosis 
represented the main cause for late retransplantation in children and the second cause 
in adults (following recurrent disease). The results of Chapter 3, the protocol biopsy 
cohort, suggest that this pattern of idiopathic chronic hepatitis and fibrosis is a slowly-
progressing form of rejection with an antibody-mediated component. 
The findings from the explanted allografts motivated analysis of protocol 
biopsies in the search of similar histological injury at an earlier stage after 
transplantation, asymptomatic liver recipients with normal/nearly normal liver function 
tests and with the advantage of being able to perform DSA test. In this series of 
protocol biopsies, evidence was found to support the hypothesis that unexplained 
inflammation (especially interface activity, central perivenulitis and lobular 
inflammation) and fibrosis in sinusoids and/or centrilobular areas probably result from 
chronic AMR. Of note, the presence of AMR does not exclude a concomitant 
component of (late) TCMR. 
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Interestingly, in the context of allograft failure leading to retransplantation, three 
fourths of paediatric recipients who lost their graft because of IPTH associated with 
fibrosis had former biopsies showing central perivenulitis. Centrilobular fibrosis was 
also previously detected in over half of them (58%). As no obvious reason had been 
found to justify the inflammation, it is possible that such central-based injuries resulted 
from AMR. 
In the protocol biopsy paediatric cohort, fibrosis in each location was 
significantly associated with higher numbers of plasma cells (and portal fibrosis also 
with more B cells), but not T cells. This provides an additional indication of the 
involvement of antibody-mediated mechanisms in the development of fibrosis. 
 Specific association between B cells (and plasma cells) and fibrosis was 
confirmed. This association had been previously described in mouse models and in 
other human organs, but not in the liver. Furthermore, B lymphocytes in the liver 
allograft were found to express granzyme B.  To the best of current knowledge, this 
finding has not been reported in human liver, and could represent a potential local role 
of B cells involved in the development and progression of fibrosis. This would mean 
that the functions of B cells extend beyond antibody-mediated immunity.  
 The digital measurement of fibrosis through CPA did not add useful information 
compared to the conventional assessment of fibrosis in three compartments (portal, 
centrilobular and sinusoidal) in the context of protocol biopsies. Nonetheless, previous 
studies support the role of CPA measurement in other settings, such as predicting 
decompensation in patients with post-transplant recurrent HCV[44-45,233-234]. 
In the protocol biopsy group, C4d+ in portal microvascular endothelium (portal 
veins and portal capillaries) was associated with a humoral inflammatory profile (B 
cells and plasma cells). Although the tissue injury in this setting is not enough to cause 
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significant abnormality in liver enzymes and liver function tests, it might cause 
irreversible allograft changes such as advanced-stage fibrosis, and eventually allograft 
failure. Routine protocol biopsy is currently the only reliable way to diagnosis 
significant allograft injury in paediatric liver recipients. 
In the third study cohort, a possible role for humoral-mediated injury was 
investigated in the context of clinically evident allograft dysfunction, in biopsies with 
cellular rejection. C4d positivity in portal microvascular endothelium and specifically in 
portal veins was a reliable and specific indicator of the presence of DSA II. Moreover, 
bile duct loss was strongly associated with DSA (only present in patients with these 
antibodies). Portal fibrosis was strongly linked to C4d+ and to DSA+C4d+ in portal 
microvascular endothelium. 
These observations demonstrate that the portal tract is a target of AMR in the 
setting of acute TCMR. It also shows that histological parameters frequently 
interpreted as consequence of ongoing TCMR, such as bile duct loss and portal 
fibrosis, might be also linked to AMR. Thus, the pathologist should always have in 
mind the possibility of AMR when establishing a diagnosis of TCMR, especially in 
severe episodes of rejection or those that do not respond to steroid treatment; 
otherwise, the diagnosis of concurrent AMR will likely be overlooked. 
Interface and lobular inflammation were also potentially but not significantly 
associated with C4d+ and DSA+C4d+ in the rejection cohort. In the protocol biopsy 
group, interface and lobular inflammation were respectively linked to DSA+C4d+ and 
to DSA and C4d+ separately. Thus, these two compartments should be carefully 
assessed for inflammation, since they might indicate antibody-mediated injury in both 
acute rejection and long-term protocol biopsy settings. Other aetiologies for the liver 
insult should be excluded before the diagnosis of AMR is established. Because portal 
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fibrosis results of long-standing or repeated/successive injuries, the link between 
portal fibrosis and DSA+C4d+ in the context of acute allograft dysfunction could reflect 
an ongoing injury with a humoral component prior to the rejection episode. 
 In both biopsy cohorts, C4d+ in portal veins was exclusively present in patients 
with circulating DSA (100% specificity). In the for cause biopsy group, C4d+ in portal 
microvascular endothelium was also a specific indicator of the presence of DSA II 
(92% of patients with DSA II had C4d+ in this location versus none of the patients 
without these antibodies, p<0.001). 
In view of the low sensitivity of C4d staining in chronic post-transplant FFPE 
biopsies, the possibility of AMR should not be discarded in cases with minimal or 
absent C4d staining, even though a definite diagnosis cannot be made. Considering 
the current Banff criteria for chronic active AMR, over a fourth (26%) of paediatric 
protocol biopsies in the present research were diagnosed as either probable or 
possible AMR. Over the next years, as the histological parameters for the diagnosis 
of chronic AMR are refined and more extensively validated, it might be possible to 
confirm cases of chronic AMR despite negative C4d staining. AMR with negative C4d 
staining has been recognised in other allografts, such as kidney[72]. 
Considering the Banff criteria for acute AMR, a definite diagnosis of AMR could 
be made retrospectively in almost a fourth of patients formerly diagnosed with cellular 
rejection. This emphasizes the importance of looking for signs of AMR after a 
diagnosis of TCMR is established. 
In the acute rejection cohort, all patients who showed bile duct loss had 
circulating class II DSA (p=0.001).  Patients with bile duct loss also showed more than 
double the proportion of C4d+ and of DSA+C4d+ in the portal microvascular 
endothelium, but this was not statistically significant, probably due to the very small 
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number of the sample (only 6 patients with bile duct loss had C4d staining performed). 
In the failed allografts cohort, for both adults and children, chronic rejection (CR) 
accounted for over 10% of allograft loss in the most recent era, despite its decrease 
through the years, particularly after the introduction of tacrolimus.  Considering the 
link between bile duct loss and DSA (and possibly DSA+C4d+), and the recognised 
role of microvascular endothelial damage in the destruction of bile ducts in CR, it is 
possible that the use of tacrolimus efficiently prevents the development of CR resulting 
from pure TCMR or from TCMR associated with mild AMR. Tacrolimus however, might 
not be capable of treating more severe forms of AMR. This is consistent with previous 
evidence that therapeutic agents targeting the cellular component of immunity might 
efficiently treat less severe cases of AMR. 
The close link between both TCMR and AMR is progressively becoming more 
evident. The fact that T cell-mediated injury might indirectly increase antibody-
production through upregulation of antigen expression in the liver allograft further 
corroborates this association.  Therefore, at present, the finding of bile duct loss/CR 
in liver allografts might indicate AMR or combined T-cell and antibody-mediated 
rejection, rather than an evolution of pure TCMR. 
 Liver pathologists should consider the diagnosis of AMR when bile duct loss 
becomes evident in liver allograft biopsy. Interestingly, this parameter is not included 
in the Banff diagnostic criteria of AMR. C4d staining should be recommended in all 
cases of bile duct loss as it is a simple and relatively inexpensive test that might add 
valuable information. DSA testing should be considered, since results might lead to a 
change in therapeutic strategy if a diagnosis of AMR is confirmed. 
 The RNASeq found no association between the presence of circulating 
DSA/DSA II and particular patterns of gene expression. However, the genes analysed 
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in the samples were evaluated in comparison to previously recognized pathologies of 
the liver allograft, such as recurrent HCV and TCMR, and to AMR in kidney allografts 
(since specific gene expression patterns of AMR are still not known in the liver 
allograft). Because AMR often occurs intertwined with TCMR, it is possible that some 
of the gene signatures which are currently considered to be markers of TCMR could 
also include an antibody-mediated component of rejection. In Londoño et al. recent 
study on adult liver 10-year protocol biopsies[138], subclinical inflammation (particularly 
in portal tracts and interface) and portal fibrosis were associated with gene expression 
profiles of TCMR. In fact, the patients who had the highest expression levels of these 
genes developed progressive graft fibrosis. Thus, it is possible that these gene 
signatures considered as TCMR include AMR. 
Considering the present research limitations, the impossibility of having DSA 
data for the failed allografts group, together with the retrospective nature of the study, 
restricted further interpretation of the histology. Additionally, because many of the 
allograft losses happened before the use of electronic patient records, it was not 
possible to retrieve clinical information to correlate with histology, such as the specific 
immunosuppression regime for each patient. Another limitation in this first cohort was 
that only the allografts that were removed at retransplantation were studied, when 
some recipients whose allografts failed died without undergoing retransplantation. 
 The study of paediatric protocol biopsies was limited by several factors, such 
as its retrospective nature, the small number of patients who had a protocol biopsy 
performed compared to the size of King’s transplantation programme, the impossibility 
of testing for DSA in over a third of the patients, the absence of adult recipients in the 
cohort and the lack of clinical data for some patients, especially at the time of 
transplantation (such as initial immunosuppression regime). 
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 In terms of the histology, many of the liver recipients in the protocol biopsy 
group did not have previous biopsies for comparison, which could enable a temporal 
correlation of histological findings. Numerous patients only had a previous biopsy in 
the first-year post-transplant and no other histological assessment until the “10-year” 
protocol biopsy. The time at which the long-term protocol biopsy was performed also 
showed considerable variation (from 8.6 to 15.6 years), which made the cohort less 
homogeneous. Furthermore, multiplex staining revealed itself to be technically 
challenging, both with Qdots and immunofluorescence. It is not easily performed and 
reproducible and might not be applicable to diagnostic clinical practice. However, 
considerable experience was gained and some success was achieved, which can 
certainly help in the development of useful research protocols. 
 Similarly, in the rejection cohort, the retrospective nature of the analysis was a 
limiting factor. Another important limitation is that only patients who had been 
previously tested for DSA were selected. This means that AMR was considered at 
some point in these patients, either before or after the biopsy findings or after poor 
response to treatment, so the proportion of AMR was certainly higher in the study 
series when compared to all liver recipients with an episode of TCMR. 
 Technical issues resulting in unavailability of a continued supply of C4d 
antibody limited the number of biopsies that were stained for C4d.  This narrowed the 
number of significant associations that could be established between C4d+ and/or 
DSA+C4d+ and other clinical and histological parameters. For instance, patients with 
bile duct loss were noted to have double the frequency of C4d+ compared to those 
without, but there were only 6 patients with bile duct loss who had C4d staining 
performed, and this link was not statistically significant. The lack of C4d data for many 
patients also limited the diagnosis of definite AMR, since C4d+ is one of the mandatory 
	 263	
diagnostic criteria for this condition. The choice of C4d antibody was made based on 
a multicentre study of C4d performance on FFPE liver allograft tissue. 
 In summary, IPTH has been an increasingly significant cause of allograft loss 
in recent years. Supporting evidence was found for the role of chronic AMR in the 
development of active graft injury, including inflammation and fibrosis in different 
compartments, frequently present in protocol biopsies of asymptomatic children with 
normal/mildly abnormal liver biochemistry. Concurrent AMR was also present in 
episodes of TCMR, and the finding of bile duct loss was associated with DSA. Despite 
not being included in the criteria for acute or chronic AMR, this histological finding 
should be considered as a potential sign of humoral injury. 
 C4d positivity in immunohistochemistry of FFPE biopsies was a good marker 
of antibody-mediated tissue injury and strongly associated with DSA in rejection 
setting. Although sensitivity in the (long-term) protocol biopsies (older samples) was 
low, when positive, C4d was specifically associated with plasma cells and B cells. C4d 
positivity in portal veins was restricted to patients with DSA in both biopsy series. 
 The histological criteria for chronic AMR are in need of further consideration. In 
order to better understand and characterise AMR in the liver graft, prospective 
multicentre studies that correlate detailed histological findings, tissue C4d, circulating 
DSA and outcome of the graft are necessary. This correlation might help overcome 
the limitations of C4d staining in this context. 
 Future research is also needed to better comprehend the relationship between 
B cells and fibrosis. The expression of granzyme B by B cells (and perhaps plasma 
cells) also needs to be better characterized in liver grafts, and the significance of such 
expression clarified. In particular, studies with live B cells obtained by liver recipients 
could provide useful information in this direction. 
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 Further progress in multiplex staining with protocols optimization could also 
enable a more detailed characterization of coexisting cell populations and the analysis 
of the relationships among different cells and between such cells and the liver 
compartments. This could add a considerable and relevant amount of information to 
the diagnosis of liver injuries. Besides quantification, more complex data analysis can 
be performed, such as studying the locations and relationships between cells. This 
complex examination, however, brings a new challenge, how to analyse vast amounts 
of data. This requires knowledge about the physiology of the cells studied and of 
experience with image analysis software, and is greatly time consuming. 
 The analysis of specific inflammatory cell populations could be useful in a 
variety of settings. In immunosuppression withdrawal studies, for instance, it could 
help to identify patients who are likely to be tolerant or to develop rejection at an earlier 
stage, before liver biochemistry or conventional histological analysis can detect 
abnormalities. Further studies correlating gene expression through RNA sequencing 
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